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Abstract 
Lsr2 is a small, basic DNA binding protein that is highly conserved in 
mycobacteria and related actinomycetes. Lsr2 is essential for growth in 
Mycobacterium tuberculosis and previous studies have shown that Lsr2 is 
involved in down-regulating a wide range of genes involved in cell wall synthesis 
and metabolic functions. This regulatory function is likely to influence bacterial 
growth and survival. 
This research investigated the biochemistry and 3D structure of Lsr2 from 
M. tuberculosis.  Transmission electron microscopy (TEM) analysis of Lsr2 in 
complex with DNA revealed a regular fibril-like arrangement of protein coating 
double-stranded DNA.  In addition, it was shown that Lsr2 physically protected 
DNA from DNase activity.  The structure of the C-terminal DNA binding domain 
of Lsr2, determined by others part way through this research, prompted site 
directed mutagenesis of residues proposed to interact with DNA.  Modification 
of arginine residues significantly reduced the binding of Lsr2 to DNA and 
fibril-like structures were not observed using TEM, for arginine mutants. 
The first crystal structure of the N-terminal domain of Lsr2 is reported here.  Two 
high resolution structures in monoclinic and hexagonal space groups were solved 
using X-ray crystallography and ab initio phasing.  Proteolytic processing of the 
N-terminus of Lsr2 was revealed by the structure in P21 and this process was 
recreated using the protease trypsin which resulted in crystal formation in a 
P3121 space group.  Both structures show linear chains of dimeric N-terminal 
Lsr2, as shown by crystallographic symmetry, linked by overlapping anti-parallel 
β-sheets, revealing a mechanism of protein oligomerisation.  Oligomerisation 
only occurs after the removal of the first three residues M1, A2 and K3.  In 
solution, protein oligomerisation was recreated with trypsin, resulting in the 
formation of large protein complexes.   A change in DNA topology after the 
addition of trypsin to full-length Lsr2/DNA complexes was observed using TEM.  
This mechanism is likely to be important to M. tuberculosis under “stress” 
conditions where proteases are known to be upregulated and where 
cross-linking and condensation of DNA is critical.  
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rTEV  recombinant tobacco etch virus 
xvi 
SEC  size exclusion chromatography 
SDS  sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SOC  super optimal broth with catabolite repression 
SSRL  Stanford synchrotron radiation laboratory 
TAE  tris acetate ethylene diamine tetraacetic acid 
TB  tuberculosis or terrific broth 
TBS  tris buffered saline 
TBS-T  tris buffered saline and tween 20 
TE  tris ethylene diamine tetraacetic acid 
TEMED tetramethylethylenediamine 
TG-SDS tris glycine sodium dodecyl sulphate 
Tm  melting temperature 
TOF  time of flight 
Tris HCl 2-amino-2-hydroxymethyl-propane-1,3-diol-HCl 
μm  micrometer 
UV  ultraviolet light (280 nm) 
V  volts 
v/v  volume per volume 
WHO  world health organisation 
w/v  weight per volume 
XDR  extensively drug resistant 
X-gal  5-bromo-4-chloro-indolyl-β-D-galactopyranoside 
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1 Chapter One – Mycobacteria and Disease 
 
1.1 Tuberculosis, the global disease 
One hundred and thirty years have passed since the identification of 
Mycobacterium tuberculosis by Robert Koch in 1882.  Koch’s studies 
demonstrated that the disease tuberculosis (TB) was caused by the bacterium 
M.  tuberculosis and that this organism is transmissible between animals (Koch, 
1882).  Today, infection with M. tuberculosis remains a major global health 
problem. 
Tuberculosis is the leading cause of death from a curable infectious disease (Dye, 
2006).  Current World Health Organisation (WHO) statistics show that globally, 
an estimated 8.8 million new cases and 1.1 million deaths from TB occurred in 
2010 (WHO, 2011).  Reassuringly, the numbers of new cases of TB and the 
prevalence rates have been declining and the mortality rates have fallen by more 
than one third since 1990.  Conversely, even though the global incidence is falling, 
it continues to slowly increase in one of the high burden countries, South Africa, 
where the proportion of TB cases co-infected with human immunodeficiency 
virus is also highest (WHO, 2011).  Of further concern is the appearance of multi-
drug resistant cases of TB (MDR-TB) that are more difficult to treat.   Although 
the trend in the global occurrence of MDR-TB cannot be reliably assessed 
(because of the lack of direct measurement) a survey in 2000 estimated 273,000 
new cases of MDR-TB (Dye, Espinal et al., 2002) and in 2008 there were an 
estimated 440,000 cases (WHO, 2010), which suggests that MDR-TB cases are 
increasing worldwide.  These statistics show that TB remains a major global 
health problem. 
In New Zealand, although the annual TB disease notification rates have dropped 
more than 50% over the last 30 years (1980-2010), this trend has slowed and in 
the last five years there has been little change (Bissielo et al., 2011).   Cases of 
MDR-TB have remained steady in New Zealand over the last ten years but 
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notably the first case of extensively drug resistant TB (XDR-TB) was identified in 
2010 (Bissielo et al., 2011).  The emergence of drug resistant strains of 
M. tuberculosis (Dye, Espinal et al., 2002) creates further challenges for the 
successful treatment of this already deadly global disease. 
 
1.2 Tuberculosis infection 
M. tuberculosis is an aerobic organism that has alternative intracellular or 
extracellular life-states.  It is a non-motile bacilli that is characterised by its slow 
growth (a generation time of approximately 24 hours), dormancy and distinctive 
cell envelope that differs substantially from the cell wall structures of both Gram-
negative and Gram-positive bacteria (Cole et al., 1998; Glickman & Jacobs Jr, 
2001). 
Primary infection with M. tuberculosis will lead to the manifestation of the 
disease in only around 10% of cases (Lillebaek et al., 2002).  It is widely known 
that the disease outcome is linked with the host environment, that is, the 
immune response of the natural host – humans (Glickman & Jacobs Jr, 2001).  
Most infected individuals are able to generate an immune response to the 
bacteria which will provide partial immunity but although the response against 
the bacteria is highly effective in controlling the proliferation and primary 
infection, the organism is almost never eradicated (Glickman & Jacobs Jr, 2001).  
This failure to eradicate the bacteria leads to asymptomatic latent infection.  
M. tuberculosis is exceptional amongst other pathogenic bacteria in its ability to 
establish and maintain latency, a period where a person does not exhibit any 
clinical signs, but the disease may be reactivated at a later date (Glickman & 
Jacobs Jr, 2001; Parrish et al., 1998).  The majority of latent infections never 
develop into the clinical form of the disease (nor transmit the disease) however 
the resilience of M. tuberculosis should not be underestimated as it has the 
potential to reactivate after thirty three years (Lillebaek et al., 2002).   
Most TB infections develop in the respiratory system but can involve other 
organs such as the lymph nodes, bones and joints.  The disease is a chronic 
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wasting illness characterised by fever, weight loss and coughing (with blood in 
later stages) – which is both a symptom and the mechanism by which the disease 
is spread (Glickman & Jacobs Jr, 2001; Smith, 2003).  In pulmonary TB, lesions 
develop in the alveoli of the lungs caused by the interaction of the immune 
system with the bacteria and this tissue becomes damaged and necrotic, forming 
cavities and causing bleeding (Schluger, 2005; Smith, 2003).   
For most pathogens, such as Staphylococcus aureus, patients treated with 
antibiotics for two weeks are cleared of bacteria (Connolly et al., 2007).  
However in M. tuberculosis infections the host immune response packages the 
bacteria into structures called granulomas, physically confining them (Schluger, 
2005; Wayne & Sohaskey, 2001).  Here the bacteria survive by evading the host 
immune system and drug treatment by adapting their metabolism and shifting 
into a non-replicating state (Murphy & Brown, 2008).  Thus treatment of TB 
requires long treatment times – typically six to twelve months – as most 
antibiotics require actively dividing bacteria for their mode of action and while in 
the non-replicating state M. tuberculosis is phenotypically resistant to otherwise 
bactericidal antibiotics (Arcus et al., 2006; Connolly et al., 2007).    
 
1.3 Mycobacterium tuberculosis persistence and resistance  
Many of the symptoms of TB are a result of the host immune response to 
M. tuberculosis infection rather than any directly toxic effect of the bacterium 
itself.  Understanding the interaction between the host immune response and 
M. tuberculosis remains a major goal of research into the pathogenic mechanism 
of this bacterium.  Based on the clinical behaviour of M. tuberculosis there are 
several tasks that it must accomplish to successfully cause infection.  It must be 
able to grow within the host macrophage, evade or modify the host immune 
response and be able to persist within the host in a non-replicating state but 
have the ability to reactivate (Glickman & Jacobs Jr, 2001).   
In contrast to other bacterial pathogens, M. tuberculosis infects macrophages 
rather than avoids them and once inside, the bacteria reside within a vacuoule 
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called the phagosome.   If the phagosome maturation cycle occurs (phagosome-
lysosome fusion), the bacteria can encounter a hostile environment that is acidic 
in pH, contains reactive oxygen intermediates, lysosomal enzymes, reactive 
nitrogen intermediates and toxic peptides (Smith, 2003; Warner & Mizrahi, 2006).  
However it is known that M. tuberculosis alters the phagosome maturation cycle 
by modifying the cell proteins and transport mechanisms, reducing the hostility 
of the environment (to a slight decrease in pH), but in this process also restricting 
the supply of nutrients and essential elements.  Persistence of M. tuberculosis 
relies on its ability to survive and replicate in these modified phagosomes (Smith, 
2003; Warner & Mizrahi, 2006). 
Persistence refers to the state of the bacterium where it stops growing when it 
encounters unfavourable conditions but is able to resume growth when the 
conditions improve.  It is thought that initiation of the persistent state may be 
due to depletion of nutrients, changes in pH, the production of growth 
suppressing products and the depletion of oxygen (Wayne & Sohaskey, 2001).  
These conditions are present in the phagosome but there is much less 
information known about how the bacteria survives and grows during later 
stages of infection in the lung (Smith, 2003).  Conditions in the necrotic centre of 
the granulomas are acidic and low in oxygen as a result of the battle between the 
immune system and M. tuberculosis, and it is postulated that the bacteria cannot 
multiply and remain dormant but alive.  Depending on the effectiveness of the 
host’s immune system, an infection may be arrested at this point or progress to 
the next stage.  An arrested infection can persist throughout a person’s life and 
they may never develop clinical signs of disease or it may become reactivated 
due to a change in their immune system.  Treatment of dormant infections is 
difficult due to the lack of information in relation to how M. tuberculosis exists 
within the environment of the lung (Smith, 2003; Wayne & Sohaskey, 2001). 
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1.4 Treatment of tuberculosis 
The current standard chemotherapy regime for active TB, called directly 
observed therapy short course or DOTS, involves the supervised administration 
of a multidrug combination for a minimum period of six months (Warner & 
Mizrahi, 2006).  Because the majority of antibiotics require actively dividing 
bacteria for their mode of action, the dormant state of M. tuberculosis is thought 
to effectively make it resistant to usually bactericidal antibiotics (Connolly et al., 
2007).  The strict DOTS treatment protocol involves administering four different 
drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) and is designed to 
overcome the phenotypic resistance that M. tuberculosis exhibits while in the 
non-replicating state (Murphy & Brown, 2008).   
The need for multi-drug and long-term therapy for TB is the result of both the 
phenotypic and inherited genetic resistance of M. tuberculosis to current front-
line antibiotics.  Simultaneous use of multiple antibiotics makes it less likely that 
a mutant resistant to any one of the drugs will survive whilst the extended 
treatment period ensures that bacteria leaving the persistent state will be killed 
as they begin to replicate (Connolly et al., 2007).  However, complications in 
curing the disease may arise if the treatment is abandoned mid-course, risking 
selection for resistant strains and in light of the emergence of multi-drug 
resistant strains (resistant to at least rifampicin and isoniazid) of M. tuberculosis, 
this has occurred.   
No new antibiotics against TB have been developed in the past 30 years.  The 
antibiotics isoniazid, rifampicin and pyrazinamide are considered first-line drugs 
with antibiotics such as ethambutol, streptomycin and para-aminosalicylic acid 
considered second-line (Arcus et al., 2006).  There is evidence that first-line 
therapy is effective in treating TB and containing MDR strains of TB (Dye, 
Williams et al., 2002; WHO, 2008).  However in 2006 the WHO announced that a 
deadly new strain of XDR-TB (MDR plus resistant to at least three of the six 
classes of second-line drugs) had been detected that was virtually untreatable 
and subsequently had extremely high fatality rates (Singh et al., 2007).  An 
urgent need for new antibiotics towards TB is widely acknowledged and the 
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goals of the Global Alliance for TB Drug Development that was established in 
2000 include shortening treatment times, improving persistent M. tuberculosis 
and MDR/XDR TB treatment and the development of new adjuvant drugs (Arcus 
et al., 2006). 
 
1.5 The genetics of Mycobacterium tuberculosis 
The complete DNA sequence of the virulent M. tuberculosis strain H37Rv was 
completed by investigators at the Pasteur Institute and published in June 1998 
(Cole et al., 1998).  The genome comprises 4,411,529 base pairs (bp) and 
contains around 4,000 genes.  Some of the features of the genome include 
guanine + cytosine (G+C) rich sequences and a large number of genes devoted to 
the synthesis of fatty acids (Cole et al., 1998; Schluger, 2005).  A general 
classification of M. tuberculosis H37Rv genes reveals that over 500 genes are 
annotated as coding for enzymes involved in cell wall and cell wall processes 
(13%) and over 200 genes (6%) encode enzymes involved in the metabolism of 
fatty acids (Smith, 2003).  This result is not surprising as the cell envelope of 
M. tuberculosis contains an additional layer that is rich in unusual lipids, 
glycolipids and polysaccharides (Cole et al., 1998) and as such there are original 
pathways to synthesise cell wall components such as mycolic acids, mycocerosic 
acid, lipoarabinomannan and arabinogalactan (Chatterjee, 1997; Morita et al., 
2011; Norman et al., 1994).  The large number of possible enzymes that may be 
involved in fatty acid metabolism in M. tuberculosis could be linked to the ability 
of this organism to grow in an environment where fatty acids may be the main 
carbon source.  In comparison, other organisms such as Escherichia coli and 
Streptomyces coelicolor have noticeably fewer genes involved in fatty acid 
metabolism (Smith, 2003).   
The completion and publication of the whole genome sequence of the virulent 
M. tuberculosis H37Rv strain enabled Gordon and researchers (Gordon et al., 
1999) to perform a complete genome comparison between M. tuberculosis 
H37Rv and the vaccine strain Mycobacterium bovis BCG-Pasteur using bacterial 
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artificial chromosome libraries together with the genome sequence of 
M. tuberculosis H37Rv.  Their studies revealed 10 deleted loci in M. bovis BCG 
compared with M. tuberculosis H37Rv.  Primers for polymerase chain reaction 
(PCR) of these 10 loci were used to investigate the presence of these regions in 
the other species that make up the M. tuberculosis complex (Mycobacterium 
africanum, M. bovis and Mycobacterium microti) and revealed an interesting 
distribution amongst the group.  These differences in loci deletion between 
species provides information on their heritage and may offer clues to phenotypic 
and virulence differences (Gordon et al., 1999).   
Prior to Gordon’s studies, sequence analysis of 26 structural genes or loci from 
M. tuberculosis strains and strains from three members of the M. tuberculosis 
complex (M. africanum, M. bovis and M. microti) revealed an absence of neutral 
gene mutations indicating that M. tuberculosis is young on an evolutionary scale 
and possibly underwent a recent evolutionary bottleneck resulting in a modern 
global spread (Sreevatsan et al., 1997).  Analysis of the combination of 
polymorphisms at two genetic markers enabled the authors to assign the 
members of the M. tuberculosis complex into one of three distinct genotypic 
groups.  Interestingly M. tuberculosis fell into each of the three groups (1-3) 
whereas isolates of M. bovis, M. microti and M. africanum all fell into group one 
(1).  Sreevatsan and colleagues propose an evolutionary scenario: that group 1 
bacteria are ancestral to, and have greater genetic diversity than, groups 2 and 3.   
Their results from the analysis of 842 M. tuberculosis complex isolates from 
diverse geographic locations show that the M. tuberculosis genome is still 
evolving and indicate that the use of antibiotics may be a driving factor 
(Sreevatsan et al., 1997). 
At the time of writing, the genome sequences for fifteen mycobacterial species 
had been completed.  These include five of the M. tuberculosis complex species 
(M. tuberculosis H37Rv, M. africanum, M. bovis, M. bovis BCG, M. canettii); the 
commonly studied pathogenic species Mycobacterium leprae, Mycobacterium 
avium subsp. paratuberculosis, Mycobacterium avium and Mycobacterium 
ulcerans; and the common laboratory model organisms Mycobacterium 
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smegmatis and Mycobacterium marinum (Shiloh & DiGiuseppe Champion, 2010) 
with the genome sequencing of ten more species in progress (NCBI, 2012).  In 
the future, comparisons of sequences between additional mycobacterial species 
will allow the construction of evolutionary trees and improve our understanding 
about the evolution of these bacteria that inhabit such diverse environments. 
 
1.6 M. tuberculosis Proteomics and Structural Biology 
Just as the study of the DNA sequence of M. tuberculosis H37Rv can reveal a 
wealth of information about the organism, so too can the study of the proteins 
that are encoded by this DNA.  Measuring the levels of proteins during different 
M. tuberculosis H37Rv growth conditions, such as nutrient starvation (Betts et al., 
2002) and high temperature (Stewart et al., 2002), provides information on 
global gene expression of the organism.  Technology to identify proteins of 
interest is available and along with sequence annotation, the putative function of 
many proteins may be predicted.  However predicting protein function is not 
always a straight forward procedure.  Bioinformatic analysis of sequenced 
genomes reveals that around 40% of gene products have an unknown function 
and of the 60% of gene products that have been functionally annotated, some 
are likely to be incorrect because these classifications are often derived by 
inference rather than by experimental means (Johnston et al., 2003).  
Furthermore, annotated predicted protein function may still not give a complete 
account of a proteins’ role in the bacterial cell as there may be additional 
posttranslational modification of the protein in vivo (Smith, 2003). 
Despite this limitation, the mass of rapidly accumulating genomic sequence data 
provides an opportunity for researchers such as structural biologists because, as 
gene annotation in combination with molecular techniques reveals genes that 
are essential to organisms under specific growth conditions, biologists can target 
specific encoded proteins for structural studies (Arcus et al., 2006).  Structural 
biologists are concerned with the three dimensional (3D) molecular structure 
and function of biological macromolecules such as proteins.  In most cases the 
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3D structures of proteins are solved through X-ray crystallography.  The 
characterization of 3D structures of proteins is technically difficult and this is 
reflected by the smaller number of protein structures that have been solved over 
time in comparison with the vast amount of genetic data that has been revealed 
(Hrmova & Fincher, 2009).  The 3D structure of a protein enables the prediction 
of its function and it is possible to find out information such as the mechanism of 
action of an enzyme, substrate binding site, protein-protein interaction sites or 
the binding sites in protein-DNA interactions.  This information can be used to 
assist the selection of amino acids for mutation studies, to further study protein 
function (Hrmova & Fincher, 2009). 
Approximately ten years ago, only eight protein structures (only two of which 
were not duplicates) from M. tuberculosis were available via the Protein Data 
Bank (PDB).  Currently, there are over 1000 protein structures with around 500 
of these being unique proteins within M. tuberculosis and the numbers are 
increasing daily with 10 structures submitted in the month of January 2012 alone.  
Hence, despite the technical challenges of successfully determining the 3D 
structure of proteins, this field of research is proving productive in nature and is 
providing valuable information about the biological function of proteins from 
M. tuberculosis. 
 
1.7 LSR2 origins from Mycobacterium leprae studies 
The bacterium Mycobacterium leprae is responsible for the disease leprosy 
which is a chronic infectious disease that mainly affects the skin and peripheral 
nerves.  The protein LSR2 was first identified and named in February 1991 as the 
result of a study investigating antigen responses in the sera isolated from 
lepromatous leprosy patients to an expression library of M. leprae (Laal et al., 
1991).  In this study, a M. leprae λgt11 recombinant DNA expression library was 
screened using pooled sera from patients and 4 clones that coded for 
β-galactosidase fusion proteins were identified.  These clones were given the 
name “LSR” but the authors do not indicate their logic for this name and so it is 
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speculated that it may be derived from the phrase “lepromatous sera responder”.  
Clone LSR2 was used for further investigation of antibody and T-cell responses 
and the results demonstrated that the fusion protein LSR2 was able to act as a 
T-cell antigen and generate the same antibody response in leprosy patients as 
the sonicated native M. leprae bacilli.  DNA sequencing of the LSR2 clone 
revealed an open reading frame (ORF) that coded for an 89 amino acid (aa) 
protein with a calculated size of approximately 10 kilodaltons (kDa) and an 
isoelectric point (pI) of 12 (Laal et al., 1991). 
Later in the same year, research was published where a M. leprae cosmid library 
was screened with sera from lepromatous leprosy patients (Sela et al., 1991).  
The use of a cosmid library enabled DNA clones to be expressed from their 
natural transcription-translation start signals instead of being fused with another 
protein.  Cloned proteins that showed a strong reaction to sera from patients 
with lepromatous leprosy were identified as being 15 kDa in size as shown by 
Western blot.  Sequence analysis of the clone containing the coding sequence for 
this protein revealed an ORF with genetic information for this 15 kDa protein 
that included an upstream ribosome binding site and promoter region.  A 
comparison of the 15 kDa protein sequence with the recently isolated clone LSR2 
from a λgt11 recombinant DNA expression library (Laal et al., 1991) revealed that 
LSR2 was identical to the 89 amino acids at the C-terminal end of the 15 kDa 
protein (Sela et al., 1991).   
These two studies both confirmed the antigenic nature of this protein but their 
contrasting sequence results suggest that the exact protein size is probably 
between 10 kDa and 15 kDa.  Both authors searched sequence databases 
available at the time and were not able to identify similar sequences in other 
organisms.  However, through Southern blotting experiments, sequences 
homologous to the 15 kDa gene were found in chromosomal DNA from M. avium, 
M. bovis BCG and M. tuberculosis H37Rv (Sela et al., 1991).  Both authors 
analysed the sequence of this protein for evidence of a signal sequence - as 
signified by a hydrophobic domain at the N-terminal end (Oliver, 1985).  
However signal sequence features were not found, which indicated that it is 
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unlikely that this protein is secreted or is part of the cell membrane.  Incredibly, 
it would take thirteen years for their prediction that LSR2 was not secreted to be 
confirmed in vivo when it was isolated from the soluble fraction of armadillo 
derived M. leprae bacilli (Marques et al., 2004). 
Meanwhile, the amino acid residues responsible for generating an immune 
response to LSR2 in patients with inflammatory episodes of erythema nodosum 
leprosum were being investigated by researchers in the same laboratory as Laal 
and colleagues (Singh, Jenner et al., 1994; Singh, Narayanan et al., 1994).  In this 
work, LSR2 was now called “LSR” and even though the discovery of the full-
length (123 aa) protein by Sela et al (1991) was acknowledged in the manuscripts, 
these researchers focussed their experimental design on the original 10 kDa 
truncated annotation which lacks the N-terminal amino acids 1-23 shown by Sela 
and colleagues.  Analysis of antibody responses to overlapping peptides 
generated from the LSR2 amino acid sequence shows two peptides of interest.  
Peptides 2 (p2) and 3 (p3), with an overlapping consensus sequence of 
IDLTNKNAA, gave the best antibody reaction (Singh, Narayanan et al., 1994).  A 
modern amino acid multiple sequence alignment of LSR2 reveals that residues 
IDL and NA from the overlapping consensus sequence are highly conserved 
amongst Lsr2 homologues (Figure ‎1.1).  The consensus sequence had an 
antibody response that was lower than with the individual peptides used alone 
(Singh, Jenner et al., 1994) but by sequentially removing the flanking amino acids 
N-terminal of p2 and C-terminal of p3 and testing for antibody response, the 
exact residues that were important for antibody recognition in erythema 
nodosum leprosum patients were identified (Singh, Jenner et al., 1994).  These 
are the residues GVTYE at the N-terminal end of p2 and the residues KLRGD at 
the C-terminal end of p3, that extend from the consensus sequence IDLTNKNAA. 
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Figure ‎1.1.  An amino acid multiple sequence alignment of Lsr2.  The alignment was generated in Geneious Pro 5.4.2. (Drummond et al., 2011).  Dashes represent 
alignment gaps.  The most highly conserved residues are shaded in black, followed by dark grey, then light grey with no shading for dissimilar residues.  The amino acid 
sequence for M. tuberculosis H37Rv Lsr2 is shown above the alignment with predicted secondary structure elements (http://www.predictprotein.org) shown as blue 
arrows for β-sheets, pink cylinders for α-helices and a grey line for random coil.  It was discovered that the start site of M. avium 104 was mis-annotated and as a 
consequence of this, the first four residues (MAKK) were manually added.  
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In contrast to these studies, a different subset of peptides gave the best T-cell 
response when the same overlapping peptides were used in a study with an aim 
to define the details of T cell recognition of LSR2 (Chaduvula et al., 2012).  A 
number of peptides were stimulatory but the best reaction across all treatment 
groups in this study was due to peptide 9 (residues GRSNSGRGRGAIDREQSA).  An 
amino acid multiple sequence alignment of LSR2 reveals that the residues from 
peptide 9 are in a region of low conservation (Figure ‎1.1).  It is clear that the 
peptides that preferentially activate T-cell responses are different from those 
that bind to circulatory antibodies. 
In 2000, an extensive search of the newly completed M. tuberculosis H37Rv 
genome with the M. leprae LSR2 DNA sequence revealed a homologous 
M. tuberculosis ORF of 336 bp, translating to 112 residues and encoding a 12.1 
kDa protein (Oftung et al., 2000).  This gene was annotated as Rv3597c within 
the M. tuberculosis H37Rv genome (Cole et al., 1998) and a sequence alignment 
showed 93% identity between M. leprae LSR2 and M. tuberculosis Rv3597c at the 
amino acid sequence level (Oftung et al., 2000).  With the identification of a 
homologous counterpart to the LSR2 antigen from M. leprae, in M. tuberculosis, 
and evidence that a corresponding M. tuberculosis antigen exists at the protein 
level (Sela et al., 1991) LSR2 had now caught the interest of researchers studying 
M. tuberculosis. 
Researchers of LSR2 in M. leprae have used the term LSR2 (Laal et al., 1991; 
Marques et al., 2004) and LSR (Oftung et al., 2000; Singh, Jenner et al., 1994; 
Singh, Narayanan et al., 1994) and more recently, Lsr2 (Chaduvula et al., 2012).  
The term Lsr2 is characteristic with research on the equivalent M. tuberculosis 
H37Rv protein and from now on this protein will consistently be referred to as 
Lsr2. 
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1.8 Lsr2 from Mycobacterium tuberculosis 
1.8.1 Lsr2 DNA and protein sequence analysis 
Lsr2 is encoded by the 339 bp gene Rv3597c of M. tuberculosis H37Rv.  It is 112 
amino acids in length (Figure ‎1.2), has a molecular weight of 12.1 kDa and a 
theoretical pI of 10.   
 
 
 
Figure ‎1.2.  The nucleotide sequence and the amino acid translation of Lsr2 (Rv3597c).  The 
gene for Lsr2 is 339 bp in length and encodes 112 aa.  Numbering indicates the number of base 
pairs and the stop codon is indicated by a *.  This image was prepared in Geneious Pro 5.4.2. 
(Drummond et al., 2011). 
 
Examination of the amino acid composition of the protein sequence reveals that 
it is arginine rich (13.4%) making it highly basic and positively charged.  The total 
number of positively charged residues (Arginine-15, Histidine-2 and Lysine-5) 
outnumbers the number of negatively charged residues (Aspartic Acid-10 and 
Glutamic Acid-5).  A large number of the small residues glycine and alanine are 
present in Lsr2 and make up 13.4% and 12.5% of the total residues, respectively 
(Table ‎1.1).  There is a region of low complexity present within the unstructured 
region between residues 53 and 74 (Figure ‎1.1). 
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Table ‎1.1.  The amino acid composition of Lsr2 (Rv3597c).  The twenty amino acids are listed in 
alphabetical order and their corresponding three-letter and single-letter codes noted alongside.  
The dominant characteristics of each residue are listed.  Lsr2 is arginine rich making it highly basic 
and positively charged. 
 
Amino Acid Codes No. of Residues Percentage (%) Residue Characteristics 
Alanine Ala (A) 14 12.5% Aliphatic, hydrophobic 
Arginine Arg (R) 15 13.4% Basic, positive charge 
Asparagine Asn (N) 3 2.7% Amide group, uncharged 
Aspartic Acid Asp (D) 10 8.9% Acidic, negative charge 
Cysteine Cys (C) 0 0.0% Sulphur-containing 
Glutamine Gln (Q) 2 1.8% Amide group, uncharged 
Glutamic Acid Glu (E) 5 4.5% Acidic, negative charge 
Glycine Gly (G) 15 13.4% Aliphatic, hydrophobic 
Histidine His (H) 2 1.8% Basic, positive charge 
Isoleucine Ile (I) 5 4.5% Aliphatic, hydrophobic 
Leucine Leu (L) 5 4.5% Aliphatic, hydrophobic 
Lysine Lys (K) 5 4.5% Basic, positive charge 
Methionine Met (M) 1 0.9% Sulphur, hydrophobic 
Phenylalanine Phe (F) 2 1.8% Aromatic, hydrophobic 
Proline Pro (P) 1 0.9% Aliphatic, hydrophobic 
Serine Ser (S) 6 5.4% Polar, uncharged 
Threonine Thr (T) 8 7.1% Polar, uncharged 
Tryptophan Trp (W) 2 1.8% Aromatic, hydrophobic 
Tyrosine Tyr (Y) 2 1.8% Aromatic, hydrophobic 
Valine Val (V) 9 8.0% Aliphatic, hydrophobic 
 
DNA sequence analysis revealed that lsr2 orthologues are present in all 
sequenced mycobacterial genomes, including M. tuberculosis, M. smegmatis, 
M. bovis, M. leprae, M. africanum, M. ulcerans, M. marinum, M. avium, and 
M. avium subsp. paratuberculosis.  The amino acid sequence of Lsr2 is highly 
conserved among mycobacteria and other actinobacteria. The high level of 
sequence identity among the Lsr2 homologues can be seen in a multiple amino 
acid sequence alignment of a selection of organisms (Figure ‎1.1) and suggests 
that these proteins perform a similar function amongst the identified group of 
related organisms.   
Residues that are highly conserved are thought to be involved in the three 
dimensional or higher order structures of proteins and/or involved with protein 
function.  The predicted secondary structure of M. tuberculosis H37Rv Lsr2, 
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alongside the multiple sequence alignment (Figure ‎1.1) shows that 60% of the 
most highly conserved residues are positioned within a secondary structure 
motif.  Secondary structure regions make up 53% of the total residues.  The 
remaining highly conserved residues flank a secondary structure motif.  In the 
area of low residue conservation across species, there is lack of predicted 
secondary structure. 
Another method of examining amino acid conservation is by generating a model 
based on the probability of the position of each amino acid by performing a 
Hidden Markov Model (HMM) analysis.  A graphical representation of HMM 
analysis (called an HMM logo; (Schuster-Bockler et al., 2004)) of Lsr2 sequences 
shows the conservation of amino acid positions in the alignment (Figure ‎1.3).  
Amino acid conservation is represented in stacked columns and letter height 
indicates residue frequency at each position.  The HMM logo reveals several 
additional residues of significance compared with the highly conserved residues 
identified in the protein sequence alignment (Figure ‎1.1) such as alanine in 
position 2, aspartic acid at position 14 and leucine in positions 44 and 48.  HMM 
logos also provide valuable information about residue characteristics at each 
position as colour is used to represent residue properties.  For example, the 
other (green-coloured) aromatic residues tyrosine (Y) and phenylalanine (F) 
substitute tryptophan (W) more often in other family members compared with 
Lsr2 in M. tuberculosis H37Rv.  Analysis and characterisation of the amino acid 
residues in a protein is an informative tool as it can give clues about how the 
protein may behave in vitro and in vivo.   
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Figure ‎1.3.  Hidden Markov Model (HMM) logo of the Lsr2 family shows the distribution of 
amino acids from a multiple alignment (http://pfam.sanger.ac.uk/family/PF11774).  The height 
and width of each letter at each position is proportional to its occurrence and relative role, 
respectively.  The pink bars represent regions of residue insertion in the alignment.  Amino acid 
colours reflect their biological properties (red = charged; blues = polar, uncharged; yellows = 
aliphatic; greens = aromatic).  The M. tuberculosis Lsr2 amino acid sequence is shown across the 
top of the HMM logo for comparison.  Residues in bold type are highly conserved as identified in 
the consensus sequence alignment (Figure ‎1.1) generated in Geneious Pro 5.4.2. 
 
1.8.2 Early studies on Lsr2 
Lsr2 (Rv3597c) was first described as a negative regulator of transcription in 
studies investigating the transcriptional regulation of multi-drug tolerance in 
M. tuberculosis H37Rv (Colangeli et al., 2007).  Prior to this, Alland et al. 
discovered a mechanism of multi-drug tolerance in M. tuberculosis while 
investigating differential gene expression in response to the antibiotic isoniazid 
(INH) that inhibits cell wall synthesis (Alland et al., 1998).  In their study, three 
previously uncharacterised genes (iniB, iniA and iniC, organised in an operon 
(iniBAC)) were shown to be induced by INH, with the exception of iniA that was 
also induced by the antibiotic ethambutol, a cell wall synthesis inhibitor with a 
mechanism distinct from INH.  The promoter region of this three-gene operon 
was further characterised, revealing genetic regulatory elements essential for 
gene expression and providing evidence that both activator and repressor 
molecules are involved in regulating this operon (Alland et al., 2000).  In vivo 
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studies of the individual genes of the iniBAC operon in M. tuberculosis H37Rv and 
M. bovis BCG confirmed they are induced by INH and reiterated that iniA is also 
responsive to ethambutol (Colangeli et al., 2005).   This in vivo research focused 
on iniA and showed that deleting iniA from M. tuberculosis H37Rv decreased its 
survival when exposed to INH and over-expressing iniA in M. bovis BCG increased 
its survival under INH induced stress.  Analysis of two-dimensional protein 
crystals of iniA revealed a structure that could function as a transmembrane 
pump and led to the authors’ hypothesis that this could be a mechanism that 
could provide multi-drug tolerance in M. tuberculosis H37Rv. 
Colangeli and colleagues’ transcription regulation research in 2007 involved 
generating a transposon mutagenesis library in M. smegmatis mc2155 of the 
M. tuberculosis H37Rv iniBAC promoter fused to a lacZ reporter gene.  The 
purpose of this library was to identify genes involved in the down-regulation of 
expression of the M. tuberculosis H37Rv iniBAC genes.  In a colourimetric growth 
assay, mutants that had transposon insertions in genes involved in repressing the 
transcription of the iniBAC promoter were identified as blue colonies on media 
containing X-gal.  The interrupted gene identified in these blue mutants in 
M. smegmatis mc2155 was lsr2.  In growth assays, the lsr2 transposon mutant 
was shown to be more resistant to ethambutol and this was postulated to be due 
to lack of repression of the iniA gene in the iniBAC operon, as complementation 
of the gene restored antibiotic susceptibility.  The researchers also performed a 
microarray analysis of a lsr2 knock-out in M. smegmatis mc2155 to identify genes 
that were up- or downregulated by deletion of lsr2, and showed that iniA and 
genes involved with cell wall and metabolic function were upregulated.  Further 
experiments over expressing lsr2 in M. tuberculosis H37Rv reduced the INH-
induced transcription of the iniBAC genes, adding additional evidence to the 
hypothesis that Lsr2 has an important role in the regulation of multi-drug 
tolerance (Colangeli et al., 2007).   
In addition to transcription response studies, these researchers showed that 
overexpression of Lsr2 enabled M. smegmatis mc2155 to survive for longer in 
culture when exposed to H2O2 and also within murine macrophages.  The lsr2 
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knock-out in M. smegmatis mc2155 was more susceptable when exposed to H2O2 
and survival was significantly affected within murine macrophages  This 
suggested that Lsr2 protects mycobacteria against reactive oxygen intermediates 
in vitro and during macrophage infection (Colangeli et al., 2009). 
 
1.8.3 The role of Lsr2 in colony morphology and biofilm formation 
M. smegmatis mc2155 transposon insertion mutants generated by Colangeli et 
al., (Colangeli et al., 2007) that successfully alleviated the repression of the 
iniBAC promoter had unusual round, wet and shiny colony morphology 
compared with the wild-type undulate, dry and rough colony phenotype.  This 
altered colony phenotype was also reported previously for M. smegmatis mc2155  
lsr2 transposon mutants obtained during the generation of colony morphology 
mutants in the investigation of cell wall composition (Chen et al., 2006).  These 
lsr2 transposon (colony morphology) mutants were also defective in pellicle and 
biofilm formation, and apolar lipid formation.  In spontaneously occurring 
M. smegmatis mc2155 transposon mutants, that show smooth colony 
morphology, lsr2 was again identified as the inactivated gene and varying 
features such as increased sliding mobility, lack of biofilm formation (Arora et al., 
2008), or increased biofilm formation, increased glycopeptidolipids and lack of 
pigment formation have been reported (Kocíncová et al., 2008).  These diverse 
morphological results nevertheless indicate that Lsr2 plays an important role in 
colony morphology and biofilm formation in M. smegmatis mc2155, possibly 
through control of lipid production (Chen et al., 2006). 
It should be noted that there were a variety of techniques used in the literature 
(Table ‎1.2) to generate M. smegmatis lsr2 knock-out mutants. Hence such 
varying morphological features noted in M. smegmatis mc2155 strains could 
potentially be influenced by mutation technique. 
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Table ‎1.2.  Description of M. smegmatis lsr2 knock-out mutants and their construction.   
 
Strain Description Reference 
NJS20.1 M. smegmatis strain mc
2
155 containing pG21898-
12 inserted into chromosome at attP and a 
transposon element inserted into lsr2. 
Alland et al., (2000) 
Colangeli et al., (2007) 
NJS22 M. smegmatis strain mc
2
155 with lsr2 deleted 
(unmarked deletion). 
Colangeli et al., (2007) 
MS8444 M. smegmatis strain mc
2
155 containing 
transposon insertion in lsr2 gene. 
Chen et al., (2006) 
Gordon et al., (2010) 
Sm8/Sm9 Spontaneous mutants of M. smegmatis strain 
ATCC607 with mobile element inserted into lsr2 
gene. 
Kocincova et al., (2008) 
DL1215 Spontaneous mutant appearing from 
M. smegmatis mc
2
155 ∆relMsm strain.  Single base 
pair deletion in lsr2. 
Arora et al., (2008) 
DL2008 M. smegmatis strain mc
2
155 containing lsr2 single 
base pair deletion mutant gene from DL1215.   
Arora et al., (2008) 
∆esx-1 lsr2:Km M. smegmatis strain mc
2
155 ∆esx-1 containing 
transposon insertion in lsr2 gene (Hygro/Kana). 
Nguyen et al., (2010) 
MKD158∆lsr2 Derivative of M. smegmatis strain mc
2
155 lsr2 
knock out containing kanamycin resistance 
cassette. 
Nguyen et al., (2010) 
 
 
1.9 Bacterial DNA binding proteins 
Eukaryotic organisms contain small abundant DNA binding proteins responsible 
for compacting DNA into nucleosomes (Drlica & Rouviere-Yaniv, 1987).  In 
prokaryotes, the chromosomal DNA is folded into a compact structure called a 
nucleoid and a number of proteins, collectively named histone-like proteins or 
nucleoid-associated proteins (NAP), are thought to be involved in this process 
(Dame, 2005; Dame & Goosen, 2002).  The wide range of diverse DNA binding 
proteins found in bacteria suggest that there are multiple mechanisms used to 
solve the DNA packing conundrum (Tendeng & Bertin, 2003).  The most studied 
and abundant members of the histone-like proteins are heat unstable protein 
(HU), factor for inversion stimulation (Fis), and heat stable nucleoid structuring 
protein (H-NS) (Dame & Goosen, 2002). 
 Chapter One – Mycobacteria and Disease  21 
1.9.1.1 Heat unstable protein - HU 
HU is similar to the eukaryotic histone protein as it is small (90 aa, 9.7 kDa), basic 
in nature and expressed at a high level.  The amino acid sequence of HU is well 
conserved and homologues have been identified in all bacteria studied to date.  
HU is found as both a homodimer and heterodimer, binding and wrapping DNA 
in a non specific manner, and is capable of forming higher-order structures 
(Dame & Goosen, 2002; Drlica & Rouviere-Yaniv, 1987).  The exact mode of DNA 
binding of HU is still being actively researched (Koh et al., 2011) but it is known 
that HU prefers supercoiled over relaxed or linear lengths of DNA (Shindo et al., 
1992).  Studies have also shown that at low concentrations HU binds to DNA and 
introduces bends, but as protein levels increase, polymerisation of HU occurs 
causing it to form rigid helical filaments that coat DNA without causing 
compaction (Figure ‎1.4)(Thanbichler et al., 2005).  The three dimensional 
structure of a Bacillus stearothermophilus HU protein reveals that there are 
several positively charged arginine and lysine residues implicated in binding in 
the minor groove of DNA (Tanaka et al., 1984; White et al., 1999). 
 
1.9.1.2 Factor of inversion stimulation - FIS 
Like the DNA binding proteins HU and H-NS, FIS is small (98 aa, 11.2 kDa), binds 
DNA in both a sequence-specific and non-specific manner and is abundant during 
exponential cell growth (Schneider et al., 2001; Thanbichler et al., 2005).  FIS 
association with DNA introduces between 40° - 90° bends (Zhang et al., 2004) 
and at low concentrations, forms aggregations at apical loops, giving a branched 
appearance.  As the amount of FIS protein increases, the DNA becomes 
progressively more compacted as FIS binds to less specific sites 
(Figure ‎1.4)(Schneider et al., 2001).   FIS exists as a homodimer and has the 
common DNA binding protein “helix-turn-helix” structural motif which is found 
at the C-terminal end of the protein (Dame, 2005; Yuan et al., 1991).   The 
binding mechanism for FIS is proposed to cause the change in DNA topology. The 
three dimensional structure of FIS shows that the distance between the two 
helix-turn-helix motifs in the dimer is too small for binding in adjacent major 
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grooves in straight DNA helices but is the perfect spacing once the DNA is 
modelled with a 59° bend angle  (Yuan et al., 1991).  Mutation of the positive 
arginine residues in the helices of the helix-turn-helix motif that interact with the 
phosphate backbone of the DNA results in a significant reduction in DNA binding 
(Yuan et al., 1991). 
 
 
Figure ‎1.4.  The effect of histone like proteins FIS, H-NS and HU on the conformation of a 
supercoiled plasmid.  (A)  The binding of FIS introduces bends in the DNA and promotes 
branching of supercoiled plasmid DNA; (B) At high concentrations, H-NS assembles into groups 
that interact with each other forming filament-like DNA structures; (C) HU forms rigid helical 
filaments that coat the DNA.  This figure was recreated from (Thanbichler et al., 2005). 
 
1.9.1.3 Heat stable nucleoid structuring protein – H-NS 
There is a wealth of information available on the DNA binding protein H-NS.  Like 
HU, H-NS is small (137 aa, 15.5 kDa), binds DNA in a non specific manner and can 
form higher-order structures (Dame & Goosen, 2002).  H-NS is organised into 
two domains separated by a flexible linker; the N-terminal dimerisation domain 
and the C-terminal DNA binding domain (Rimsky, 2004; Tendeng & Bertin, 2003).  
Three dimensional structures for each domain have been solved separately 
(Shindo et al., 1995) (Renzoni et al., 2001) presumably because obtaining the full 
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length protein structure is difficult due to the flexible linker (Dame, 2005).  The 
most recent N-terminal dimerisation domain structure shows this domain in a 
super helical structure with anti-parallel dimerisation and provides an excellent 
model of oligomerisation and DNA compaction by H-NS (Arold et al., 2010).  
Within the conserved sequence residues in the C-terminal domain, a motif 
“X-G-R” is found (situated in the loop) that is involved with DNA binding and the 
arginine residues have subsequently been shown to interact with the minor 
groove of DNA (Figure ‎1.6B)(Gordon et al., 2011; Tendeng & Bertin, 2003).  H-NS 
is able to assemble into groups of oligomers on DNA strands that then interact 
with each other, linking regions of DNA together, with subsequent protein 
polymerisation leading to rod like filament formation (Figure ‎1.4)(Schneider et al., 
2001; Thanbichler et al., 2005). 
H-NS homoloques are widespread in Gram-negative bacteria but not so in Gram-
positive bacteria (Gordon et al., 2010).  A homologue of the H-NS protein in 
M. tuberculosis H37Rv has been identified (Sharadamma et al., 2010) as well as 
other DNA binding proteins such as Hlp (Lee et al., 1998) and MsDps2 
(Saraswathi et al., 2009) during investigations of dormancy, and nutritional 
starvation. 
 
1.9.2 DNA binding and biological function of Lsr2 
Lsr2 was first described as a DNA binding protein in the 2007 study on 
transcriptional regulation of multi-drug tolerance in M. tuberculosis H37Rv 
(Colangeli et al., 2007).  In this study Lsr2 was likened to a histone-like protein as 
it has a small molecular weight and a high isoelectric point, properties that are 
also features of histone-like proteins.  Even though Lsr2 shows no sequence 
homology with proteins in the histone-like protein class, experimental evidence 
showed that it had an ability to bind DNA, forming large oligomers, and could 
inhibit in vitro transcription and topoisomerase activity.  This experimental 
evidence demonstrated that Lsr2 had an ability to interact with DNA and 
suggested that Lsr2 could regulate gene expression by controlling chromosomal 
topology (Colangeli et al., 2007). 
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In other biochemical studies, the interaction of M. tuberculosis H37Rv Lsr2 with 
DNA provided evidence that Lsr2 binds non-specifically to DNA (but with greater 
preference for AT-rich DNA sequences) and forms increasingly larger complexes 
with DNA as DNA length increases.  DNA fragments were designed to test if Lsr2 
preferred curved DNA and could therefore be compared to the H-NS proteins 
and the results show that Lsr2 has no preference for curved or non-curved DNA, 
setting it apart from H-NS (Chen et al., 2008).  In vivo complementation 
experiments in M. smegmatis mc2155 were used to determine the key amino 
acid residues of M. smegmatis mc2155 Lsr2 by examining the ability of mutants 
to restore the colony morphology phenotype of an lsr2 knockout.  Lsr2 mutants 
with the amino acid substitutions D28A, R45A and R86A were unable to restore 
the colony phenotype.  Residues R45 and R86 were noted to be within predicted 
helical regions whereas residue D28 was within a predicted random coil 
(Figure ‎1.5)(Chen et al., 2008).  Further experiments utilising these three mutants 
enabled the authors to conclude that residues D28 and R45 are involved in Lsr2 
dimer formation and residue R86 and its equivalent in M. tuberculosis H37Rv 
(R84) are important for DNA binding (Figure ‎1.5).  Although some of the features 
of Lsr2 noted in this study are unlike the H-NS proteins the authors also provided 
evidence that Lsr2 has DNA bridging ability (as shown by atomic force 
microscopy) which is characteristic of H-NS and they suggested that Lsr2 may 
have its own DNA binding domain, connecting Lsr2 to a role in nucleoid 
compaction and transcription repression (Chen et al., 2008). 
 
 
 
Figure ‎1.5.  Lsr2 protein sequences from M. smegmatis mc
2
 155 and M. tuberculosis H37Rv 
showing predicted secondary structure and residues involved in protein dimerisation and DNA 
binding.  Mutations of the residues aspartate 28 (D28A) and arginine 45 (R45A) in M. smegmatis 
Lsr2 (boxed regions) prevented Lsr2 dimer formation; whereas mutation of the equivalent 
arginine 86 (R86) residue in M. tuberculosis Lsr2 (R84A) (circles) showed reduced DNA binding.  
This image was partially generated in Geneious Pro 5.4.2. (Drummond et al., 2011).  Predicted 
secondary structure elements (http://www.predictprotein.org) for M. tuberculosis are shown as 
blue arrows for β-sheets, pink cylinders for α-helices and grey line for random coil. 
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Direct evidence that Lsr2 is a functional homologue of H-NS was demonstrated 
soon after by researchers from the same lab as Chen and colleagues.  In these 
studies, in vivo complementation experiments showed that the M. tuberculosis 
lsr2 gene was able to complement all the phenotypes related to hns gene 
mutations in E. coli.  Equally, hns from E. coli was able to complement the 
phenotype of an lsr2 mutant in M. smegmatis, demonstrating the functional 
similarity of Lsr2 and H-NS.  In addition to these phenotypic studies, it was 
demonstrated that Lsr2 could bind specifically to H-NS regulated genes in vivo 
suggesting similar transcriptional repression mechanisms between Lsr2 and H-NS, 
and similar global gene regulation functions (Gordon et al., 2008). 
Considering the lack of sequence similarity between Lsr2 and H-NS it is 
remarkable that they share apparently identical functions.  Especially considering 
that there is an H-NS homologue in M. tuberculosis H37Rv.  These two proteins 
also lack any similarity in their predicted secondary structures, however they 
may share similar domain organisation.  All H-NS proteins are predicted to be 
organised into two functional domains, the N-terminal oligomerisation domain 
and the C-terminal DNA binding domain, separated by a flexible linker (Bertin et 
al., 1999).  More specifically, residues 1 - 83 make up the N-terminal domain and 
residues 91 - 137 make up the C-terminal domain of H-NS (Arold et al., 2010).  
Recently, the three dimensional structure of the C-terminal DNA binding domain 
of Lsr2 was determined (Gordon et al., 2010) indicating that the N-terminal 
dimerisation domain of Lsr2 is between residues 1-65 and the C-terminal DNA 
binding domain is within residues 51-112.  This also confirmed the domain 
similarities between Lsr2 and H-NS. 
The structure of the C-terminal DNA binding domain of Lsr2 from M. tuberculosis 
H37Rv was solved using nuclear magnetic resonance techniques (Figure ‎1.6A).  
The structure of this domain highlights the specific residues that may be involved 
in interacting with DNA and shows that there is functional similarity to H-NS but 
no structural similarity (Gordon et al., 2010).  The DNA binding domain contains 
two α-helices (α1, residues 79-89; α2, residues 102-112) linked by a long loop 
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(residues 90-101).  This structure is unlike that of H-NS which has two short 
β-sheets and an α-helix linked by a loop (Figure ‎1.6B)(Shindo et al., 1995).   
 
 
Figure ‎1.6.  The C-terminal DNA binding domains of Lsr2 and H-NS are structurally distinct.  A 
cartoon representation of the structure solutions of the Lsr2 (A) DNA binding domain containing 
two α-helices linked by a long loop (PDB; 2KNG) and the H-NS (B) DNA binding domain has two 
short β-sheets linked to an α-helix (PDB; 1HNR).  The arginine residues R84, R97 and R99, 
responsible for DNA interactions in Lsr2 are depicted as sticks.  The arrow indicates the loop in 
H-NS thought to interact with DNA.  The chain termini, α-helices and β-sheets are labelled and 
protein depictions were rendered with PYMOL. 
 
A structure model generated to depict Lsr2 in complex with DNA revealed that 
the C-terminal domain of Lsr2 can bind DNA in two different orientations by 
grabbing either edge of the minor groove of DNA much like a clamp, orientating 
and inserting residues R97, G98 and R99 into the minor groove.  Outside of the 
minor groove, a number of arginine (e.g. R84) and serine residues interact with 
the phosphate backbone on either edge of the minor groove, increasing the 
binding affinity of Lsr2 to DNA (Gordon et al., 2010).  The mechanism of DNA 
recognition by the residues R97-G98-R99 – as a result of their positive charge 
and extended loop conformation - was shown to be unique in these studies.  In a 
multiple sequence alignment of the Lsr2 family it is clear that residue R84, in 
addition to the R97-G98-R99 motif, are highly conserved (Figure ‎1.3) indicating 
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their significance in the mechanism of DNA binding.  Even though the solution 
structures of the C-terminal domains of Lsr2 and H-NS are so different there is 
strong evidence for their functional similarity as shown with protein domain 
swapping experiments where the N-terminal and C-terminal domains of each 
protein were interchanged and complete Lsr2 and H-NS protein function was still 
demonstrated (Gordon et al., 2010). 
H-NS is a regulator of transcription, controlling the expression of a larger number 
of genes involved in virulence (Lucchini et al., 2006).  There are a large number of 
bacterial nucleoid associated proteins (such as histone-like proteins) that are all 
involved in the regulation of transcription and evidence now suggests that Lsr2 
from M. tuberculosis H37Rv also belongs to this group.  Microarray studies show 
that Lsr2 regulates genes involved in M. smegmatis mc2155 metabolism 
(Colangeli et al., 2007) and that Lsr2 is up-regulated at high temperatures 
(Stewart et al., 2002) and after nutrient starvation (Betts et al., 2002), 
highlighting its importance in global gene regulation and bacterial response to 
environmental changes.  To date, the generation of an M. tuberculosis H37Rv lsr2 
knockout has been unsuccessful, suggesting that Lsr2 is an essential gene in 
M. tuberculosis H37Rv (Sassetti et al., 2003) and is worthy of continued 
investigation into its role and function in mycobacteria. 
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1.9.3 PhD study objectives 
Lsr2 is encoded by an essential gene in M. tuberculosis and is an important DNA 
binding protein found in M. tuberculosis and other mycobacteria (Sassetti et al., 
2003).  This protein has been shown to be involved in a number of critical 
biological functions including chromosome organisation and gene regulation 
(Colangeli et al., 2007).  The structural organisation of this protein is able to tell 
us a number of things about its potential biological roles. 
Proteins are commonly made up of domains that perform specific functions. 
Biochemical studies have illustrated that Lsr2 comprises an N-terminal 
dimerisation domain and a C-terminal DNA binding domain and is capable of 
functioning in a similar manner to other histone-like DNA binding proteins (Chen 
et al., 2008). 
The aims of this research were to determine how Lsr2 interacts with and binds to 
DNA, and how higher order Lsr2/DNA structures were formed.  The 3D structure 
of Lsr2 was of great interest as it may reveal critical functional information.   
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2 Chapter Two - Materials & Methods 
 
2.1 General materials and methods 
2.1.1 Primer design, supplier and reconstitution 
Primers for restriction digest and ligation cloning were designed to have 5’ and 3’ 
restriction enzyme sites with an additional number of bases (depending on the 
enzyme used) at each end to allow for efficient cleavage.  Primers designed for 
site directed mutagenesis, amplification of plasmid inserts or plasmid sequencing 
did not contain flanking restriction enzyme sites or additional bases.  All primers 
were designed and analysed using either VectorNTI (Invitrogen) or Geneious Pro 
(BioMatters Ltd, NZ) to check for primer dimer or hairpin formation.  Primers 
were supplied by Invitrogen (USA), Sigma Aldrich (USA) or IDT (USA).  Primers 
were supplied purified with standard desalting techniques and were 
reconstituted in MQ H2O to a concentration of 100 μM with working stock 
concentrations prepared at 10 μM in MQ H2O. 
 
2.1.2 Polymerase chain reaction (PCR) 
Taq DNA polymerase (Invitrogen) was used to PCR amplify inserts for ligation and 
genes for diagnostic purposes.  PCR annealing temperature and magnesium 
concentration was optimised for each primer set using a temperature gradient 
designed around the calculated Tm and a selection of MgCl2 concentrations 
between 0.5 mM and 1.5 mM.  In the event of the amplification of non-specific 
DNA products, the products of expected size were excised from an agarose gel 
and purified. 
PCR reactions were carried out in 25 μl volumes using the following 
concentrations and reaction conditions.  1 X PCR buffer, 0.2 mM deoxynucleotide 
mix (dATP, dCTP, dGTP and dTTP), 1.5 mM MgCl2 (unless mentioned otherwise), 
1.25 U Taq DNA polymerase, 0.6 μM each primer and 60 - 200 ng template DNA.  
The amount of template DNA from transformant colonies for PCR reactions was 
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unknown but was performed using 1 μl of a colony suspension which was made 
by re-suspending a pipette tip-full of cells in 10 μl of MQ H2O.  Colony PCR was 
performed as above but with either 1.0 or 1.5 mM MgCl2. 
 
Cycle conditions:  94°C  2:45   (min:sec) 
94°C  0:15 
X 29 Tm* 0:30 
72°C 0:45** 
72°C 7:00 
4°C HOLD 
 
*Tm determined by gradient PCR 
** Elongation time dependent of the insert size (1 kb = 1 minute) 
 
2.1.3 Purification of PCR products and restriction enzyme digests 
PCR products for restriction digest and ligation reactions were purified using the 
QIAquick® PCR purification Kit (if purified from solution) or QIAquick® Gel 
Extraction Kit (if purified after gel electrophoresis) (Qiagene, Netherlands), 
according to the manufacturer’s instructions.  Restriction enzyme digested PCR 
products and plasmids were purified using the QIAquick® PCR purification Kit.  
PCR products for gel excision were separated by electrophoresis with 1 x TAE, in 
a 1% agarose gel, stained with SYBR Safe™ DNA dye (Invitrogen) and excised with 
a clean scalpel blade under blue light (Invitrogen).  DNA was eluted in 30 – 50 μl 
of elution buffer depending on preferred final concentration. 
 
2.1.4 Agarose gel electrophoresis 
DNA was separated via agarose gel electrophoresis for visualisation.  All samples 
were separated on a 1% agarose gel in 1 x TAE buffer unless specified otherwise.  
Samples were mixed with 10 x DNA loading dye prior to loading onto the gel.  
Gels were either stained post-electrophoresis with 0.5 μg/ml ethidium bromide 
in 1 x TAE or in-gel with 1 x SYBR Safe™ DNA dye (Invitrogen) and visualised by 
UV light on a UV transilluminator.  Alternatively, SYBR Safe™ stained gels were 
visualised on a blue light box (Invitrogen) if the DNA bands were to be excised.  
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The DNA size marker 1kb Plus DNA ladder (Invitrogen) was run on each agarose 
gel to determine DNA fragment size. 
 
2.1.5 DNA quantification 
DNA was quantified using a Nanodrop ND-1000 spectrophotometer (Nanodrop 
Technologies, USA).  This measures the absorbance of DNA at 260 nm. 
 
2.1.6 Restriction enzyme digestion and ligation of DNA 
Restriction enzymes were purchased from Invitrogen (USA) or Roche Applied 
Science (Switzerland).  Restriction enzyme digestion of DNA was performed in a 
final volume of 100 μl using the appropriate reaction buffer as recommended by 
the manufacturer, at 37°C for approximately 2 hours.  The reaction was 
performed with 20 – 30 U of each enzyme and a maximum of 2000 ng of DNA.  
For digestion reactions with two enzymes, an appropriate buffer that would give 
the maximum dual enzyme activity was chosen.  Digested DNA was purified from 
solution using the QIAquick® PCR purification Kit (Qiagen, Netherlands) according 
to manufacturer’s instructions and eluted in 30 - 50 μl of elution buffer 
depending on preferred final concentration. 
DNA ligation reactions were performed in a final volume of 10 μl using T4 DNA 
ligase (Invitrogen), at 4°C overnight or 6 hours at room temperature.  Reactions 
were performed using 0.5 U of T4 DNA ligase, 100 ng of plasmid and with a 
2 - 5 M mass ratio of excess insert DNA to plasmid DNA, in 1 x T4 ligase buffer.  
 
2.1.7 Plasmid DNA amplification and purification 
Plasmid DNA was amplified by transformation into electrocompetent E. coli, 
subsequent growth and DNA purification.  DH5α or TOP10 E. coli were 
transformed with the plasmid of interest, plated onto selective LB and low salt LB 
agar, respectively, and grown overnight at 37°C.  Small volume (5 ml) cultures 
from single colonies were then grown overnight in selective LB or low salt LB 
media for DH5α E. coli and TOP10 E. coli respectively.  Plasmid DNA was 
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extracted from the overnight cultures using the QIAprep Spin Miniprep Kit 
(Qiagen, Netherlands) according to manufacturer’s instructions and eluted in 
30 - 50 μl of elution buffer depending on preferred final concentration. 
 
2.1.8 Plasmid DNA sequencing 
Purified plasmid DNA preparations were sequenced for verification of cloned 
genes inserted and any sequence modifications engineered.  Samples were sent 
to The University of Waikato DNA Sequencing Facility (Hamilton, NZ) along with 
appropriate primers that flanked the ends of the inserted gene or the ends of the 
multiple cloning sites of the plasmid of interest.  Sequence results were analysed 
using either VectorNTI (Invitrogen) or Geneious Pro (BioMatters Ltd, NZ) to check 
for correct in-frame insertion of the gene and engineered modifications. 
 
2.1.9 Preparation of electrocompetent E. coli and M. smegmatis 
2.1.9.1 Preparation of electrocompetent E. coli 
A glycerol stock of the appropriate strain of E. coli was freshly streaked out on an 
LB agar plate and grown overnight at 37°C.  A single colony was used to start a 10 
ml LB overnight seeder culture grown shaking at 180 rpm at 37°C.  The overnight 
culture was used to seed a 1 L LB culture which was grown shaking at 180 rpm at 
37°C to an OD600 of 0.5 – 0.7.  The cells were chilled on ice for at least 30 minutes 
before centrifugation at 4°C for 15 minutes at 4000 g in chilled sterile bottles.  
After discarding the supernatant, the cells were gently resuspended in 1 L of ice 
cold sterile 10% glycerol and centrifuged again at 4°C for 15 minutes at 4000 g.  
The supernatant was discarded and the cells gently resuspended in 500 ml of ice 
cold sterile 10% glycerol and centrifuged again at 4°C for 15 minutes at 4000 g.  
The supernatant was discarded and the cells resuspended in 20 ml of ice cold 
sterile 10% glycerol and transferred to a chilled sterile 50 ml centrifuge tube and 
centrifuged again at 4°C for 15 minutes at 4000 g.  The supernatant was 
discarded and the cells resuspended in 2 to 3 ml of ice cold sterile 10% glycerol, 
using the smaller volume if the OD600 of the 1 L culture was 0.5 and using the 
larger volume if the OD600 of the 1 L culture was 0.7.  A 500 ml culture may also 
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be used for preparation of competent cells and the volume of 10% glycerol 
halved at each step.  Aliquots of cells of 50 μl in small tubes were flash frozen in 
liquid nitrogen and stored at -80°C. 
 
2.1.9.2 Preparation of electrocompetent M. smegmatis 
A glycerol stock of the appropriate strain of M. smegmatis was freshly streaked 
out on a LBT agar plate and incubated for three days at 37°C.  A single colony was 
used to start a 2 ml LBT overnight seeder culture grown shaking at 180 rpm at 
37°C.  One ml of the overnight culture was used to seed a 100 ml 7H9/ADC/T 
culture which was grown shaking at 200 rpm at 37°C to an OD600 of around 0.7.  
The cells were chilled on ice for 1.5 hours before centrifugation at 4°C for 20 
minutes at 4000 g in chilled sterile bottles.  After immediately discarding the 
supernatant to prevent cell pellet dispersal, the cells were gently resuspended in 
100 ml of ice cold sterile 10% glycerol and centrifuged again at 4°C for 20 
minutes at 4000 g.  The supernatant was mostly discarded but a little was left to 
resuspend the cells in so they could be transferred to smaller centrifuge tubes, 
and they were centrifuged again at 4°C for 20 minutes at 4000 g.  The 
supernatant was discarded and the cells resuspended in approximately 0.20 ml 
of ice cold sterile 10% glycerol and 40 μl aliquots put into small tubes, flash 
frozen in liquid nitrogen and stored at -80°C. 
 
2.1.10 DNA transformation for amplification and expression 
2.1.10.1 Electroporation of Escherichia coli 
All components were kept on ice prior to electroporation.  One or two μl of 
plasmid DNA or ligation reaction was added to a freshly thawed 50 μl glycerol 
stock of DH5α, TOP10, BL21 or DL41 electrocompetent E. coli as appropriate.  
The mixture was placed into a 0.2 cm electroporation cuvette (Biorad 
Laboratories, USA), the bottom tapped on a surface to settle the mixture 
between the electrodes and electroporated with a BioRad Gene Pulser™ (BioRad 
Laboratories, USA) at 2.5 KV, 25 μF capacitance and 200 Ω resistance.  One ml of 
SOC media was immediately added to the electroporated cells, the cells 
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transferred to a 1.5 ml tube and incubated while shaking at 180 rpm at 37°C for 
1 hour.  Two different sized aliquots (e.g. 50 μl and 100 μl) were spread onto 
selective LB agar plates or selective low salt LB agar plates as appropriate and 
grown overnight at 37°C.  Resulting colonies were either used to start 5 ml 
cultures for plasmid DNA amplification (section ‎2.1.7), or 20 ml seeder cultures 
for protein expression, or used for colony PCR to confirm successful ligation 
reactions (section ‎2.1.2).  Cultures were incubated overnight at 37°C (180 rpm) 
using selective LB, low salt LB or TB media as appropriate. 
 
2.1.10.2 Electroporation of Mycobacterium smegmatis 
Electroporation of M. smegmatis requires adjustment of transformation 
resistance, alternative media and increased incubation time.  All components 
were kept on ice prior to electroporation.  One μl of plasmid DNA and 260 μl of 
10% glycerol were added to a freshly thawed 40 μl glycerol stock of 
electrocompetent mc2155 lab strain or lsr2 knock out mc2155 lab strain 
M. smegmatis as appropriate.  The mixture was placed into a 0.2 cm 
electroporation cuvette (Biorad Laboratories, USA), the bottom tapped on a 
surface to settle the mixture between the electrodes and electroporated with a 
BioRad Gene Pulser™ (BioRad Laboratories, USA) at 2.5 KV, 25 μF capacitance 
and 1000 Ω resistance.  One ml of 7H9/ADC/T media was immediately added to 
the electroporated cells, the cells transferred to a 1.5 ml tube and incubated 
while shaking at 180 rpm at 37°C for 3 hours.  Two different sized aliquots (e.g. 
50 μl and 100 μl) were spread onto selective 7H10/ADC/T agar plates or selective 
LBT agar plates and grown for 3 days at 37°C. 
 
2.1.11 Glycerol stock preparation for bacterial strain storage 
Glycerol stocks for long term storage of expression strains, laboratory strains and 
transformed strains were made by combining 0.5 ml of fresh culture with 0.5 ml 
of sterile 50% glycerol, mixing and placing at -80°C.  A fresh culture represented 
an overnight culture in selective LB or low salt LB media for E. coli strains or a 
3 day culture in selective 7H9/ADC/T or LBT media for M. smegmatis strains. 
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2.1.12 Small scale protein expression of His tagged proteins and Ni 
Sepharose™ bead assay 
A single colony of the appropriate transformed E. coli strain grown on a selective 
LB agar plate was used for a 3 ml selective LB culture grown at 37°C overnight 
whilst shaking at 180 rpm.  This culture was used to inoculate 3.5 ml of fresh 
selective LB at a 1:10 dilution ratio.  After growth (whilst shaking) for 1 hour at 
37°C, a 0.75 ml sample of the culture was taken as an uninduced control and the 
remainder induced with IPTG at a final concentration of 0.5 mM and growth 
continued at 37°C for 3 to 4 hours.  A sample of 0.75 ml for whole cell analysis 
and a sample of 1.5 ml for cell lysis and Ni sepharose™ bead assay were taken.  
All samples were centrifuged immediately after collection for 2 minutes at 
13,000 rpm to pellet the cells.  The supernatant was discarded and the cells 
resuspended in 0.1 ml and 0.2 ml 50 mM phosphate (pH 7.4), 200 mM NaCl, 20 
mM imidazole buffer, for 0.75 ml and 1.5 ml samples respectively.  A 10 to 20 μl 
aliquot of the uninduced control and whole cell samples were mixed with an 
equivalent amount of 4 x SDS loading dye.   The resuspended 1.5 ml sample was 
lysed on ice using a sonicator® ultrasonic processor XL fitted with a microtip 
probe at level 3 for 3 x 30 seconds (Misonix Incorporated, USA).  After sonication 
the sample was centrifuged for 2 minutes at 13,000 rpm to pellet the cell debris.  
The supernatant was removed for use in the Ni Sepharose™ bead assay whilst 
the cell pellet was resuspended in 0.2 ml of phosphate buffer, and a 10 to 20 μl 
aliquot was mixed 1:1 with 4 x SDS loading dye.  The supernatant was mixed with 
20 μl of washed Ni sepharose™ high performance beads (GE Healthcare, Sweden) 
and incubated at room temperature for 20 minutes with periodic mixing.  Beads 
were pre-washed with 1 ml of phosphate buffer.  The supernatant was removed 
and a 20 μl aliquot mixed 1:1 with 4 x SDS loading dye.  The beads were then 
washed three times with phosphate buffer and each time a 20 μl aliquot was 
mixed 1:1 with 4 x SDS loading dye.  The remaining Ni Sepharose™ beads were 
mixed with 20 μl of 4 x SDS loading dye.  All samples mixed with loading dye 
were heated at 95°C for 5 minutes before analysis by SDS-PAGE using an 
appropriate percentage acrylamide gel. 
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2.1.13 Large scale expression of his tagged proteins and immobilised 
metal affinity chromatography (IMAC) fast protein liquid 
chromatography (FPLC) 
A single colony of the appropriate transformed E. coli strain grown on a selective 
LB agar plate was used for a 20 ml selective LB culture grown at 37°C overnight 
whilst shaking at 180 rpm.  This culture was used to inoculate 1 L of fresh pre-
warmed selective LB or TB and was then grown at 37°C, shaking at 180 rpm until 
it reached an OD600 of 0.4 – 0.6.  Protein expression was induced by adding IPTG 
to a final concentration of 0.5 – 1.0 mM and growth was continued at 37°C for 
3 – 4 hours or 30°C overnight while shaking at 180 rpm.  The culture was pelleted 
by centrifugation at 6000 rpm for 20 minutes at 4°C, and resuspended in 
30 - 40 ml 50 mM phosphate (pH 7.4), 200 mM NaCl, 20 mM imidazole lysis 
buffer, and a Complete Mini EDTA-free protease inhibitor cocktail tablet added 
(Roche Diagnostics, USA) prior to cell lysis.  Cells were lysed on ice using a 
sonicator® ultrasonic processor XL fitted with a flat probe at level 8 for 4 x 30 
seconds (Misonix Incorporated, USA).  After sonication the sample was 
centrifuged for 20 minutes at 13,000 rpm at 4°C to pellet the cell debris.  The 
supernatant was filtered through 1.2 μm and 0.45 μm Minisart syringe filters 
(Sartorius AG, Germany) prior to protein purification via IMAC. 
A 5 ml HiTrap™ Chelating HP column (GE Healthcare, Sweden) was prepared by 
washing with 20 ml MQ H2O, priming with 10 ml of 100 mM NiCl2, and 
equilibrating with 20 ml of 50 mM phosphate (pH 7.4), 200 mM NaCl, 20 mM 
imidazole lysis buffer.  The filtered supernatant was then loaded onto the 
prepared column using a syringe and the column was attached to either an ÄKTA 
Prime™ or ÄKTA Basic™ FPLC system which monitors protein elution by 
absorbance at 280 nm.  The FPLC system was washed with MQ H2O and lines A 
and B equilibrated in lysis buffer and elution buffer respectively prior to column 
attachment.  Unless noted otherwise, the elution buffer consisted of 50 mM 
phosphate (pH 7.4), 200 mM NaCl, 1 M imidazole.  At a flow rate of 1 ml/min, the 
column was washed with 15 ml of lysis buffer to remove unbound proteins and 
then bound proteins were eluted by running a gradient of 0 - 100% elution buffer 
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over 60 minutes.  Fractions containing protein of interest were analysed by SDS-
PAGE.  After each use, the chelating column was stripped of Ni2+ ions using 10 ml 
of 100 mM EDTA (pH 8.0), washed with 20 ml of MQ H2O and rinsed with 10 ml 
of 20% ethanol for storage at 4°C. 
 
2.1.14 SDS polyacrylamide gel electrophoresis (SDS-PAGE) and native 
polyacrylamide gel electrophoresis of protein samples 
Polyacrylamide gels were cast in a Hoefer® multiple gel casting system SE275 
(Hoefer® Inc, USA).  SDS-PAGE gels consisted of a pH 8.8, 15%, 16.5% or 18% 
resolving gel overlaid with a pH 6.8, 5% acrylamide stacking gel.  Proteins of 
15 kDa or larger were resolved on a 15% gel whereas proteins of approximately 
11 kDa or smaller were resolved on a 16.5% or 18% gels.  SDS-PAGE gels were 
made with 30% acrylamide/bis solution 37.5:1 (BioRad Laboratories, USA), and 
included 0.1% (w/v) SDS, 375 mM Tris (pH 8.8) in the resolving gel or 128 mM 
Tris (pH 6.8) in the stacking gel, and were polymerised by the addition of 0.05% 
(w/v) ammonium persulphate and 0.05% (v/v) TEMED.  Native PAGE gels 
consisted of a pH 8.8, 10% resolving gel overlaid with a pH 6.8, 5% stacking gel.  
Native PAGE gels were made as above but omitting the SDS.  Samples for native 
PAGE analysis were separated using a 5 x native loading dye and a TG running 
buffer, whereas samples for SDS-PAGE analysis were separated using a 4 x SDS 
loading dye and TG-SDS running buffer. 
Protein samples were mixed at a 3:1 ratio with 4 x SDS or at a 4:1 ratio with 5 x 
native loading buffers for denaturing or native gel electrophoresis, respectively, 
and samples for denaturation were heated to 95°C for 5 minutes before loading 
onto gels.  A Precision Plus Protein™ Unstained Standard (BioRad Laboratories, 
USA) was used as a molecular weight marker.  Gels were run in appropriate 
running buffer at 15 mA until the dye front entered the resolving gel and then at 
20 – 25 mA until the dye front reached the end of the gel. 
Gels were stained using the quick coomassie blue staining method (Wong et al., 
2000).  Gels were microwaved in a box with a loose lid, with approximately 50 ml 
of Fairbanks A stain, for 30 seconds, and then cooled to room temperature while 
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shaking gently.  Gels were then rinsed with tap water and Fairbanks B stain 
applied and the heating and cooling repeated.  This sequence was repeated for 
Fairbanks C and Fairbanks D stains with solution D as the destain.  A rolled up 
tissue was placed in the warmed Fairbanks D solution to assist destaining. 
 
2.1.15 Protein measurement, concentration and dialysis 
Protein was quantified using a Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies, USA).  This measures the absorbance of protein at 280 
nm and calculates the protein concentration using the Beer’s Law equation,        
A = ε с ℓ, where A is the absorbance, ε is the theoretical molar extinction 
coefficient (M-1 cm-1), с is the concentration (M), and ℓ is the pathlength (cm).  
Theoretical molar extinction coefficients were calculated from the amino acid 
sequence using the online ProtParam tool (Gasteiger et al., 2005). 
Protein samples were concentrated using Vivaspin 500, 2 or 20 concentrators 
(GE Healthcare, Sweden) with a 5 kDa molecular weight cut off.  Membranes 
were pre-wet with 1 x TBS, 10 % glycerol and rinsed with protein purification 
buffer prior to adding protein to help prevent protein adherence.  Concentrators 
were centrifuged at speeds recommended by the manufacturer at 4°C routinely 
or at 18°C when protein solubility was noticed to be an issue. 
Large scale protein dialysis was performed using 6 – 8 kDa molecular weight cut 
off Specta Por® dialysis tubing (Spectrum Laboratories, UDA).  The tubing was cut 
to the appropriate length for the protein volume to be dialysed and soaked in 
MQ H2O before the addition of the protein sample, and the ends were sealed 
with dialysis clips.  Dialysis was performed in 1 L of appropriate buffer with 
gentle stirring for several hours at 4°C before the solution was refreshed and 
dialysis continued overnight.  Small scale protein dialysis was performed using 
20 μl or 200 μl dialysis buttons (Hampton Research, USA) and 6 – 8 kDa 
molecular weight cut off Specta Por® dialysis tubing.  The tubing was cut to fit 
the buttons and soaked in MQ H2O before use.  Dialysis was performed in 
20 - 50 ml volumes of appropriate buffer overnight at 4°C or for several hours at 
room temperature with one buffer change each.  
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2.1.16 Analytical and preparative size exclusion chromatography (SEC) 
fast protein liquid chromatography (FPLC) 
Size exclusion chromatography was used to further purify proteins.  Analytical 
SEC was performed using either a Superdex™ 75 10/300 GL (3 – 70 kDa 
separation range) or a Superdex™ 200 10/300 GL column (10  - 600 kDa 
separation range) depending on the size of the protein of interest.  Preparative 
SEC was performed using either a HiLoad™ 16/60 Superdex™ 75 column or a 
HiLoad™ 16/60 Superdex™ 200 column, based on the size of the protein of 
interest.  All columns were supplied by GE Healthcare, Sweden.  Columns were 
used while attached to either an ÄKTA Prime™ or ÄKTA Basic™ FPLC system 
which monitors protein elution by absorbance at 280 nm. 
The FPLC system was washed with MQ H2O prior to column attachment.  
Analytical SEC columns were prepared by washing with 25 ml of 0.2 μm filtered 
MQ H2O and equilibrating with 25 ml of 20 mM  Tris (pH 7.4), 150 mM NaCl, at a 
flow rate of 1 ml/min.  Preparative SEC columns were prepared by washing with 
130 ml of 0.2 μm filtered MQ H2O and equilibrating with 130 ml of 20 mM Tris 
(pH 7.4), 150 mM NaCl, at a flow rate of 0.3 ml/min, as an overnight method.  
After protein separation, SEC columns were washed with filtered MQ H2O and 
rinsed with 20% ethanol with the appropriate volumes and flow rates as 
mentioned above. 
Protein solutions were concentrated to 0.5 ml for analytical SEC and 5 ml for 
preparative SEC, and filtered with a 13 mm Ø, 0.2 μm Acrodisk® syringe filter 
(Pall Lifesciences, USA) before loading onto prepared columns.  Proteins were 
separated with one column volume of buffer at 0.5 ml/min.  Fractions containing 
protein of interest were analysed by SDS-PAGE (section ‎2.1.14).   
Calibration of Superdex™ 200 10/300 GL, Superdex™ 200 16/60 and Superdex™ 
75 10/300 GL SEC columns was performed using the high and low molecular 
weight gel filtration calibration kits (GE Healthcare, Sweden) according to 
manufacturer’s instructions.  Calibration curves were prepared by plotting the 
Kav (elution volume function) of the protein standards against their log 
molecular weight and a linear equation determined.  Kav is calculated with the 
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equation (Ve – Vo/Vc – Vo), where Ve is the elution volume, Vo is the column 
void volume and Vc is the geometric column volume.  Kav values of the protein 
of interest are substituted into the equation to determine the molecular weight 
of the protein.  The equation for Superdex™ 75 10/300 GL was determined in this 
study while the other equations were previously determined. 
 
Table ‎2.1.  Size exclusion chromatography calibration curve molecular weight equations. 
SEC Column Equation Vo (ml) Vc (ml) 
Superdex™ 200 10/300 GL MW = e
((Kav – 1.6833)/ -0.115)
    8.11    24.0 
Superdex™ 75 10/300 GL MW = e
((Kav – 1.6951)/ -0.142)
    8.08    23.6 
HiLoad™ 16/60 Superdex™ 200 MW = e
((Kav – 2.1739)/ -0.159)
   46.26  124.0 
 
 
2.1.17 Transmission electron microscopy (TEM) of protein samples 
Specimens for negative stain electron microscopy were prepared as follows:  5 μl 
of IMAC purified protein sample (various concentrations) was applied to a 300 
mesh copper EM grid (GCU300 ProSciTech, Australia) covered with carbon-film 
supported by plastic that had been rendered hydrophilic by glow discharge.  
Glow discharge was performed under vacuum (1 atm) at 50% apparatus voltage 
for 10 seconds.  After 90 seconds, the sample was blotted from the edge of the 
drop with filter paper (Whatman No 1) and washed 3 times with filtered MQ H2O 
by applying a drop onto the grid and blotting from the edge with filter paper.  
The sample was then stained with 5 μl of 1% uranyl acetate for 45 seconds, 
blotted and restained for 25 seconds, blotted, then air dried.  Low-dose images 
were recorded at nominal magnification of 40,000 at ≈ 1 - 2 μm under focus in 
either a Phillips CM12 or a FEI TecNai G2 electron microscope when higher 
quality images were desired.  Both electron microscopes were equipped with a 
LaB6 filament and operated at 120 kV.  Images with scale bars of 0.2 μm, 0.5 μm 
and 1 μm were captured at 52,000 x, 40,000 x and 11,500 x magnification 
respectively. 
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2.1.18 Protein crystallography 
2.1.18.1 Initial crystallisation screens 
Concentrated protein for crystallisation screens was centrifuged at 13,000 g for 
5 min at 4°C to remove particulates from the solution.  Initial crystallisation 
screens for proteins were set up at the crystallisation facility at The University of 
Auckland using a high-throughput method of 480 conditions developed to 
minimise the protein used (Moreland et al., 2005).  A Multiprobe® II HTEx robot 
(PerkinElmer, USA) was used to dispense 75 μl of each condition into wells of a 
96-well Intelli-plate (Art Robbins Instruments, USA), then a Cartesian honey bee 
liquid handler (Cartesian™ Dispensing system, USA) dispensed 100 nl of protein 
with 100 nl of precipitant solution into sitting drops in the 96-well Intelli-plates.  
Plates were sealed with ClearSeal film™ (Hampton Research, USA) and left at 
18°C on shock-resistant shelves. 
At a later time during this study, a liquid handling robot was obtained at the 
Proteins and Microbes research group at The University of Waikato.  Subsequent 
crystallisation trials using Hampton crystallisation screens totalling 384 
conditions (HR2-086, HR2-130, HR2-136, HR2-144; Hampton Research, USA) 
were used.  One hundred μl of each crystallisation condition was dispensed by 
multi-channel pipette into 96-well Intelli-plates and a mosquito® crystal robot 
(TTP LabTech, Ltd, UK) was used to dispense 100 nl of protein with 100 nl of 
precipitant solution into sitting drops in the 96-well Intelli-plates and the plates 
were sealed with ClearSeal film™, and left at 18°C on shock-resistant shelves. 
 
2.1.18.2 Fine screening and additive screening for the optimisation of 
crystallisation conditions 
Promising crystallisation conditions revealed by initial crystallisation screens 
were optimised by modifying the pH, crystallisation component concentrations 
or the addition of specific selected components.  All trials were carried out in 
24-well VDX crystallisation plates (HR3-140; Hampton Research, USA) at 18°C, on 
shock-resistant shelves.   
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A hanging drop method was most commonly used for fine screening of 
crystallisation conditions.  The top of the wells were greased using glisseal®N 
grease (Borer chemie, Switzerland) and 500 μl of each condition was pipetted 
into each well.  On the surface of a 22 mm square siliconised coverslip (Hampton 
Research, USA) 1 -2 μl of protein was added to an equal amount of precipitant 
solution and the coverslip inverted and placed onto the top of the greased well.  
At times, an unequal amount of protein to precipitant solution was combined to 
alter crystallisation conditions. 
Additive screens based on the most promising condition with the addition of 
selected components were performed using the hanging drop method above.  
Component selection was based on the reagent formulation details in a 
Hampton Additive Screen (HR2-428; Hampton Research, USA) and reagents were 
added at the suggested drop concentrations (Table ‎2.2).   
 
Table ‎2.2.  Reagents used in additive screening for the optimisation of crystallisation conditions. 
Reagent Drop Concentration Reagent Drop Concentration 
ATP.Na2 10 mM KNaTartrate4H2O 100 mM 
CaCl2 10 mM LiCl2 100 mM 
CoCl2 10 mM (NH4)2SO4 100 mM 
CuCl2 10 mM Acetonitrile 4.0% (v/v) 
EDTA (pH 7.6) 10 mM Butantol-1 0.7% (v/v) 
Ni(II)Cl26H20 10 mM Ethanol 3.0% (v/v) 
Nicotinamide ADP 10 mM Glycerol 3.0% (v/v) 
MgCl2 10 mM D-glucose 3.0% (w/v) 
L-proline 10 mM Isopropyl alcohol 3.0% (v/v) 
Spermidine 10 mM Methanol 3.0% (v/v) 
ZnCl2 10 mM Methyl pentanediol 3.0% (v/v) 
CsCl2 100 mM PEG 400 5.0% (w/v) 
Glycine 100 mM Sucrose 3.0% (w/v) 
KCl2 100 mM   
 
Sitting drop methods and streak seeding was also used with individual promising 
crystallisation conditions.  For sitting drop preparation, the top of the wells of 
24-well VDX crystallisation plates were greased using glisseal®N grease and 
500 μl of each condition was pipetted into each well.  A sitting drop was 
generated by pipetting 1 – 2 μl of protein and an equal amount of precipitant 
solution into a MicroBridge reservoir (Hampton Research, USA).  The well was 
 Chapter Two - Materials & Methods 43 
sealed by placing a 22 mm siliconised glass coverslip onto the greased top.  In 
preparation for streak seeding, fine screen conditions were set up using the 
hanging drop method and the drops allowed to equilibrate for 2 -3 hours.  The 
technique for streak seeding involved brushing a cleaned cat’s whisker against an 
existing crystal to pick up small crystal fragments and then lightly running it 
through an equilibrated drop.  This was repeated for each drop.   
 
2.1.18.3 Crystal freezing for data collection 
A cryoprotectant reagent was added to a replicated sample of the crystallisation 
condition, for the preparation of crystal freezing if required.  In this study, 
glycerol was routinely used unless the crystallisation condition already contained 
an appropriate concentration of PEG suitable to use as a cryoprotectant.  For 
data collection at The University of Auckland home source, cryoprotectants were 
able to be tested to assess for ice formation prior to freezing the crystals.  The 
crystallisation condition containing the cryoprotectant was tested by sampling it 
with a CryoLoop™ (Hampton Research, USA), flash freezing it in liquid nitrogen 
and mounting it for X-ray testing.  The resulting X-ray diffraction pattern was 
examined for ice ring diffraction and the lowest concentration cryoprotectant 
that did not result in ice rings was selected for crystal freezing.  For data 
collection at the Australian Synchrotron, crystals were frozen without testing 
cryoprotectants due to logistical constraints.  To minimise the chance of ice 
formation, slightly higher cryoprotectant concentrations were used during crystal 
freezing unless previous conditions had been determined during testing at the 
home source.   
2.1.18.4 Crystal testing and X-ray diffraction data collection 
Crystals were transferred to the precipitant solution containing cryoprotectant 
using a CryoLoop™ and magnetic CrystalWand™ then immersed in liquid 
nitrogen inside a thick walled cryogenic vial (Hampton Research, USA) for home 
source data collection, or immersed in liquid nitrogen inside a SSRL automated 
mounting cassette (Crystal Positioning Systems, USA) for data collection at the 
Australian Synchrotron. 
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Home source data collection was performed at the School of Biological Sciences 
at The University of Auckland.  X-rays were generated using CuKα radiation 
(λ = 1.5418 Å) from a rotating copper anode MicroMax™-007HF generator 
(Rigaku, Japan) and reflections were detected using a Mar345 detector (Mar 
Research GmbH, Germany).  The loops were mounted on a MAR234dtb 
goniometer using an automated system (Mar Research GmbH, Germany) and 
kept cold with a stream of liquid nitrogen from a Cobra cryosystem (Oxford 
Cryosystems, UK).  Prior to data collection, the MOSFLM’s strategy function was 
used with 2 images 90° apart, to aid in data collection. 
Synchrotron data collection was performed at the Australian Synchrotron, 
Melbourne, Australia using the MX1 or MX2 beamline.  Reflections were 
measured using an ADSC Quantum 210r detector (Area Detector Systems 
Corporation, USA) with radiation at a wavelength of 0.9786 Å.  Prior to data 
collection, the MOSFLM’s strategy function was used with 2 images 90° apart, to 
aid in data collection. 
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2.2 Methods for Chapter Three:  Lsr2 expression, 
purification & characterisation 
2.2.1 Cloning of Lsr2 into pET30b 
This expression vector was kindly supplied by Roberto Colangeli (Colangeli et al., 
2007) at the Division of Infectious Disease and the Center for Emerging 
Pathogens, Department of Medicine, New Jersey Medical School, University of 
Medicine and Dentistry of New Jersey, New Jersey.  The lsr2 gene (Rv3597c) was 
amplified by PCR from genomic DNA from M. tuberculosis and cloned into 
pET30b (Novagen) using the NdeI/XhoI restriction sites, positioning a 6 x histidine 
tag at the C-terminal end of the protein.  The plasmid was transformed into BL21 
E. coli for expression. 
 
Table ‎2.3.  Primers used for cloning M. tuberculosis H37Rv lsr2 into pET30b 
Primer Sequence Length 
pET30-lsr2F TTC CGA GCC GGT CCA CAT GAG A 22 bp 
pET30-lsr2R CTC GCT TAT GGA TTA CAT CCT GAG 24 bp 
 
 
2.2.2 Cloning of Lsr2 into pMAL-c2x 
The lsr2 gene was cloned into the maltose binding protein fusion tag E. coli 
expression vector pMAL-c2x (New England Biolabs, USA) as follows.  Lsr2 was 
amplified from the lsr2-pET30b vector via PCR using forward and reverse primers 
containing the restriction enzyme sites XbaI and PstI, respectively. 
 
Table ‎2.4.  Primers used for cloning M. tuberculosis H37Rv lsr2 into pMAL-c2x. 
Primer Sequence Length 
Rv3597c_Xba1_Fwd GCT CTA GAA TGG CGA AGA AAG TAA CCG TC 29 bp 
Rv3597c_Pst1_Rev AAC TGC AGT CAG GTC GCC GCG 21 bp 
 
Standard Taq DNA polymerase PCR was performed at 52°C annealing 
temperature and 1.0 mM MgCl2 concentration after optimisation of annealing 
 Chapter Two - Materials & Methods 46 
temperature and magnesium concentration.  Gel extraction of a combined 8-fold 
PCR reaction size was performed and the DNA product quantified.  The PCR 
product was inserted into pMAL-c2x via appropriate enzyme digestion and 
ligation, transformed into DH5α for plasmid preparation for sequence 
verification and then transformed by electroporation into BL21 E. coli for 
expression. 
 
2.2.3 Large scale expression and purification of His tagged Lsr2 
Large scale expression was performed using standard techniques but with the 
inclusion of a DNase digestion step and with an elution buffer consisting of 
50 mM phosphate (pH 7.4), 200 mM NaCl, 500 mM imidazole.  After cell lysis, 
200 μl of DNase1 (1 mg/ml; Sigma, USA) was added to the lysate and incubated 
at 4°C for approximately 2 hours (while gently shaking) before centrifuging for 
immobilised metal affinity chromatography (IMAC) purification.  Fractions 
containing protein of interest were prepared appropriately and analysed by 1% 
agarose gel electrophoresis and 15% SDS-PAGE. 
Size exclusion chromatography (SEC) of Lsr2 was performed using a HiLoad™ 
16/60 Superdex™ 200 column according to standard techniques but in a high salt 
buffer to dissociate the co-purified E. coli genomic DNA.  The buffer included 
50 mM phosphate (pH7.4), 2 M NaCl, for protein characterisation studies or 
20 mM Tris (pH 7.4), 2 M NaCl, when the protein was required for crystallisation 
studies.  Phosphate purified protein was subsequently concentrated and dialysed 
into 20 mM Tris (pH 7.4), 150 mM NaCl buffer if required for crystallisation 
studies.  Fractions of interest were prepared for analysis by 1% agarose gel 
electrophoresis and 15% SDS-PAGE. 
 
2.2.4 Small scale expression and purification of MBP tagged Lsr2 
A 3 ml overnight culture of lsr2-pMAL-c2X in BL21 E. coli in selective rich media + 
glucose was grown at 37°C, at 180 rpm.  This culture was used to inoculate 4 ml 
of fresh selective rich media + glucose at a 1:10 dilution ratio.  After growth 
(whilst shaking) for 1 hour at 37°C, a 1 ml sample of the culture was taken as an 
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uninduced control and the remainder induced with IPTG at a final concentration 
of 0.3 mM.  Growth was continued at 37°C for 3 hours with 1 ml samples for 
whole cell analysis taken at 1, 2, and 3 hour time points.  The remaining 2.5 ml 
was pelleted by centrifugation and resuspended in 0.5 ml of column buffer 
(20 mM Tris (pH 7.5), 200 mM NaCl, 1 mM EDTA) for cell lysis using sonication.  
Sonication was performed on ice using a sonicator® ultrasonic processor XL fitted 
with a microtip probe at level 3 for 3 x 30 seconds (Misonix Incorporated, USA).  
The sample was centrifuged for 5 minutes at 13,000 rpm to pellet the debris and 
15 μl of the supernatant was added to 5 μl of 4 x SDS loading dye whilst the cell 
pellet was resuspended in 0.5 ml of column buffer, and a 10 μl aliquot mixed 1:1 
with 4 x SDS loading dye.  The remaining supernatant was mixed with 40 μl of 
washed amylose resin (NEB, USA) and incubated for 15 minutes in ice with 
periodic mixing.  Resin was washed with 1 ml of binding buffer prior to use.  The 
supernatant was removed and a 15 μl aliquot mixed with 5 μl 4 x SDS loading dye.  
The resin was washed once with column buffer and 15 μl of the wash solution 
mixed with 5 μl 4 x SDS loading dye.  The resin was mixed with 20 μl of 4 x SDS 
loading dye.  All samples mixed with loading dye were heated at 95°C for 5 
minutes before analysis on a 15% SDS-PAGE gel. 
 
2.2.5 Large scale expression and purification of MBP tagged Lsr2 
A 20 ml overnight culture of lsr2-pMAL-c2X in BL21 E. coli in selective rich media 
+ glucose was grown at 37°C, at 180 rpm.  This culture was used to inoculate 1 L 
of fresh pre-warmed selective rich media + glucose which was then grown at 
37°C, shaking at 180 rpm until it reached an OD600 of 0.4 – 0.6.  Protein 
expression was induced by adding IPTG to a final concentration of 0.3 mM and 
growth was continued at 37°C for 3 hours while shaking at 180 rpm.  The culture 
was pelleted by centrifugation at 5000 rpm for 30 minutes at 4°C, and 
resuspended in 30 ml of column buffer (20 mM Tris (pH 7.5), 200 mM NaCl, 
1 mM EDTA) and a Complete Mini EDTA-free protease inhibitor cocktail tablet 
added (Roche Diagnostics, USA) prior to cell lysis.  Cells were lysed on ice using a 
sonicator® ultrasonic processor XL fitted with a flat probe at level 8 for 3 x 30 
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seconds (Misonix Incorporated, USA).  After sonication the sample was 
centrifuged for 20 minutes at 13,000 rpm at 4°C to pellet the cell debris.  The 
supernatant was filtered through 1.2 μm and 0.45 μm Minisart syringe filters 
(Sartorius AG, Germany) prior to protein purification. 
A 5 ml MBPTrap™ HP column (GE Healthcare, Sweden) was prepared by washing 
with 30 ml MQ H2O and equilibrating with 30 ml of column buffer.  The filtered 
supernatant was then loaded onto the column using a syringe and the column 
was attached to either an ÄKTA Prime™ or ÄKTA Basic™ FPLC system which 
monitors protein elution by absorbance at 280 nm.  The FPLC system was 
washed with MQ H2O and lines A and B equilibrated in column buffer and elution 
buffer (20 mM Tris (pH 7.5), 200 mM NaCl, 1 mM EDTA, 10 mM maltose) 
respectively prior to column attachment.  At a flow rate of 5 ml/min, the column 
was washed with 50 ml of column buffer to remove unbound proteins and then 
bound proteins were eluted with 25 ml of 100% elution buffer.  Fractions 
containing protein of interest were prepared appropriately and analysed by 1% 
agarose gel electrophoresis and 15% SDS-PAGE.  After use, the Dextrin 
Sepharose™ column was regenerated by washing with 10 ml of 0.1% SDS, and 20 
ml of MQ H2O and rinsed with 10 ml of 20% ethanol for storage at 4°C. 
 
2.2.6 Transmission electron microscopy (TEM) of Lsr2/DNA complexes 
Examination of the effect of DNase treatment on the Lsr2/DNA complexes was 
performed as follows.  Two units of DNaseRQ1 (1U/μl; Promega, USA) was added 
to 20 μg of IMAC purified Lsr2 in a 20 μl volume and incubated at 37°C for the 
appropriate time period and then placed on ice for sampling.  A 5 μl aliquot was 
prepared at each time point for TEM analysis as per standard procedure. 
Examination of the effect of high salt buffer on the Lsr2/DNA complexes was 
performed as follows.  IMAC purified Lsr2 sample (at 7.6 mg/ml) was mixed 1:1 
with 2 M, 3 M and 4 M NaCl to create final concentrations of 1.0 M, 1.5 M and 
2.0 M NaCl, and incubated for 15 minutes at room temperature.  The sample was 
diluted 1 in 20 with MQ H2O and a 5 μl aliquot was prepared for TEM analysis as 
per standard procedure with the addition of 3 extra MQ H2O washes. 
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2.2.7 MALDI-TOF peptide mass analysis of Lsr2 
An SDS-PAGE gel band representing Lsr2 was excised using a clean scalpel blade, 
cut into small fragments and transferred to a 1.5 ml tube.  Gel fragments were 
repeatedly destained with 0.5 ml aliquots of 1:1 acetonitrile (ACN) : 25 mM 
NH4HCO3 for several hours at room temperature and left destaining overnight.  
The destain was removed and the gel fragments rinsed with 100 μl of 1:1 ACN : 
25 mM NH4HCO3 and the tube was spun briefly at high speed to allow the 
remaining solution to be removed.  Fifty μl of ACN was added for 15 minutes at 
room temperature to dehydrate the gel fragments and then removed.  The gel 
fragments were dried in a vacuum desiccator for 1 hour before the addition of 
trypsin.  A 1 μl trypsin aliquot (1 mg/ml; stored at -80°C) was diluted to 200 μl 
with 25 mM NH4HCO3 and 20 μl added to the desiccated gel fragments and the 
tube was incubated inverted at 37°C overnight.  Ten μl of 20% ACN / 0.1% 
trifluoro acetic acid (TFA) solution was added to the rehydrated gel slices and left 
for 30 minutes at room temperature before analysis. 
For analysis of peptides, a α-cyano-4-hydroxycinamic acid (HCCA) matrix (Sigma, 
USA) was used.  Ten μg of matrix was added to 30 μl of 2:1 ACN : 0.1% TFA, 
mixed well, sonicated for 10 minutes in a sonicating water bath (Elma, Germany) 
and then centrifuged for 10 minutes at 13,000 rpm.  Protein samples and peptide 
calibration standards (Bruker Daltonics, USA) were mixed in a 1:1 ratio (0.5 μl:0.5 
μl) with HCCA matrix on an AnchorChip™ MALDI-TOF target plate (Bruker 
Daltonics, USA) and left to air dry. 
An autoflex™ II MALDI-TOF mass spectrometer (Bruker Daltonics, USA) was used 
to analyse samples.  Samples were analysed in RP mode, with the mass range 
selector adjusted as required (suppressing < 500 Da ions) and data in the range 
of 500 – 4000 Da collected.  Settings included a pulsed ion extraction of 60 ns, a 
detector gain of 1400 V, an acceleration voltage of 19 kV, and a reflector voltage 
of 20 kV, with lazer power typically around 60%.  Spectra for peptide calibration 
standards were first collected and the spectrometer calibrated with an automatic 
polynomial correction.  Spectra were exported to FlexAnalysis™ software (Bruker 
Daltonics, USA), and the peaks identified and labelled.  The processed spectra 
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were opened in BioTools (Bruker Daltonics, USA) and compared with masses 
from a predicted trypsin digest of Lsr2 with one missed cleavage. 
 
2.2.8 Biotinylated DNA oligonucleotide design and binding assay 
Short complementary DNA oligonucleotides that were high in adenine and 
thymine bases were designed with a 5’ biotin molecule on the forward primer.  
Alternative biotin labelled forward primers were designed, with one containing a 
short 4 base pair linker for DNase cleavage that was designed based on preferred 
DNase I cleavage sites (Herrera & Chaires, 1994). 
 
Table ‎2.5.  Primers used to generate double stranded AT-rich DNA oligonucleotides. 
Primer Sequence Length 
AT-Rich_F_Biotin Biotin - ATG CGG GTA ATA TCA CGG 18 bp 
AT-Rich_R CCG TGA TAT TAC CCG C 16 bp 
AT-Rich_F_Linker_Biotin Biotin - ATG GAT GCG GGT AAT ATC ACG G 22 bp 
 
To generate a double stranded DNA biotin labelled oligonucleotide, 200 pmol 
each of forward and reverse oligonucleotide were combined with annealling 
buffer (10 mM Tris (pH8.0), 30 mM NaCl, 0.2 mM EDTA), in a final volume of 50 
μl, heated at 95°C for 5 minutes and allowed to passively cool to room 
temperature.  Ten μl of double stranded biotinylated oligonucleotide was 
incubated with 500 μl of IMAC or SEC purified Lsr2 protein fraction at 4°C 
overnight.  The protein and biotinylated oligonucleotide mixture was added to 20 
μl of washed streptavidin magnetic particles (Roche Diagnostics, Germany) and 
incubated at room temperature for 2 hours with intermittent mixing.  Prior to 
use streptavidin beads were washed 3 times with 200 μl of binding buffer (50 
mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA), using a magnet to draw down the 
particles, allowing the supernatant to be removed.  After incubation the solution 
containing unbound molecules was removed and the beads were washed twice 
with 200 μl binding buffer containing 1 M NaCl and resuspended in 20 μl of 
buffer.  Fifteen μl samples of unbound molecules and wash solutions and the 
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resuspended beads were prepared appropriately and analysed by 1% agarose gel 
electrophoresis and 15% SDS-PAGE. 
Attempts to remove the bound oligonucleotide and Lsr2 complex from the 
streptavidin beads was performed by using an elution buffer containing 50 mM 
Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 5 mM biotin to resuspend the beads at 
the last step of the method.  Treatment of the streptavidin beads at the last step 
of the method with 1 unit of DNase RQI in 20 μl of suitable buffer (20 mM Tris 
(pH 8.0), 100 mM MgCl2, 10 mM CaCl2) at room temperature overnight or 37°C 
for 1 – 2 hours was also attempted to dissociate the complex. 
 
2.2.9 Glutaraldehyde cross-linking of Lsr2 
Glutaraldehyde was added to approximately 8 μg of IMAC affinity purified Lsr2 or 
dextrin sepharose purified Lsr2-MBP to a final 0.1% (v/v) concentration in a 15 μl 
volume and incubated at room temperature for 2 and 5 minutes.  The reaction 
was stopped by the addition of 5 μl of 4 x SDS loading dye and heating for 
5 minutes at 95°C.  Cross-linking ability was assessed by 18% SDS-PAGE analysis. 
 
2.2.10 Western blot analysis of mycobacterial Lsr2 
Whole cell lysates of Mycobacterium bovis BCG and Mycobacterium smegmatis 
mc2155 culture were subjected to SDS-PAGE along with IMAC purified Lsr2 as a 
positive control and 5 μl of Benchmark™ prestained protein ladder (Invitrogen, 
USA).  Whole cell lysates were prepared by resuspending a 50 μl cell pellet of 
each strain in 200 μl of 1 x PBS and transferring to a 2 ml screw cap tube 
containing approximately 0.3 g of 0.1 mm and 2.5 mm zirconia beads (Biospec 
Products Ltd, USA).  Beads were mixed in a Fastprep FP120 bead beater 
(Thermosavant, USA) for 20 seconds at setting 6, cooled for 1 minute, then the 
steps repeated for 30 second and 40 second time periods.  Samples were 
centrifuged for 10 minutes at 13,000 rpm to remove froth and 2 – 8 μl used for 
15% SDS-PAGE gel separation. 
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Antigens and other cellular proteins were electrophoretically transferred to a 
Protran™ nitrocellulose membrane (Whatman, UK) as follows.  A transfer 
sandwich was set up and added to the transfer apparatus (BioRad Laboratories, 
USA) with an ice insert and magnetic stirring bar, and cold transfer buffer added 
to submerge the sandwich.  Proteins were transferred for 1 hour at 100 V, after 
which the sandwich was disassembled and successful transfer confirmed by 
staining the nitrocellulose membrane with Ponceau S stain for 2 minutes and 
rinsing with water. 
The membrane was blocked for 1 hour at room temperature or overnight at 4°C 
in BLOTTO solution before incubation with antibodies.  Rabbit anti-Lsr2 
polyclonal antibody diluted 1:5000 in BLOTTO was added to the membrane and 
incubated for 1 hour at room temperature and then the membrane was washed 
5 x 5 minutes with 1 X TBS-T + 0.5 M NaCl.  After washing, a goat anti-rabbit HRP 
conjugate antibody (Pierce Antibodies, USA) diluted 1:1000 in BLOTTO was 
added to the membrane and incubated for 1 hour at room temperature and then 
the membrane was washed 5 x 5 minutes with 1 X TBS-T + 0.5 M NaCl.  The 
membrane was treated with SuperSignal chemiluminescence substrate (Pierce, 
USA) at a 1:1 dilution with water.  The chemiluminescent signal from the 
membrane was visualised using a FujiFilm LAS-1000 Luminescent Image Analyzer 
with Intelligent Dark Box II (Fuji Photo Film Co., Ltd, Tokyo). 
Lsr2 antibodies were produced at the AgResearch antibody facility, Ruakura, 
Hamilton.  Lsr2 was expressed in E. coli and purified by IMAC for antibody 
production in four month old white rabbits.  A pre-immune serum sample was 
taken from each rabbit and then a 0.5 ml primary immunisation consisting of 
0.2 ml of 1 mg/ml Lsr2 protein and 0.3 ml Freunds Complete adjuvant was 
injected subcutaneously.  Every two weeks for a period of 6 weeks after the 
primary immunisation, the rabbits were injected subcutaneously with a 
secondary immunisation consisting of 0.1 ml of 1 mg/ml Lsr2 protein, 0.1 ml 
phosphate buffered saline (PBS) and 0.3 ml Freunds Incomplete adjuvant.  
Rabbits were anaesthetised with sodium pentobarbitone prior to the terminal 
bleed. 
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2.2.11 Lsr2 lysine - alanine mutagenesis design, generation and cloning 
Three lysine to alanine mutations (designated 2K2A, 3K3A and 5K5A), each with a 
different combination of the 5 lysine residues altered, were manufactured by 
Geneart (Geneart, Germany) to include the attB1 recombination sites used in 
Gateway® cloning (Invitrogen).  Supplied plasmid DNA was resuspended in sterile 
MQ H2O to 100 ng/μl and 50 ng was used in a Platinum Pfx DNA polymerase 
(Invitrogen) PCR reaction to amplify the inserted lsr2 gene.   
Pfx PCR reactions were carried out in 25 μl volumes using the following 
concentrations and reaction conditions.  1 X Pfx buffer, 1 x Pfx Enhancer, 0.3 mM 
deoxynucleotide mix, 1.0 mM MgSO2, 0.5 U Platinum Pfx DNA polymerase, 
0.2 μM generic forward attB primer, 0.2 μM generic reverse attB primer and 10 - 
50 ng template DNA.   
Cycle conditions:  94°C  1 :00   (min:sec) 
94°C  0:20 
X 10 55°C 0:30 
68°C 1:00 
94°C  0:20 
X 20 65°C 0:30 
68°C 1:00 
68°C 2:00 
 
The PCR product was run on a 1% agarose gel and the amplified insert excised for 
purification and 10 – 15 ng was then used as the template in a further Pfx PCR 
reaction, which was then purified for a BP cloning reaction.   
In the BP cloning reaction, approximately 25 femtomoles of each PCR product 
and 80 ng of pDONR221 vector DNA were mixed with 1 μl of 5 x BP clonase 
enzyme (Invitrogen) and TE buffer (pH 8.0) was added to a final volume of 5 μl.  
The reaction was incubated at room temperature for 6 hours and stopped by the 
addition of 0.5 μl Proteinase K enzyme (2 ug/ul; Invitrogen) and an incubation at 
37°C for 10 minutes.  Two μl of this reaction was transformed into DH5α E. coli 
and grown overnight on selective media as per standard procedure.  Triplicate 5 
ml selective LB overnight cultures for each mutant were grown and plasmid was 
purified using standard procedures.  To confirm the insertion of the lsr2 gene 
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into pDONR221 prior to the LR cloning reaction, a standard Taq PCR was 
performed (using 0.4 μM each of M13 forward and reverse primers and 50 ng of 
plasmid at a 55°C annealing temperature), and the products analysed on a 1% 
agarose gel as per standard procedure. 
In the LR cloning reaction, approximately 75 ng each of entry clone DNA and 
destination vector DNA pDEST17 were mixed with 1 μl of 5 x LR clonase enzyme 
(Invitrogen) and TE buffer (pH 8.0) was added to a final volume of 5 μl.  The 
reaction was incubated at room temperature for 4 hours and stopped by the 
addition of 0.5 μl Proteinase K enzyme (2 ug/ul; Invitrogen) and an incubation at 
37°C for 10 minutes.  Two μl of this reaction was transformed into DH5α E. coli 
and grown overnight on selective media as per standard procedure.  Colony PCR 
was performed in triplicate from the resulting transformants, as per standard 
procedure using T7 primers, to confirm successful incorporation of the lsr2 gene 
into the pDEST17 expression vector.  Overnight selective LB cultures using the 
remaining colony suspension from positive clones were grown for plasmid 
preparation and sequence confirmation by DNA sequencing.  Correctly cloned 
plasmids were transformed into BL21 E. coli for protein expression. 
 
2.2.12 Small and large scale expression of Lsr2 lysine mutants 
Small scale protein expression and Ni sepharose bead purification was 
performed using standard techniques but at a variety of expression 
temperatures (20°C, 25°C, 30°C and 37°C).  Large scale expression of Lsr2 lysine 
mutants was performed using standard techniques but cultures were incubated 
at 20°C overnight.  Large scale purification was performed using a HiTrap 
chelating column and following standard procedures.   
 
2.2.13 Fluorescent staining of recombinant E. coli using Lsr2 antibodies 
A 100 μl aliquot of each of the bacterial cultures was centrifuged for 5 minutes at 
13,000 rpm to pellet the cells.  The supernatant was removed and the pellet was 
washed with 1 ml of PBS, centrifuged again and resuspended in 50 μl of PBS.  A 
 Chapter Two - Materials & Methods 55 
glass slide was cleaned by flaming in 100% ethanol and 3 x 20 μl volumes of the 
resuspended cells applied to the surface and left to dry.  The cells were fixed to 
the slide by immersion in 95% ethanol for 1 minute at room temperature, 
draining the alcohol off the slide and dipping it in PBS and air drying before 
finally heating at 55°C for 10 minutes. 
The fixed slides were rehydrated by rinsing with PBS and draining off the excess.  
The slides were incubated with rabbit anti-Lsr2 polyclonal antibody diluted 1:500 
in PBS for 30 minutes at 37°C in a humidified chamber.  They were then rinsed by 
placing in a tray of PBS at room temperature for 30 minutes and then drained.  
FITC conjugated goat anti-rabbit IgG fluorescent secondary antibodies (Sigma, 
USA) were diluted 1:100 in PBS and a solution applied to the slides for 30 
minutes at 37°C in a humidified chamber.  The slides were rinsed in PBS as 
previously and then drained and dried by careful blotting around the cell spots.  
Each spot was covered with a drop of mounting media (Cargille Type A) and a 
glass coverslip laid on top.  Cells were visualised at 100 x oil immersion under 
blue light (ex = 485, em = 498) and photographed with a digital camera. 
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2.3 Methods for Chapter Four:  DNA binding for three Lsr2 
mutants 
2.3.1 Site directed mutagenesis using QuikChange™ protocol 
Site directed mutagenesis to generate four alternative mutations was performed 
based on the protocol from the Stratagene QuikChange™ II-E kit (Stratagene, 
USA).  Mutagenesis primers for arginine to alanine mutations were designed with 
the twin base pair residue change in the centre, flanked by approximately 15 
bases on either side as recommended.   
 
Table ‎2.6.  Primers for site directed mutagenesis to generate arginine to alanine mutations. 
Primer Sequence Length 
Lsr2Arg84-Ala84-F AGC AGA GCG CGG CGA TCG CCG AAT GGG CTC GTC GTA 36 bp 
Lsr2Arg 84-Ala84-R TAC GAC GAG CCC ATT CGG CGA TCG CCG CGC TCT GCT 36 bp 
Lsr2Arg97-Ala97-F ACA ATG TGT CGA CGG CAG GCC GGA TCC CGG CCG ACG 36 bp 
Lsr2Arg97-Ala97-R CGT CGG CCG GGA TCC GGC CTG CCG TCG ACA CAT TGT 36 bp 
Lsr2Arg99-Ala99-F ACA ATG TGT CGA CGC GAG GCG CGA TCC CGG CCG ACG 36 bp 
Lsr2Arg99-Ala99-R CGT CGG CCG GGA TCG CGC CTC GCG TCG ACA CAT TGT 36 bp 
Lsr2-R97/R99-
A97/A99-F 
ACA ATG TGT CGA CGG CAG GCG CGA TCC CGG CCG ACG 36 bp 
Lsr2-R97/R99-
A97/A99-R 
CGT CGG CCG GGA TCG CGC CTG CCG TCG ACA CAT TGT 36 bp 
 
A fresh plasmid purification of lsr2-pET30b for the template DNA was prepared 
to ensure a high degree of supercoiled DNA.  Mutagenic Pfu Ultra DNA 
polymerase (Aligent Technologies, USA) PCR was performed in a total volume of 
50 μl with the following final concentrations and reaction conditions.  1 X Pfu 
buffer, 0.2 mM deoxynucleotide mix, 2.5 U Pfu Ultra DNA polymerase, 125 ng 
each forward and reverse primer and 25 ng of template DNA.   
Cycle conditions:  95°C  0 :30   (min:sec) 
95°C  0:30 
X 17 55°C 1:00 
68°C 6:00 
4°C HOLD 
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Successful PCR amplification of the DNA was confirmed by 1% agarose gel 
electrophoresis of a reaction aliquot as per standard procedure prior to digestion 
of the DNA with 10 U of DpnI (New England Biolabs, USA) at 37°C for 1 hour.  
Following DNA digestion, 4 μl of the product was transformed into DH5α E. coli 
which were grown overnight on selective media as per standard procedure.  
Overnight selective cultures were grown from successful transformants for 
plasmid preparation and DNA sequencing as per standard procedure.  Correctly 
mutated variants were transformed by electroporation into BL21 E. coli for 
expression. 
 
2.3.2 Expression and purification of Lsr2 DNA binding mutants 
Large scale expression was performed using a 5 ml HiTrap™ Chelating HP column 
according to standard techniques.  Fractions containing protein of interest were 
prepared appropriately and analysed by 1% agarose gel electrophoresis and 15% 
SDS-PAGE. 
Size exclusion chromatography of the Lsr2 R97A-R99A DNA binding mutant was 
performed using a HiLoad™ 16/60 Superdex™ 200 column using standard 
techniques but in a high salt buffer to dissociate the co-purified E. coli genomic 
DNA.  The buffer included 50 mM phosphate (pH 7.4), 2 M NaCl, for protein 
characterisation studies.  Phosphate purified protein was subsequently 
concentrated and dialysed into 20 mM Tris (pH 7.4), 150 mM NaCl buffer if 
required for crystallisation studies.  Fractions of interest were prepared for 
analysis by 1% agarose gel electrophoresis and 15% SDS-PAGE. 
 
2.3.3 Transmission electron microscopy (TEM) analysis of mutants 
A 5 μl aliquot of IMAC purified Lsr2 and Lsr2 R97A, R99A and R97A-R99A DNA 
binding mutant protein at approximately 0.5 mg/ml was prepared for TEM 
analysis as per standard procedure. 
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2.3.4 A fluorescence assay for protein thermal stability 
Protein thermal stability was assessed based on the interaction of a hydrophobic 
fluoroprobe SYPRO™ orange (Sigma, USA) with protein as previously published 
(Ericsson et al., 2006).  IMAC purified Lsr2, Lsr2 DNA binding mutant protein 
samples (at approximately 0.5 mg/ml), and buffer control samples, were 
prepared in triplicate in thin walled PCR tubes in a total volume of 25 μl with the 
following final concentrations and reaction conditions.  90 x SYPRO orange dye, 
10 μl of protein, in 50 mM Na acetate buffer (pH 5.2).   
Protein denaturation was performed using a 36-well rotor in a RotorGene-6000 
real time PCR machine and data recorded with the supplied software (Corbett 
Research, Australia).  Denaturation conditions were as follows.  Samples were 
equilibrated for 90 seconds at 25°C, and the temperature ramped up to 99°C in 
0.2°C increments with a 5 second delay per increment.  Samples were excited at 
470 nm and emission measured at 555 nm with autogain settings selected.  Data 
was exported to an excel spreadsheet and analysed by averaging the sample 
data and subtracting the average buffer reading.  The protein unfolding 
temperature was measured visually from the middle of the peak. 
 
2.3.5 Secondary structure analysis using circular dichroism (CD)  
Circular dichroism was performed at The University of Auckland, in the School of 
Biological Sciences, using an Applied Photophysics PiStar (π*) 180 machine fitted 
with a Series 800 temperature controller (AlphaOmega Instruments, USA) and 
B-12 water bath (Techne, UK), and data was collected using the accompanying 
PiStar ProDataViewer software.  The instrument was purged with nitrogen at a 
flow rate of 8 L/min for 30 minutes prior to lamp ignition and assays were 
performed at a flow rate of 6 L/min.  For the analysis of secondary structure, 
data was collected in the far UV CD spectrum (180 – 260 nm) with samples 
assayed in a 1 mm (type 21Q) quartz cuvette positioned with a cell spacer (Starna 
Scientific Ltd, UK), in a total volume of 360 μl.  Baseline data was collected for no 
cuvette present and the empty cuvette was quickly scanned prior to collecting 
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buffer only data to ensure cuvette cleanliness.  Samples were diluted 
appropriately to ensure spectra absorbance was within the maximum detection 
limit of 1000 MV of the instrument.  The cuvette was cleaned between protein 
samples by filling with a 3:1 solution of concentrated sulphuric acid and nitric 
acid and leaving for 5 minutes, then thoroughly rinsing with dH2O followed by 
100% ethanol and drying. 
SEC purified “DNA-free” protein samples were dialysed into 5 mM phosphate (pH 
7.4) buffer and diluted to 6 μM – a concentration which was previously 
optimised to give absorbance readings within the detection limits – for analysis.  
Five replicate scans were collected per sample, at 20°C, with 3 seconds per time 
point, and a 1 nm step size and bandwidth.   
Data sets were analysed by averaging the sample data and subtracting the 
average buffer data using ProData PiStar software and then exported in a excel 
compatible file format for further analysis.  Raw data in millidegrees was 
converted into mean residue ellipticity (θMRW; deg.cm
2/dmol) units using the 
equation below and multiplied by 0.001 for secondary structure analysis using 
the K2D2 method (Perez-Iratxeta & Andrade-Navarro, 2008). 
 
θMRW = S/10*C*npept*L 
 
S = raw signal (millidegrees) 
C = protein concentration (mol/L) 
npept = number of peptide bonds in protein (residues-1) 
L = optical path length (cm) 
 
For the analysis of nucleic acid conformational changes, data was collected 
between 230 and 360 nm following established techniques (Cary & Kneale, 2008).  
Samples were assayed using the same settings and buffer as for secondary 
structure analysis.  Five replicate scans of plasmid DNA at 0.008 μM were 
performed to establish an elliptical pattern for DNA and then a protein titration 
experiment was performed with five replicate scans after the addition of 
approximately 1 μM, 2 μM, 3 μM, and 4 μM amounts of SEC purified Lsr2 protein.  
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An equivalent protein only titration experiment was performed to confirm that 
the protein was not contributing to the elliptical signal shown in the DNA and 
protein titration experiment.  Change in ellipticity at 272 nm was examined 
against protein concentration to determine the influence of protein binding on 
DNA conformation. 
Thermal unfolding analysis of SEC purified Lsr2 was performed at a fixed 
wavelength of 223 nm.  Lsr2 protein was assayed at 6 μM in a 5 mm quartz 
cuvette (with magnetic stirring ball; Starna Scientific Ltd, UK), which required a 
minimum of 1.7 ml of sample.  CD analysis was performed over a 35°C to 90°C 
temperature range, with an increase of 1°C per minute, collecting for 14.4 
seconds per time point, and with a 2 nm step size and bandwidth.  The raw data 
was analysed visually. 
 
2.3.6 Plasmid DNA binding gel shift assay 
Plasmid DNA (200 ng or 400 ng) was mixed with an excess quantity of SEC 
purified Lsr2 or Lsr2 R97A-R99A mutant protein (3100 ng or 3600 ng respectively) 
and diluted to a final volume of 20 μl using specific pH buffers.  For native Lsr2 
DNA binding assessment, the mixtures were required to be dialysed overnight at 
4°C (using 20 μl dialysis buttons according to standard procedure), as the SEC 
purified protein was in a 2M NaCl buffer, however for the R97A-R99A mutant 
this was not required as the protein was already highly concentrated and in a low 
salt buffer.  The following buffers were used in the assay conditions – 50 mM Na 
acetate (pH 5.0), 150 mM NaCl, or 50 mM Na hepes (pH 7.0), 150 mM NaCl, or 50 
mM Bis Tris Propane (pH 9.0), 150 mM NaCl.  The samples were analysed by 1% 
agarose gel electrophoresis according to standard procedures. 
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2.3.7 Dynamic light scattering analysis (DLS) of purified protein 
Concentrated R97A-R99A Lsr2 mutant protein used in crystallography robotic 
screens was assessed post-use for its aggregation and polydispersity properties 
using dynamic light scattering.   The remaining R97A-R99A Lsr2 sample was 
centrifuged for 15 minutes at 14,000 rpm at 4°C to remove any precipitated 
protein and 20 μl was then added to a cleaned and dried quartz cuvette without 
generating bubbles.  DLS analysis was performed using a DynaPro MTSV Dynamic 
Light Scattering instrument (Protein Solutions Inc., UK), using 40% laser power to 
collect approximately 800,000 counts.  Histogram analysis of the distribution of 
particle sizes was performed to assess protein uniformity. 
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2.4 Methods for Chapter Five:  Structure of the N-terminal 
dimerisation domain of Lsr2 
2.4.1 Cloning of the N-terminal domain of Lsr2 into pPROExHTb 
A total of seven variations of the N-terminal domain of Lsr2 were cloned into the 
E. coli expression vector pPROExHTb (Invitrogen) as follows.  The N-terminal 
domain was amplified from the lsr2-pET30b plasmid via PCR using forward and 
reverse primers containing the restriction enzyme sites NcoI and XhoI, 
respectively, positioning a 6 x histidine tag and an rTEV protease cleavage site at 
the N-terminal end of the protein.   
 
Table ‎2.7.  Primers used for cloning seven variations of the N-terminal domain of 
M. tuberculosis lsr2 into pPROExHTb. 
Primer Sequence Length 
Lsr2 Nco1 Fwd GGG GCC ATG GCG AAG AAA GTA ACC GTC ACC 30 bp 
Lsr2 Nterm Xho1 Rev GGG GCT CGA GTC AAC CGA CGC GAC GGC CC 29 bp 
Lsr2 Nterm+ Xho1 Rev GGG GCT CGA GTC AGG ATC CGG AAC GGC CGC 30 bp 
Lsr2 Nterm-1 Xho1Rev GGG GCT CGA GTC AAC GGC CCG CCG CCA CC 29 bp 
Lsr2 Nterm-2 Xho1Rev GGG GCT CGA GTC AGC GCC CAC CGA CGC GAC 30 bp 
Lsr2 Nterm-3 Xho1Rev GGG GCT CGA GTC AGC CGC GCC GGC GCC CA 29 bp 
Lsr2 Nterm-4 Xho1Rev GGG GCT CGA GTC ATC CAC GGC CGG ATC CGG 
AAC 
33 bp 
Lsr2 Nterm-5 Xho1Rev GGG GCT CGA GTC ACG CGC CAC GTC CAC GGC 30 bp 
 
Standard Taq DNA polymerase PCR was performed at 58°C annealing 
temperature and with 1.0 mM MgCl2.  A large scale PCR was performed, the 
product checked on an agarose gel, and then purified from solution and 
quantified using standard procedures.  The PCR product was inserted into 
pPROExHTb via appropriate enzyme digestion and ligation and transformed into 
DH5α E. coli.  Colony PCR using cloning primers was performed to select positive 
transformants.  The cell suspension from positive clones was used to inoculate 
selective LB media which was incubated overnight at 37°C for plasmid 
preparation for sequence verification.  Correctly cloned variants were then 
transformed by electroporation into BL21 E. coli for expression, using standard 
techniques.   
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2.4.2 Expression and purification of His tagged N-terminal domain 
Small scale expression testing of the N-terminal domain variants was performed 
using a Ni Sepharose™ bead assay according to standard techniques.  Large scale 
expression and IMAC purification using a 5 ml HiTrap™ Chelating HP column was 
performed according to standard techniques.  Fractions containing protein of 
interest were prepared appropriately and initially analysed both by 1% agarose 
gel electrophoresis and 16.5% SDS-PAGE.  In subsequent purifications, protein 
fractions were analysed by SDS-PAGE only.  Analytical SEC was performed using a 
Superdex™ 75 10/300 GL column as per standard techniques with a 20 mM Tris 
(pH 7.4), 150 mM NaCl buffer.  Preparative SEC purification was performed using 
a HiLoad™ 16/60 Superdex™ 75 column according to standard techniques using a 
20 mM Tris (pH 7.4), 150 mM NaCl buffer.  Fractions of interest were prepared 
for analysis by 16.5% SDS-PAGE. 
 
2.4.3 Glutaraldehyde cross-linking of Nterm and SEC analysis 
Glutaraldehyde was added to approximately 15 μg of SEC purified Nterm Lsr2 to 
a final 0.1% (v/v) concentration in a 15 μl volume and incubated at room 
temperature for 2 and 5 minutes.  The reaction was stopped by the addition of 
5 μl of 4 x SDS loading dye and heating for 5 minutes at 95°C.  Cross-linking 
ability was assessed by 18% SDS-PAGE analysis. 
Analytical SEC was performed, with a duplicate assay reaction, using a 
Superdex™ 75 10/300 GL column as per standard techniques with a 50 mM 
phosphate (pH 7.4), 200 mM NaCl, 20 mM imidazole buffer. 
 
2.4.4 Crystallisation screens and fine screening of N-terminal domains 
SEC purified protein of the N-terminal domain constructs were concentrated 
using standard techniques and subjected to crystallisation screens according to 
standard procedures.  Robotic crystallisation screens were performed at The 
University of Auckland for Nterm, and both robotic crystallisation screens and 
Hampton crystallisation screens at The University of Waikato, were performed 
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for Nterm2 and Nterm3.  Fine screens, additive screens and crystal seeding of the 
N-terminal domain variants were performed according to standard procedures.  
Co-crystallisation Hampton screens and fine screens of Nterm2 with trypsin were 
performed by the addition of trypsin (immediately prior to use), to a volume of 
concentrated protein suitable for completing an entire screen, at mass ratios of 
1:500, 1:5000 and 1: 50000 as required.  For a 24-well hanging drop fine screen 
at a 1:500 mass ratio dilution, this typically involved the addition of 1 μl of 
trypsin (1 mg/ml) to 35 μl of Nterm2 (15 mg/ml). 
 
2.4.5 Isoleucine and leucine to methionine mutagenesis in Nterm2 for 
selenomethionine protein generation 
2.4.5.1 Site directed mutagenesis using QuikChange™ protocol 
Site directed mutagenesis to generate three alternative mutations of Nterm2 
was performed based on the protocol from the Stratagene QuikChange™ II-E kit 
(Stratagene, USA).  Primers for isoleucine to methionine and leucine to 
methionine mutations were designed with the single base pair residue change in 
the centre, flanked by approximately 15 bases on either side as recommended.   
 
Table ‎2.8.  Primers for site directed mutagenesis to generate methionine mutations. 
Primer Sequence Length 
Lsr2 I34M34 Fwd CGG GGT GAC CTA TGA GAT GGA CCT TTC CAC TAA G 34 bp 
Lsr2 I34M34 Rev CTT AGT GGA AAG GTC CAT CTC ATA GGT CAC CCC G 34 bp 
Lsr2 L44M44 Fwd AAG AAT GCC ACG AAA ATG CGT GGC GAC CTG AAG C 34 bp 
Lsr2 L44M44 Rev GCT TCA GGT CGC CAC GCA TTT TCG TGG CAT TCT T 34 bp 
Lsr2 L48M48 Fwd CGA AAC TGC GTG GCG ACA TGA AGC AAT GGG TGG CG 35 bp 
Lsr2 L48M48 Rev CGC CAC CCA TTG CTT CAT GTC GCC ACG CAG TTT CG 35 bp 
 
A fresh plasmid purification of Nterm2-pPROExHTb for the template DNA was 
prepared to ensure a high degree of supercoiled DNA.  Mutagenic Pfu Ultra DNA 
polymerase (Aligent Technologies, USA) PCR was performed in a total volume of 
50 μl with the following final concentrations and reaction conditions.  1 X Pfu 
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buffer, 0.2 mM deoxynucleotide mix, 2.5 U Pfu Ultra DNA polymerase, 125 ng 
each forward and reverse primer and 25 ng of template DNA.   
Cycle conditions:  95°C  0 :30   (min:sec) 
95°C  0:30 
X 17 55°C 1:00 
68°C 6:00 
4°C HOLD 
 
Successful PCR amplification of the DNA was confirmed by 1% agarose gel 
electrophoresis of a reaction aliquot as per standard procedure prior to digestion 
of the DNA with 10 U of DpnI (New England Biolabs, USA) at 37°C for 1 hour.  
Following DNA digestion, 4 μl of the product was transformed into DH5α E. coli 
which were grown overnight on selective media as per standard procedure.  
Overnight selective cultures were grown from successful transformants for 
plasmid preparation and DNA sequencing as per standard procedure.  Correctly 
mutated variants were transformed by electroporation into BL21 E. coli for 
expression. 
 
2.4.5.2 Site directed mutagenesis of L44M using a standard PCR protocol 
Generation of the Nterm2 methionine mutant L44M was unsuccessful using the 
site directed mutagenesis QuikChange™ protocol and hence a standard PCR 
protocol using the mutagenesis primers and the original cloning primers flanking 
the entire Nterm2 construct were used in a two-stage PCR reaction.   
 
Table ‎2.9.  Primers for site directed mutagenesis to generate the L44M mutation. 
Primer Sequence Length 
Lsr2 Nco1 Fwd GGG GCC ATG GCG AAG AAA GTA ACC GTC ACC 30 bp 
Lsr2 L44M44 Rev GCT TCA GGT CGC CAC GCA TTT TCG TGG CAT TCT T 34 bp 
Lsr2 L44M44 Fwd AAG AAT GCC ACG AAA ATG CGT GGC GAC CTG AAG C 34 bp 
Lsr2 Nterm-2 Xho1 Rev GGG GCT CGA GTC AGC GCC CAC CGA CGC GAC 30 bp 
 
The L44M mutant was amplified in two halves from the Nterm2-pPROExHTb 
plasmid via PCR using the Lsr2 NcoI Fwd/Lsr2 L44M44 Rev primer pair and Lsr2 
L44M44 Fwd/Lsr2 Nterm-2 Xho1 Rev primer pair.  A 50 μl standard Taq DNA 
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polymerase PCR was performed at 58°C annealing temperature, with 1.0 mM 
MgCl2, and 80 ng of template DNA.  The PCR products were checked on a 1% 
agarose gel, and then purified from solution and quantified using standard 
procedures.  A standard PCR was then performed using the PCR products from 
the two halves of the Nterm2 gene as template and the Lsr2 Nco1 Fwd/Lsr2 
Nterm-2 Xho1 Rev primer pair.  A 50 μl standard Taq DNA polymerase PCR was 
performed at 58°C annealing temperature, with 1.0 mM MgCl2, and 40 - 60 ng of 
each template DNA.  The PCR product was checked on a 1% agarose gel, and 
then purified from solution and quantified using standard procedures. 
 
2.4.5.3 Cloning of the L44M Nterm2 mutant into pPROExHTb 
The L44M Nterm2 PCR product was inserted into pPROExHTb via appropriate 
enzyme digestion and ligation and transformed into DH5α E. coli.  Colony PCR 
was performed using cloning primers to select positive transformants.  The cell 
suspension from positive clones was used to inoculate selective LB media which 
was incubated overnight at 37°C for plasmid preparation for sequence 
verification.  A correctly cloned mutant was then transformed into BL21 E. coli 
for expression, using standard techniques.   
 
2.4.6 Expression and purification trials of the I34M, L44M and L48M 
Nterm2 methionine mutants 
To confirm that each of the three methionine mutations had not compromised 
protein expression or behaviour, large scale expression followed by IMAC 
purification using a 5 ml HiTrap™ Chelating HP column, and analytical SEC 
purification using a Superdex™ 75 10/300 GL column was performed using the 
same procedures used with the native Lsr2 N-terminal domain constructs. 
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2.4.7 Incorporation of selenomethionine into L48M Nterm2 protein 
A common procedure to express selenomethionine incorporated protein 
included the use of a methionine auxotroph DL41 E. coli strain in conjunction 
with autoinduction media supplemented with an appropriate ratio of methionine 
to selenomethionine.  The L48M Nterm2-pPROExHTb plasmid was transformed 
into DL41 cells using standard procedures, and a single colony from the resulting 
agar plate was used to inoculate 10 ml of PA-0.5G selective media 
(supplemented with methionine) which was then incubated overnight at 37°C, 
whist shaking at 180 rpm.  The 10 ml seeder culture was used to inoculate 400 ml 
of PASM-5052 autoinduction media (which includes selenomethionine and 
methionine) which was grown overnight at 37°C, whist shaking at 180 rpm. 
 
An alternative procedure to express selenomethionine incorporated protein 
included the use of BL21 E. coli and the methionine pathway inhibition method 
(Doublié, 1997).  This technique uses M9 minimal media supplemented with 
precise amounts of each amino acid.  A single colony of the transformed BL21 
cells was used to inoculate 10 ml of selective LB media which was grown 
overnight at 37°C, whist shaking at 180 rpm.  The overnight culture was 
centrifuged at 4600 rpm for 10 minutes and resuspended in 1 ml of M9 minimal 
media (modified from Sambrook & Russell, 2001).  This culture was used to 
inoculate 1 L of fresh pre-warmed selective M9 minimal media which was then 
grown at 37°C, shaking at 180 rpm until it reached an OD600 of 0.4 – 0.6.  Once in 
mid-log phase, the following amounts of each amino acid were added.  One 
hundred mg each of lysine, phenylalanine and threonine; 50 mg each of 
isoleucine and valine; and 60 mg of selenomethionine.  Growth was continued 
for a further 15 minutes at 37°C and then protein expression was induced with 
0.5 mM IPTG and incubation continued overnight. 
 
 
 Chapter Two - Materials & Methods 68 
2.4.8 IMAC purification and SEC of L48M selenomethionine Nterm2 
Large scale expression cultures were purified by IMAC using a 5 ml HiTrap™ 
Chelating HP column according to standard techniques except that both the 
phosphate lysis and elution buffers were at pH 7.0 (instead of pH 7.4), and they 
contained 2 mM β-mercaptoethanol.  Fractions containing protein of interest 
were prepared appropriately and analysed by 16.5% SDS-PAGE.  Preparative SEC 
purification was performed using a HiLoad™ 16/60 Superdex™ 75 column 
according to standard techniques except that a 20 mM Tris (pH 7.2), 150 mM 
NaCl, 2 mM β-mercaptoethanol buffer was used.  Fractions of interest were 
prepared for analysis by 16.5% SDS-PAGE. 
 
2.4.9 L48M Nterm2 crystallisation fine screens and co-crystallisation 
Concentrated SEC purified L48M Nterm2 was prepared and subjected to hanging 
drop fine screens and trypsin co-crystallisation screens at a 1:500 mass ratio 
according to standard techniques.  These screens were designed based on 
previous successful Nterm2 crystallisation conditions. 
 
2.4.10 X-ray diffraction data collection and processing 
Details of X-ray diffraction data collection are described in section ‎2.1.18.4.  
Nterm2 protein crystals did not require an additional cryoprotectant and were 
flash frozen and tested for diffraction at the home source, and two data sets 
from two independant crystals were successfully collected.  Crystals from 
Nterm2 co-crystallised with trypsin were bathed in the screen solution 
containing 20% glycerol and flash frozen and also tested for diffraction at the 
home source, and a single data set was collected.  A further data set from this 
crystal was also collected at the Australian Synchrotron.  Selenomethionine 
L48M Nterm2 crystals were bathed in the screen solution containing 20% 
glycerol and flash frozen and tested for diffraction at the Australian Synchrotron, 
and two multiwavelength data sets from two independent crystals were 
successfully collected. 
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The program MOSFLM was used to visualise and index images, and integrate the 
reflections (Leslie, 1992).  The program auto spot finder and auto index functions 
were used to determine the cell parameters.  Changes in RMS deviation and 
mosaicity were observed during MOSFLM integration.  The integrated reflections 
were scaled and merged using SCALA within the CCP4 program (Bailey, 1994).  
The output using all the reflections was examined for unfavoured Rmerge, I/σ(I) 
and data completeness and rescaled if necessary to improve these variables. 
 
2.4.11 Phase determination and structure solving by ab initio methods 
Phase determination and structure solving using ab initio techniques was 
performed by K. Meindl and I. Uson at the Instituto di Biologia Molecular de 
Barcelona at the Barcelona Science Park, Barcelona, Spain  (Rodriguez et al., 
2009).  The P21 structure was solved with the program ARCIMBOLDO (Rodriguez 
et al., 2012) on the supercomputer Calendula at the FCSCL, León, Spain 
(www.calendula.fcsc.es).  A model alpha helix composed of 14 alanine residues 
was used as a search fragment.  Location of two fragments led to partial 
solutions that could be distinguished from the average by a slightly increased 
correlation coefficient (CC) of the traces obtained by SHELXE (Sheldrick, 2010).  
However the solutions were stuck at mean phase errors of 73° compared to the 
phases of the final refined and deposited model.  Iterative improvements were 
made by interspersing density modification and autotracing with SHELXE jobs 
with trimming of the partial models obtained to increase their CC until a mean 
phase error of 42° was reached producing an easily interpretable map. 
The structure in the P3121 space group was determined by molecular 
replacement using PHENIX (Adams et al., 2010) and the earlier determined 
Nterm2 Lsr2 structure in the P21 space group, which had subsequently been 
manually built and refined, as a search model. 
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2.4.12 Model building and refinement 
Automated model building for the P21 structure was performed using PHENIX 
Autobuild (Adams et al., 2010) and an edited version of the ab initio structure as 
the search model.  Residues A28, A29, A33 and A34 were manually removed 
from the “test3.pdb” coordinate file and the file was renamed “test3_edit1.pdb”.  
Iterative rounds of manual building using COOT (Emsley & Cowtan, 2004) and 
refinement using PHENIX Refine (Adams et al., 2010) were performed. 
Automated model building for the P3121 structure was performed using PHENIX 
Autobuild and the final refined version of the P21 structure as the search model.  
Iterative rounds of manual building using COOT and refinement using PHENIX 
Refine were performed. 
Structure validation was performed using a subset of the full MolProbity analysis 
available within PHENIX Refine (Chen et al., 2010) and KiNG analysis within 
PHENIX Refine (Chen et al., 2009). 
 
2.4.13  Structural analysis of Nterm2 and figure generation 
All structure images and electrostatic surface potential images of structures 
depicted in this thesis were generated using PYMOL (DeLano, 2002). 
 
2.4.14 MALDI-TOF mass spectrometry of whole protein 
For analysis of whole protein, a 9:1 mixture of 2,5-dihydroxybenzoic acid and 
2-hydroxy-5-methoxybenzoic acid (DHBs) matrix (Sigma, USA) was used.  Ten μg 
of matrix was added to 30 μl of 2:1 ACN : 0.1% TFA, mixed well, sonicated for 
10 minutes in a sonicating water bath (Elma, Germany) and then centrifuged for 
10 minutes at 13,000 rpm.  Protein samples and protein calibration standards 
(Bruker Daltonics, USA) were mixed in a 1:1 ratio (0.5 μl:0.5 μl) with DHBs matrix 
on an AnchorChip™ MALDI-TOF target plate (Bruker Daltonics, USA) and left to 
air dry.  Protein samples were usually dialysed into MQ H2O before analysis. 
An autoflex™ II MALDI-TOF mass spectrometer (Bruker Daltonics, USA) was used 
to analyse samples.  Samples were analysed in linear mode, with the mass range 
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selector adjusted as required and data in the range of 2500 – 45000 Da collected.  
Settings included a pulsed ion extraction of 450 ns, a gain of 2500 V, and an 
acceleration voltage of 20 kV, with laser power typically around 60%.  Spectra for 
protein calibration standards were first collected and the spectrometer 
calibrated with an automatic polynomial correction.  Spectra were exported to 
FlexAnalysis™ software (Bruker Daltonics, USA), and the peaks identified and 
labelled.  Peaks were assessed for the presence of full protein, protein with the 
tag removed, and the tag alone and for the formation of oligomers. 
 
2.4.15 Electrospray ionisation mass spectrometry (ESI-MS) 
Electrospray ionisation mass spectrometry analysis of the N-terminal domain of 
Lsr2 was performed using a Bruker Daltonics microTOF™ machine and the data 
collected and analysed with micrOTOFControl and Bruker Daltonics DataAnalysis 
software.  Protein crystals of “matured” and trypsin co-crystallised N-terminal 
Lsr2 were washed briefly in acetonitrile and then dissolved in 5 μl 1:1 
acetonitrile:H2O.  Dissolved crystals were diluted to 100 μl in 1:1 acetonitrile:H2O 
and 25 μl of 0.2% formic acid (in 1:1 acetonitrile:H2O) added.  Calibration was 
performed immediately prior to analysis with infused sodium formate solution in 
positive ion mode and the acquired masses were matched to reference masses. 
 
2.4.16 Full length Lsr2 trypsin and DNase digestion assay 
IMAC purified Lsr2 protein (2.4 mg/ml) was mixed with trypsin (1 mg/ml, Sigma, 
USA) at a 1:500 mass ratio in a final volume of 400 μl and incubated at room 
temperature.  Duplicate samples of 15 μl were taken at 1 minute, 5 minutes, 
15 minutes, 30 minutes and 1 hour for 1% agarose and 16.5% SDS-PAGE gel 
analysis.  Samples intended for SDS-PAGE analysis has 5 μl of 4 x SDS loading dye 
added and were heated at 95°C for 5 minutes.  Samples for agarose gel analysis 
had the trypsin digestion stopped by adding an equal ng amount of tryspin 
inhibitor (0.1 mg/ml, Sigma, USA) to the aliquot and were mixed and left at room 
temperature for a minimum of 15 minutes before the addition of a DNA loading 
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dye.  Samples of 30 μl were also taken at 1 minute, 5 minutes, 15 minutes, 30 
minutes and 1 hour for subsequent DNase digestion.  All samples for DNase 
treatment had trypsin inhibitor added at each sampled time point and had a 
minimum of 45 minutes treatment time at room temperature before the 
addition of DNase.  To 30 μl of sample, 3 μl of 10 x DNase buffer and 2 μl of RQ1 
DNase (1 U/ μl, Promega, USA) was added, mixed and left at room temperature 
for 90 minutes.  To 15 μl of DNase treated sample, 5 μl of 4 x SDS loading dye 
was added and the sample heated at 95 °C for 5 minutes.  DNA loading dye was 
added to the remaining 15 μl for agarose gel analysis.  Trypsin inhibitor was 
added to control samples for agarose gel analysis.  DNA was visualised by 1% 
agarose gel electrophoresis and staining with SYBR®safe DNA stain (Invitrogen).   
 
2.4.17 Transmission electron microscopy (TEM) of trypsin digested full 
length Lsr2 
IMAC purified Lsr2 protein (2.4 mg/ml) was mixed with trypsin (1 mg/ml, Sigma, 
USA) at a 1:500 mass ratio in a final volume of 200 μl and incubated at room 
temperature.  Duplicate 5 μl samples were taken at 1 minute, 5 minutes 15 
minutes, 30 minutes and 1 hour and immediately prepared for negative staining 
duplicate grids as per standard procedure.  Electron microscopy grids were 
examined using a FEI TecNai G2 electron microscope and low dose images were 
recorded. 
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2.5 Methods for Chapter Six:  Pellicle and biofilm formation 
in M. smegmatis mc2155 Δlsr2 and Lsr2 mutant strains 
2.5.1 Mycobacterium smegmatis strains and Lsr2 variants 
The following control stains and experimental variants were generated for use in 
all biofilm and pellicle formation assays.  The M. smegmatis mc2155 lab strain 
containing an unmarked deletion of the lsr2 gene MSMEG_6092 was provided by 
R. Colangeli (NJS22; Colangeli et al., 2007). 
 
Table ‎2.10.  Mycobacterium smegmatis strains used and genes complemented with. 
Name Strain Vector 
mc
2
155 M. smegmatis mc
2
155 lab strain none 
K/O Lsr2 M. smegmatis mc
2
155 with a clean deletion of lsr2 none 
mc
2
155 + pMIND M. smegmatis mc
2
155 lab strain Empty pMIND 
K/O Lsr2 + pMIND M. smegmatis mc
2
155 with a clean deletion of lsr2 Empty pMIND 
R97A M. smegmatis mc
2
155 with a clean deletion of lsr2 R97A-pMIND 
R99A M. smegmatis mc
2
155 with a clean deletion of lsr2 R99A-pMIND 
R97A-R99A M. smegmatis mc
2
155 with a clean deletion of lsr2 R97A-R99A-pMIND 
Lsr2 M. smegmatis mc
2
155 with a clean deletion of lsr2 Lsr2-pMIND 
 
2.5.2 Mycobacterium smegmatis biofilm culture method 
Glycerol stocks of each control strain and variant strain were streaked onto LBT 
agar and hygromycin LBT agar plates respectively, and grown at 37°C for 3 days 
for use in seeder cultures.  Seeder cultures of each strain were grown in 1 ml of 
LB media, with or without hygromycin as required, for 48 hours, shaking at 180 
rpm, and were used to inoculate 4 ml of M63 biofilm media at 1:100 dilution 
ratio.  For the control lab strain and Δlsr2 strain, M63 biofilm media without 
hygromycin or tetracycline was prepared.  For all the strains containing either 
the empty pMIND vector or containing an inserted gene in pMIND, M63 media 
including hygromycin and tetracycline for induction was prepared.  All strains 
were cultured in triplicate in 6-well CellStar polystyrene plates with lids (Greiner 
BioOne, Germany) at 37°C for 7 days in a humidified box, without disturbing.  
After 7 days the plates were visually inspected and photographed prior to 
quantifying pellicle and biofilm formation. 
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2.5.3 Mycobacterium smegmatis biofilm and pellicle formation assay 
After growth for 7 days at 37°C in M63 biofilm media, control strains and variants 
were assayed for pellicle formation by examining the dry weight of the air-liquid 
interface cell layer and assayed for biofilm formation by crystal violet staining of 
the surface attached cell layer.  A technique was developed to retrieve almost 
100% of the pellicle cell layer.  Thick blotting paper (ADVANTEC®, Japan) cut to 
size for the 6-well dishes with a tag on the side was dried at 50°C overnight and 
weighed immediately before use.  A single circular blotting paper was gently laid 
on top of the surface pellicle and allowed to soak up media before withdrawing it 
and laying it pellicle side up on a tray to dry.  Blotting paper was dried at 50°C for 
2 hours and then weighed.   
Biofilm formation was assessed after the pellicle had been removed.  Each plate 
was inverted to discard the M63 biofilm media and 2 ml of MQ H2O gently 
applied to wash the wells.  The plates were inverted to discard the MQ H2O and 
blotted onto paper towels to remove the last traces of liquid and then 0.5 ml of 
0.1% crystal violet was applied and left at room temperature for 30 minutes with 
gentle swirling (60 rpm).  The stain was gently removed with a pipette for 
disposal and the wells gently washed with 3 x 2 ml MQ H2O by carefully adding 
the liquid, then gently swirling the plate by hand and inverting it and blotting 
onto paper towels.  Crystal violet stained biofilm was dissolved by adding 2 ml of 
100% ethanol to each well and incubating at room temperature for 1 hour while 
gently swirling (60 rpm).  Staining was quantified by measuring the absorbance at 
OD570 after a 1:100 dilution of the solubilised crystal violet solution into 1 ml of 
100% ethanol. 
 
2.5.4 SYTO®9 DNA staining of surface pellicle mycobacteria 
Square 22 mm glass coverslips (Deckgläser, Germany) were cleaned with a dry 
tissue and held bridged between plastic forceps, before carefully placing on top 
of the air-surface pellicle to attach it to the glass.  The coverslip was placed 
pellicle side up on a tray and dried for 30 minutes at 50°C.  The dried coverslips 
were stained with SYTO®9 DNA stain (Molecular Probes, USA) as follows.  DNA 
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stain was diluted to 5 μM in TE buffer and 200 μl applied to the coverslip surface 
and the samples incubated at room temperature in the dark for 40 minutes.  
Coverslips were then rinsed by carefully submerging in a beaker of MQ H2O for 
10 seconds.  A drop of mounting media was applied to a plain glass microscope 
slide and the stained coverslip laid facedown upon the drop.  Cells were viewed 
at 100 x oil immersion under blue light (ex = 485, em = 498) and photographed 
with a digital camera. 
 
2.5.5 Cloning into pMIND mycobacteria expression vector 
Primers were designed both with and without a ribosome binding site (RBS) for 
cloning into pMIND to be confident that this would not influence the 
experimental outcome.  Lsr2 and three DNA binding mutants of this protein were 
cloned into the mycobacteria tetracycline inducible expression vector pMIND 
supplied by R. O’Toole (Centre for Biodiscovery, School of Biological Sciences, 
Victoria University of Wellington; Blokpoel et al., 2005) as follows.  Lsr2 and the 
three DNA binding mutants, R97A, R99A and R97A-R99A were amplified from 
their respective pET30b plasmids via PCR using forward and reverse primers 
containing the restriction enzyme sites PstI and SpeI, respectively.  
 
Table ‎2.11.  Primers used for cloning M. tuberculosis lsr2 and mutants into pMIND. 
Primer Sequence Length 
Rv3597c_Pst1_Fwd GCA ACT GCA GAT GGC GAA GAA AGT AAC CGT CAC CTT G 37 bp 
Rv3597c_Pst1_RBS_F GGG GCT GCA GGG AGG AAT AAT GGC GAA GAA 30 bp 
Rv3597c_Spe1_Rev AAC TAG TTC AGG TCG CCG CGT GGT ATG CGT C 31 bp 
 
Standard Taq DNA polymerase PCR was performed at 58°C annealing 
temperature and 1.0 mM MgCl2 concentration, using 15 – 50 ng of purified 
plasmid as a template.  Gel extraction of a combined 4-fold PCR reaction size was 
performed and the DNA product quantified.  The PCR product was inserted into 
pMIND via appropriate enzyme digestion and ligation and transformed into 
TOP10 E. coli for colony PCR using cloning primers to confirm successful 
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transformants.  The cell suspension from positive clones was used to inoculate 
selective low salt LB media which was incubated overnight at 37°C for plasmid 
preparation for sequence verification.  Correctly cloned variants were then 
transformed into the Δlsr2 M. smegmatis mc2155 strain (NJS22; Colangeli et al., 
2007) using standard techniques.   
 
2.5.6 Strain typing of biofilm assay variants using colony PCR 
Primers designed for confirming cloning success in the pMIND vector by DNA 
sequencing and primers designed for the M. smegmatis mc2155 lsr2 gene 
MSMEG_6092 as well as the primers designed for cloning the variants into 
pMIND were all used for strain verification by colony PCR.   
 
Table ‎2.12.  Primers used for strain typing of M. smegmatis biofilm variants. 
Primer Sequence Product 
MSMEG_6092 Fwd ATG GCA AAG AAA GTG ACC GTC ACG CTT G 345 bp 
MSMEG_6092 Rev CTA AGT TGC CGC GTG GAA TGC GTC GAT C 345 bp 
Rv3597c_Pst1_RBS_F GGG GCT GCA GGG AGG AAT AAT GGC GAA GAA 360 bp 
Rv3597c_Spe1_Rev AAC TAG TTC AGG TCG CCG CGT GGT ATG CGT C 360 bp 
pMIND Fwd Primer GAT AAA GTG ACT GCT CGC TAC TCT 190/550 bp 
pMIND Rev Primer ATC ATC CGA ATC AAT ACG GTC GA 190/550 bp 
 
After transformation of the required pMIND vector into the appropriate strain 
and subsequent cell growth on solid media, a single colony was removed and 
resuspended in 5 μl of MQ H2O, mixed with 100 μl of PEG200/KOH solution and 
heated for 15 minutes at 95°C.  Two μl of the lysed cell mixture was used in a 
standard Taq DNA polymerase PCR performed at a 58°C annealing temperature 
and with 1.0 mM MgCl2.  pMIND sequencing primers were used at a lower 
dilution of 0.3 μM compared with the standard 0.6 μM amounts.  PCR products 
were analysed by 1% agarose gel analysis as per standard procedure.  The 
presence of an empty pMIND vector would result in a 190 bp PCR product in 
comparison with a 550 bp product if the vector contained the lsr2 gene. 
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3 Chapter Three – Lsr2 expression, purification & 
characterisation 
 
3.1 Introduction 
This chapter focuses on the expression and purification of the M. tuberculosis 
DNA binding protein Lsr2.  DNA binding proteins control cellular processes such 
as DNA replication, repair and recombination.  In bacteria, gene regulation is vital 
to be able to respond to changing environmental conditions and ultimately 
survive.  Nuclear extracts are often used for purification of DNA binding proteins 
from eukaryotes but in the case of bacteria, the whole cell lysate is usually the 
starting material.  Isolation of naturally expressed DNA binding proteins from 
within the cell is challenging as the proteins are normally expressed at low levels 
and several purification steps are required (Gadgil et al., 2001).  Use of an E. coli 
expression system alleviates these issues enabling a high level of protein 
expression and reducing the number of purification steps required.   
Lsr2 has been previously expressed in M. smegmatis mc2155 and E. coli.  Purified 
recombinant Lsr2 protein from the cytosolic fraction of M. smegmatis mc2155 
and cell lysate of E. coli has been shown to form both dimers and tetramers, 
respectively, in in vitro glutaraldehyde cross-linking experiments (Chen et al., 
2006; Chen et al., 2008).  Further cross-linking studies with E. coli expressed 
recombinant Lsr2 in complex with a 230 base pair DNA fragment indicated 
progressive oligomerisation of Lsr2 (Colangeli et al., 2007).  These in vitro studies 
give preliminary information about the association of Lsr2.  However, as this 
technique can allow non-specific protein interactions, it can give artificial results 
(Fadouloglou et al., 2008).   
Work presented in this chapter shows Lsr2 is a non specific DNA binding protein, 
is stable whilst bound to DNA (but poorly behaved without DNA), forms dimers 
and tetramers in vivo and is capable of forming large oligomeric structures when 
bound with DNA. 
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3.2 Results 
3.2.1 Lsr2 expressed in E. coli co-purifies with genomic DNA 
The E. coli expression plasmid pET30b containing the M. tuberculosis H37Rv lsr2 
gene (lsr2-pET30b) was kindly supplied by R. Colangeli and was cloned as follows 
(Colangeli et al., 2007).  The lsr2 gene (Rv3597c) was amplified by PCR from 
M. tuberculosis H37Rv genomic DNA and cloned into pET30b (Novagen) using the 
NdeI/XhoI restriction sites, positioning a 6 x histidine tag at the C-terminus of the 
protein.  DNA sequencing of amplified and purified plasmid confirmed the 
insertion of lsr2 within the NdeI/XhoI restriction sites and the positioning of the 6 
x histidine tag at the C-terminal end.  The lack of a cleavage site for the histidine 
tag gave a recombinant protein size of 13.2 kDa.  During this time, research by 
Colangeli and colleagues demonstrated that Lsr2 was a DNA binding protein 
(Colangeli et al., 2007). 
Small scale expression testing, histidine tag binding assays and large scale 
expression of Lsr2 prior to the initiation this study resulted in predominantly 
soluble protein that was purified using immobilised metal affinity 
chromatography (IMAC).  It was then realised that the large protein aggregates 
seen in the initial size exclusion chromatography (SEC) purification were Lsr2 
protein in complex with E. coli genomic DNA (as shown by agarose gel analysis).  
Consequently, a DNase enzyme digestion step was incorporated into the IMAC 
purification method to try to remove DNA from the preparation and obtain a 
more uniform protein solution.  Removal of the DNA from Lsr2 by enzyme 
digestion was unsuccessful and although the use of a urea denaturing method 
removed the DNA from Lsr2, attempts to subsequently refold the protein (and 
visualise using native gels) were not successful. 
During this study, large scale expression cultures typically took around six hours 
to reach an appropriate optical density worthy of induction, which was three 
times as long in comparison with other E. coli cultures being used to express 
proteins.  It appeared that the expression of Lsr2 in E. coli slowed the growth of 
the bacteria.  Furthermore, during this study Lsr2 consistently co-purified with 
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E. coli genomic DNA during IMAC, an observation that has never been reported 
in other publications. The chromatogram and corresponding SDS-PAGE and 
agarose gels (Figure ‎3.1) illustrate the tight binding of Lsr2 to the column used 
for IMAC and the resulting peaks and fractions that include Lsr2 bound with DNA.  
Proteins bound non-specifically to the IMAC column are eluted early in the 
imidazole elution gradient, whereas Lsr2 is eluted at 100 % elution buffer which 
corresponds to 500 mM imidazole. 
 
 
 
Figure ‎3.1.  Lsr2 co-purifies with genomic DNA during IMAC purification. (A) Chromatogram of 
the elution buffer gradient and UV absorbance profile; (B) 1% agarose gel with sample lysate (L), 
column flow through (F), and fractions from peak A and B; (C) 15% SDS-PAGE gel of the 
corresponding lysate (L), flow through (F) and fractions from peak A and B. 
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The routine DNase digestion of the cell lysate prior to IMAC was later removed 
from the purification protocol as it was felt that it was not an efficient method 
for reducing DNA co-purification as evidenced by Figure ‎3.1.  As a consequence 
of this, the cell lysate was viscous and difficult to filter prior to application on the 
IMAC column so the 0.2 μm fine filtering step was removed from the filtering 
process and a 0.45 μm filter was the finest used.  The protein yield was 
uncompromised by these alterations and further purification steps were 
investigated to remove the co-purified DNA (section ‎3.2.2).  IMAC purified 
protein was very stable at 4°C for weeks to months without showing signs of 
protein or DNA degradation. 
Transmission electron microscopy (TEM) was used as a technique to visualise the 
complex of Lsr2 bound with DNA.  Early images showed a complex arrangement 
of strands or “fibrils” that represent DNA coated by Lsr2.  These images 
confirmed that DNA was plentiful in the purified Lsr2 protein samples but that 
DNase digestion of this preparation was of limited use as a purification step as 
digestion was not uniform and was unable to completely remove the DNA 
(Figure ‎3.2). 
Throughout this study TEM was commonly used to visualise the arrangement of 
Lsr2 with co-purified DNA to monitor the affects of subsequent purification steps.  
Higher quality preparations of Lsr2 in complex with DNA were produced which 
allowed some preliminary measurements to be made to propose the manner in 
which Lsr2 was associated with the DNA.  The negatively stained protein sample 
revealed regular fibrils of around 90 Å in diameter (Figure ‎3.3A), that show Lsr2 
decorating the genomic DNA.  It was proposed that Lsr2 is able to protect DNA 
from DNase treatment by binding and shielding the DNA.  Single particle analysis 
performed by our collaborators was used to help visualise the structure of the 
complexes seen using TEM.  Class average analysis of hundreds of short linear 
sections from several micrographs of these fibrils shows a helical winding pattern, 
suggesting that Lsr2 is bound to the DNA following its helical topology 
(Figure ‎3.3B).    
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Figure ‎3.2.  Electron micrograph images of IMAC purified Lsr2 shows co-purification with 
genomic DNA and limited DNase digestion.  (A) Negative stained purified Lsr2 shows intertwined 
and coiled fibrils of DNA coated by protein; (B) after DNase digestion for 1 hour at 37°C the fibril-
like appearance remains but the coils are in smaller clumps; (C) 1% agarose gel of Lsr2 digested 
with DNase at 37°C for up to 4 hours shows limited digestion (C = control).  
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Figure ‎3.3.  Detailed electron micrograph images reveal the structure of Lsr2/DNA complexes.   
(A) Negative stained purified Lsr2 displays a filamentous structure; (B) five representative class 
averages of Lsr2 isolated from micrographs reveals a structure with helical winding and a 
diameter of 90 Å; (C) A cartoon representation of Lsr2 coating a strand of DNA that illustrates 
how Lsr2 may coat the DNA resulting in a diameter of 90 Å (micrograph images in A and B were 
published (Colangeli et al., 2009)). 
 
From the detailed micrograph images a model of DNA binding is proposed.  A 
cartoon illustration of this model (Figure ‎3.3C) shows how the non-specific DNA 
binding nature of Lsr2 would allow the formation of these large fibrils.  Our 
proposal is that the 90 Å fibril comprises of one strand of DNA (≈ 22 Å in 
diameter) coated on either side by Lsr2 (≈ 34 Å in diameter; estimated to be 
similar in size to lysozyme).  
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The large amount of DNA co-purified with Lsr2 significantly influences its 
behaviour in in vitro studies.  For example, theoretically, Lsr2 alone would 
require reversed electrode orientation to migrate through a native 
polyacrylamide gel due to its low isoelectric point (≈ 10).  However, Lsr2 purified 
using IMAC and in complex with DNA migrates with the normal electrode 
orientation.  It was also noted that the migration of the complex was retarded 
once it reached the higher percentage resolving gel which was thought to be due 
to its large mass (results not shown). 
 
3.2.2 High salt buffers disrupt Lsr2 and DNA interaction 
Initial SEC purification of recombinant Lsr2 (isolated from E. coli using IMAC) 
revealed what was thought to be large soluble aggregates of protein or 
incorrectly folded protein as a UV absorption peak appeared early and 
corresponded with the column void volume which verifies the presence of a 
large complex.  As detailed in section ‎3.2.1, it was discovered that Lsr2 was co-
purifying with DNA and subsequent unsatisfactory attempts using DNase 
treatment prior to IMAC and SEC to completely remove the DNA led to the use of 
high salt buffers for DNA removal. 
IMAC-purified Lsr2 in complex with DNA was subjected to treatment with high 
salt buffers beginning with a 1 M NaCl buffer (in small gel electrophoresis assays) 
and increasing the concentration to buffers containing 2 M and 4 M NaCl.  Small 
scale analytical SEC was initially used to determine the lowest NaCl 
concentration required to dissociate Lsr2 from the DNA.  The best procedure to 
adjust the protein buffer solution from low to high salt and to also concentrate 
the protein for SEC whilst still keeping the protein soluble was also determined.  
At this point, the addition of an equal volume of a buffer containing 4 M NaCl to 
the protein sample in the standard IMAC elution buffer (resulting in a final 2 M 
NaCl condition) and an overnight incubation at 4°C was preferred.  
Centrifugation steps to concentrate the protein in high salt were also performed 
at 4°C. 
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Large scale preparative SEC was routinely used to prepare DNA-free Lsr2 protein.  
The complex of Lsr2 and genomic DNA in a buffer containing 2 M NaCl was 
efficiently separated by SEC.  DNA contributed significantly to the UV absorption 
at 280 nm and was shown to pass quickly through the column, eluting 
immediately after the void volume whilst Lsr2 was retarded by the column and 
passed through more slowly (Figure ‎3.4A).  Agarose gel and SDS-PAGE gel 
analysis of fractions collected during SEC confirmed that the protein and DNA 
were indeed separated (Figure ‎3.4B and C).   
 
 
Figure ‎3.4.  Size exclusion chromatography of recombinant Lsr2 in a 2 M NaCl buffer dissociates 
Lsr2 from co-purified genomic DNA.  (A) Chromatogram of the UV absorbance profile of DNA(A) 
and Lsr2 (B); (B) 1% agarose gel with sample load (L) and fractions from peak A and B; (C) 15% 
SDS-PAGE gel of the corresponding sample load (L) and fractions from peak A and B. 
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Due to the high salt content of the buffer used for SEC the native size of Lsr2 was 
not able to be accurately determined as the salt influences the mobility of the 
protein.  The molecular weight of recombinant Lsr2 is predicted to be 13.2 kDa 
hence its expected dimeric form would be around 26 kDa.  A calibration curve 
equation for the analytical SEC column predicted a size of 34 kDa for Lsr2 in 2 M 
NaCl buffer, whereas a calibration curve for the preparative SEC column 
predicted between 56 kDa to 127 kDa as the exact peak position of Lsr2 was 
variable between different preparations. 
It was determined that Lsr2 unaccompanied by DNA was prone to binding to 
materials such as low protein binding PES membranes in the centrifugal 
concentrators used for preparing high concentrations of Lsr2 post SEC 
purification.  Provided Lsr2 was in a buffer with a salt concentration of 1 M or 
above, it was able to be handled without fear of it adhering to surfaces.  It 
therefore became routine to first concentrate Lsr2 in a 2 M NaCl buffer post SEC 
and then dialyse it into alternative buffers afterwards.  Other modifications to 
the purification procedure included altering the overnight high salt incubation 
temperature and centrifugation temperature to 18°C to improve protein 
solubility and to reduce the amount of sample retained by the compulsory 
0.2 μm filtration step prior to column loading. 
Attempts to visualise Lsr2 devoid of DNA on native polyacrylamide gels by 
electrophoresis with electrodes in normal and reverse orientations and with 
altered buffer pH conditions as well as on native agarose gels were unsuccessful.  
The behaviour of Lsr2 without DNA had foiled previous attempts to discover 
favourable refolding conditions due to the inability to visualise the refolded 
protein by native gel electrophoresis and this again proved to be an issue and 
many experiments attempting to unite Lsr2 with a variety of designed DNA 
fragments were abandoned. 
TEM was used to visualise how the high salt conditions used to remove the co-
purified DNA would affect the structure of the fibrils seen previously with 
IMAC-purified Lsr2.  Lsr2 samples in buffers containing increasing concentrations 
of salt were compared with a low salt sample using TEM (Figure ‎3.5).  As the salt 
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concentration increased the fibrils became narrower in diameter and less 
entwined with each other (Figure ‎3.5B), appeared in much smaller twisted 
clumps (Figure ‎3.5C) and were very sparsely distributed, appearing as short 
lengths and without intertwining (Figure ‎3.5D).  These changes in topology 
reflect the disruption of the electrostatic interactions between Lsr2 and the DNA.  
 
 
Figure ‎3.5.  Electron micrographs of Lsr2/DNA complexes in high salt buffer reveal shorter and 
less entwined fibrils of protein coating DNA strands.  (A)  Negative stained IMAC purified Lsr2 in 
complex with DNA in a low salt buffer (200 mM NaCl); (B) in a 1.0 M NaCl buffer; (C) in a 1.5 M 
NaCl buffer; (D) in a 2.0 M NaCl buffer. 
 
SEC purified Lsr2 was subjected to robotic crystallisation screens at 
concentrations of 0.1 mg/ml and 6 mg/ml.  Crystals were observed in some 
conditions and hanging drop fine screens around the crystallisation conditions 
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were prepared.  Additive screens as well as crystal seeding was used in further 
fine screen attempts but all hopeful crystal candidates were revealed to be salt 
after analysis by X-ray diffraction. 
After all attempts to completely remove contaminating genomic DNA from Lsr2, 
the presence of small fragments of DNA of around 100 base pairs in size was 
noted in a highly concentrated sample run on an agarose gel.  This protein 
sample was the remnant of protein used in crystallography trials.  This discovery 
highlights the tight association between Lsr2 and DNA and the difficulty in 
preparing DNA-free protein samples. 
 
3.2.3 MALDI-TOF analysis confirms Lsr2 purification 
Purified Lsr2 protein from both IMAC and SEC purifications was analysed by 
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) after in-gel trypsin digestion was used to generate peptide 
fragments of the protein.  A number of factors prompted the use of MALDI-TOF 
MS to confirm the exact nature of the recombinant protein that was being 
studied.  The protein ran at a larger mass on an SDS-PAGE gel than was predicted 
(15 kDa vs 13 kDa), it co-purified with large amounts of genomic E. coli DNA that 
was never reported by other researchers and attempts to replicate other 
researchers published DNA binding assays repeatedly failed.  There was concern 
that the recombinant Lsr2 protein being produced and studied in our lab may 
have differed from that studied by other researchers. 
Analysis of the peptide fragments produced by trypsin digestion of Lsr2 protein 
separated in an SDS-PAGE gel confirmed that recombinant Lsr2 from 
M. tuberculosis was successfully being produced and purified in the lab.  Mass 
peaks on the spectrum with the greatest intensity matched the predicted masses 
for a trypsin digest of recombinant Lsr2 (Figure ‎3.6) with other less intense peaks 
also matching predictions (results not shown). 
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Figure ‎3.6.  Peptide mass analysis of trypsin digested Lsr2 using MALDI-TOF MS confirms 
purification of recombinant Lsr2.  A comparison between the mass peaks on the collected 
spectrum (top) with a predicted trypsin digest of Lsr2 identified seven obvious peaks that match 
trypsin digest predictions (bottom).  Mass accuracy was 300 ppm with one missed cleavage.  Data 
was analysed by Bruker Data Analysis.  The Lsr2 amino acid sequence is shown in the centre. 
 
3.2.4 Lsr2 exchanges from co-purified genomic DNA to DNA oligos  
A number of different approaches were used to examine the ability of Lsr2 to 
bind to DNA.  Analysis of the change in mobility of DNA fragments during 
electrophoresis when bound with Lsr2 was attempted with a variety of double 
stranded DNA species including a DNA mass ladder, sequence-specific 
oligonucleotides, radiolabelled oligonucleotides and PCR products.  Results were 
variable between trials and there was a lack of a convincing gel shift with these 
experiments which was in contrast to published gel shift experiments.  
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With limited evidence that Lsr2 could bind to DNA fragments but with the desire 
to have Lsr2 uniformly bound with short lengths of DNA for crystallisation 
attempts, further binding studies were performed.  The rationale for these 
experiments was to bind Lsr2 to biotin-labelled, AT-rich DNA, and purify the 
complex by targeting the biotin label so that a uniform species of the complex 
could be used in crystallisation trials.  Both SEC Lsr2 (without DNA) and IMAC 
purified Lsr2 successfully bound to short (16 base pair) biotin-labelled DNA 
oligonucleotides and were concentrated on streptavidin magnetic particles.  
These results showed that Lsr2 was capable of binding to very short DNA pieces 
and was able to exchange from co-purified genomic DNA to DNA 
oligonucleotides (Figure ‎3.7).  An interesting observation from this experiment 
was the presence of multiple oligomeric forms of Lsr2 visible under the 
denaturing conditions of SDS-PAGE gel electrophoresis (Figure ‎3.7B). 
 
 
Figure ‎3.7.  IMAC purified Lsr2 exchanges from co-purified genomic DNA to short biotinylated 
DNA oligonucleotides.  (A)  1% agarose gel showing non-exchanged Lsr2 remains bound with 
genomic DNA in solution (lane 1) and protein attached to the streptavidin beads did not contain 
genomic DNA (lane 4).  The staining represents genomic DNA not biotinylated oligonucleotide as 
it was too dilute to be seen; (B) 15% SDS-PAGE analysis reveals that not all Lsr2 exchanged on to 
the DNA oligos (lane 1) but protein that did exchange was tightly bound as it was not dislodged 
by washing of the streptavidin beads (lanes 2 and 3).  Lane 5 of both gels represents IMAC 
purified Lsr2 co-purified with genomic DNA.  Arrows point to the progressive oligomerisation of 
Lsr2 seen (monomer, dimer, trimer, tetramer and pentamer). 
 
Removal of the streptavidin particles was necessary to use the Lsr2/oligo 
complex for crystallography.  A number of approaches were used.  The use of a 
buffer containing biotin to compete with the streptavidin particles and elute the 
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bound complex had little effect other than reducing the amount of protein 
oligomerisation observed on the SDS-PAGE gel.  “Softlink Soft Release Avidin 
Resin” was used for binding the Lsr2/oligo complex as it was claimed that biotin 
would reversibly bind to these particles, however these claims were proven false 
in this case.  The particles could not be separated using the procedure 
recommended by the manufacturer.  Finally, the biotinlyated oligonucleoides 
were redesigned, adding additional nucleotides between the end of 
complementary strand and the biotin label to allow cleavage by DNase.  The new 
biotin-labelled DNA oligonucleotides successfully bound IMAC-purified Lsr2 and 
DNase digestion was able to remove the complex from the streptavidin particles.    
However, whilst fine-tuning the DNase digestion step a flaw in this approach was 
revealed as DNase treatment was affecting protein integrity and consequently a 
uniform Lsr2/DNA complex could not be attained for use in crystallography trials. 
 
3.2.5 Evidence of Lsr2 protein oligomerisation 
Crosslinking of proteins using glutaraldehyde is often used to obtain initial 
information about the larger assembly of protein subunits.  In this study large 
oligomeric structures of Lsr2 (in complex with co-purified genomic DNA) as well 
as dimers and trimers were detected by SDS-PAGE after a two minute incubation 
with glutaraldehyde (Figure ‎3.8A).  Two dimeric Lsr2 species were observed 
which may correspond to dimers with and without the C-terminal histidine tag.  
Recombinant Lsr2 expressed with a maltose binding protein tag (section ‎3.2.6) 
(in complex with co-purified genomic DNA) is also capable of forming large 
oligomeric structures after crosslinking with glutaraldehyde (Figure ‎3.8B).  This 
simulated large complex formation, in combination with the in vitro complex 
formation observed with the binding of Lsr2 to biotinylated DNA oligos 
(Figure ‎3.7) shows the potential for a dynamic interaction between Lsr2 and DNA. 
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Figure ‎3.8.  Progressive Lsr2 oligomerisation in the presence of co-purified genomic DNA.  (A)  
IMAC purified Lsr2 forms dimers, trimers (arrows) and larger oligomeric structures when 
crosslinked with 0.1% glutaraldehyde and examined using 18% SDS-PAGE; (B) affinity purified 
Lsr2 with a MBP tag forms large oligomeric structures when crosslinked with glutaraldehyde that 
are unable to migrate through the stacking gel layer. 
 
Evidence that Lsr2 exists in the bacterial cell in units larger than a monomer was 
revealed through Western blotting.  Antibodies to M. tuberculosis H37Rv Lsr2 
were generated at the AgResearch antibody facility, Ruakura, Hamilton.  IMAC-
purified Lsr2 (1 mg/ml) was used to immunise white rabbits by subcutaneous 
injection.  Primary immunisation was performed with a solution containing 0.2 
ml of Lsr2, followed by injections every two weeks for six weeks with a solution 
containing 0.1 ml of Lsr2.  Polyclonal antibodies contained within the serum of 
the blood from immunised rabbits were used for Western blotting.   
Whole cell lysates of M. smegmatis mc2155 and M. bovis BCG separated by SDS-
PAGE and incubated with antibodies generated to E. coli recombinant Lsr2 show 
a number of bands that correspond to the molecular weight of a dimer, trimer 
and oligomer (Figure ‎3.9).  The cell lysate protein concentration of M. bovis BCG 
was higher than that of M. smegmatis mc2155 and hence the intensity of the 
bands is greater revealing a smaller band that could represent a possible Lsr2 
monomer.  The band representing the monomer in M. bovis BCG differs in 
molecular weight when compared to recombinant Lsr2 expressed in E. coli 
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(Figure ‎3.9, left panel).  Based on the intensity of all the bands in both bacterial 
cell lysates, it is speculated that Lsr2 is predominantly a dimer in the cell and that 
the protein subunits are tightly associated as they do not separate on a 
denaturing gel. 
 
 
Figure ‎3.9.  Western blot analysis of M. smegmatis mc
2
155 and M. bovis BCG whole cell lysates 
reveals multiple oligomeric forms of Lsr2.  Recombinant monomer Lsr2 (left) is shown alongside 
triplicate samples of whole cell lysate (separated on 15% SDS-PAGE gels) from M. smegmatis 
mc
2
155 (centre) and M. bovis BCG (right).  Antibodies to recombinant Lsr2 are cross-reactive in 
other species and detect monomer, dimer, trimer and larger oligomeric forms in both species 
(arrows). 
 
The three levels of experimentation (simulated, in vitro and in vivo) presented 
here provide evidence that Lsr2 is capable of forming large, tightly associating 
structures in complex with DNA.   
 
3.2.6 Expression of Lsr2 with alternative tag improves protein yield 
Protein solubility can be improved by expression as a fusion protein with maltose 
binding protein (MBP).  This fusion protein can be easily purified due to its 
affinity for amylose resin and the MBP domain can be removed using Factor Xa 
protease.  An improvement in Lsr2 solubility was sought for further 
M. smegmatis mc
2
155         M. bovis BCG 
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crystallisation attempts and this expression system gave the choice to remove 
the fusion tag which was not an option with recombinant protein expression 
using pET30b.  The lsr2 gene was amplified by PCR from the lsr2-pET30b plasmid 
and cloned into the cytoplasmic expression vector pMAL-c2X using the XbaI/PstI 
restriction sites, positioning an MBP tag at the N-terminus of the protein.  DNA 
sequencing of amplified and purified plasmid confirmed the insertion of lsr2 
within the appropriate restriction sites and the positioning of the MBP tag which 
would result in the expression of an approximately 56 kDa recombinant protein.   
 
 
Figure ‎3.10.  MBP tagged Lsr2 co-purifies with genomic DNA during amylase resin purification. 
(A) Chromatogram of the elution buffer gradient and UV absorbance profile; (B) 1% agarose gel 
with sample lysate (L), column flow through (F), and fractions from peak A; (C) 15% SDS-PAGE gel 
of the corresponding lysate, flow through and fractions from peak A. 
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Small scale expression testing, MBP binding assays and large scale expression of 
Lsr2 fused with MBP resulted in soluble protein that was purified using amylose 
or dextrin resin chromatography.  The chromatogram and corresponding agarose 
and SDS-PAGE gels (Figure ‎3.10) illustrate the tight binding of Lsr2-MBP to the 
column, and easy removal with elution buffer.  Gel analysis of the peak fractions 
reveal that Lsr2-MBP also co-purifies with genomic DNA despite MBP being fused 
to the N-terminal end of the protein which indicates that its DNA binding ability 
has not been compromised.  Amylose resin purified Lsr2-MBP showed the same 
ability as IMAC purified recombinant Lsr2 to form large complexes after chemical 
crosslinking with 0.1% glutaraldehyde (Figure ‎3.8B). 
The amylose resin purified Lsr2-MBP/DNA complex was efficiently separated by 
SEC in buffer containing 2 M NaCl (results not shown) as was routinely used for 
the purification of recombinant Lsr2 and DNA complexes (section ‎3.2.2). 
TEM was used as a technique to visualise the complex of Lsr2-MBP bound with 
DNA.  Micrograph images show an arrangement of strands that differ to the 
“fibrils” seen previously with Lsr2/DNA complexes.  Although Lsr2-MBP is able to 
bind DNA in a non-specific manner, and coat the DNA, the arrangement of the 
protein on the DNA is different.  Complexes of Lsr2-MBP and DNA have a knotted 
or “brain-like” twisted appearance and do not form a mesh-work of intertwined 
fibrils as seen in micrographs of Lsr2/DNA complexes (Figure ‎3.11).  It is 
hypothesised that the presence of the large 42 kDa MBP at the N-terminal end of 
Lsr2 (13 kDa) is affecting the mechanism of DNA binding. 
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Figure ‎3.11.  Electron micrographs of recombinant Lsr2-MBP/DNA complexes show lack of 
fibril-like structure and no intertwining compared with recombinant Lsr2/DNA complexes.  (A)  
Negative stained IMAC purified Lsr2 in complex with co-purified genomic DNA; (B) amylose resin 
purified Lsr2-MBP in complex with co-purified genomic DNA. 
 
Due to the behaviour of Lsr2 without co-purified DNA it was difficult to obtain a 
concentration suitable for successful crystallisation.   By expressing Lsr2 linked to 
MBP, a much higher concentration was achieved and crystallisation trials were 
performed without the removal of the MBP.  SEC purified Lsr2-MBP protein was 
subjected to robotic crystallisation screens at a concentration of 60 mg/ml.  No 
crystals were observed in these screens or fine screens around the promising 
crystallisation conditions. 
 
3.2.7 Alteration of positively charged residues is detrimental to E. coli 
Five lysine residues present in Lsr2 contribute greatly to the overall basic nature 
of the protein.  At this time, the domain structure of Lsr2 and the residues 
involved in DNA binding were unknown and so it was hypothesised that altering 
the lysine residues would reduce the overall positive charge of the protein and 
influence the ability of Lsr2 to bind to DNA, which in turn could improve the 
purification and behaviour of this protein.  It was previously observed that 
expression of Lsr2 in E. coli slowed the bacteria’s growth rate considerably.  
Perhaps altering the lysine residues would alleviate the influence Lsr2 may have 
on the growth rate of E. coli.   Initially, a chemical methylation method was used 
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to alter the lysine residues but this method gave variable protein modification 
results and instead genes containing point mutations to alter each lysine to an 
alanine residue were manufactured (Geneart). 
Three lysine to alanine mutants were designed.  The first mutant comprised the 
two lysine residues K3 and K4 at the N-terminal end of Lsr2 (2K2A), the second 
included the three lysine residues K39, K43 and K49 clustered in the centre of 
Lsr2 (3K3A) and the third encompassed all five lysine residues (5K5A).  All lysine 
residues are in the N-terminal dimerisation domain of Lsr2.  The manufactured 
genes were cloned into an E .coli expression vector pDEST17, positioning a 6 x 
histidine tag (lacking a protease cleavage site) at the N-terminal end of Lsr2 
which produced a 16 kDa recombinant protein.  
Small scale expression testing with histidine tag binding assays were hampered 
by the mixed ability of the three transformed mutant strains of E. coli to 
successfully grow prior to the induction of protein expression.  Mutant strain 
growth was attempted at three different temperatures and mutant strains were 
refreshed by repeating plasmid transformations but both these approaches did 
not improve cell growth.  This change in growth of E. coli suggested that the 
pDEST17 vector had “leaky” expression of the Lsr2 mutants that this was 
influencing cell health.  Poor cell growth was associated with cell clumping and 
flocculation in the liquid culture media.  Smears of bacterial cells obtained from 
poorly-growing cultures of all mutants were stained using fluorescent antibodies 
to Lsr2 (Figure ‎3.12B-D) and an example was Gram stained (Figure ‎3.12F).  Gram 
stained E. coli harbouring the 2K2A expression vector showed remarkable long 
chains of rods that have failed to dissociate after cell division. 
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Figure ‎3.12.   E. coli strains containing lysine-alanine Lsr2 mutant expression vectors have 
impaired growth, forming long chains of cells compared with E. coli containing the native Lsr2 
expression vector.  Fluorescent antibodies to Lsr2 illuminate the entire cell of E. coli harbouring 
the native recombinant Lsr2 expression vector (A), the 2K2A Lsr2 mutant expression vector (B), 
the 3K3A Lsr2 mutant expression vector (C) or the 5K5A Lsr2 mutant expression vector (D).  All 
cell samples were from un-induced cultures.  An example where the 2K2A un-induced mutant 
had flocculated growth which settled to the bottom (E) and the long chains of cells observed with 
a simple Gram stain (F).  Images were captured at 100x under oil immersion on a light microscope. 
 
A number of small scale expression tests using a variety of expression 
temperatures and with a number of lysis buffers were performed.  Results from 
the small scale expression tests with the three mutants, revealed that all three 
recombinant proteins were detected in both the insoluble and soluble cell 
fractions and were present as a monomer and dimer (Figure ‎3.13).  Large scale 
expression cultures of the three lysine to alanine mutants were purified using 
IMAC chromatography but were not successful in producing mutant Lsr2 protein 
(results not shown). 
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Figure ‎3.13.  Small scale histidine tag binding assays for Lsr2 lysine mutants showed soluble and 
insoluble protein in both monomer and dimer forms.  An example of a small scale expression 
test performed at 25°C.  The lysine mutant 2K2A was expressed as a dimer and was present in 
the insoluble cell pellet only.  Mutant 3K3A was expressed as both a monomer and dimer in both 
the soluble and insoluble fractions and the monomer was enriched on the purification beads.  
The mutant 5K5A was expressed as both a monomer and dimer in both the soluble and insoluble 
fractions with the monomer enriched on the purification beads.  U = uninduced, IN = induced, SN 
= supernatant (soluble fraction). P = pellet (insoluble fraction), UB = unbound and Bd = bead 
fraction. 
  
 Chapter Three – Lsr2 expression, purification & characterisation 99 
3.3 Discussion 
The DNA binding protein Lsr2 from M. tuberculosis H37Rv was successfully 
expressed at high levels in E. coli however a trait, not mentioned in previous 
published research, of co-purifying with large quantities of genomic DNA 
required an additional purification step in a high salt buffer to dissociate the 
protein and DNA.  The ability of Lsr2 to bind large amounts of genomic DNA 
illustrates the nonspecific DNA binding nature of this protein.  Negative stained 
TEM images of Lsr2/DNA complexes shows large “spaghetti-like” structures with 
protein coating the DNA strands, entwining lengths of DNA together and 
crosslinking neighbouring “fibrils” confirming a nonspecific association with large 
quantities of DNA. 
The handling of Lsr2 devoid of DNA presented further challenges as it was prone 
to binding to low protein binding membranes during centrifugal concentration 
and would aggregate at low temperatures and high concentrations.  DNase 
treatment of the Lsr2/DNA complex was not efficient enough to be a beneficial 
step in DNA removal during the purification process and it was also challenging 
to develop a technique to exchange Lsr2 onto short designed lengths of DNA to 
obtain a uniform sample for protein crystallisation studies.  It is hypothesised 
that Lsr2 is able to protect DNA from DNase digestion by extensive coating of the 
DNA hence explaining the limited ability of this enzyme to remove the DNA. 
Protein crystallisation attempts using Lsr2 without DNA as well as using an 
Lsr2-MBP fusion protein to increase the protein yield were unsuccessful.   It is 
crucial that a protein sample is uniform in its composition for crystallisation to be 
successful and it was discovered that after all attempts to remove co-purified 
genomic DNA from Lsr2, there still remained a small molecular weight pool of 
DNA bound to the protein which was likely to have hindered attempts to grow 
crystals.   
Lsr2 is thought to express as a dimer however it was difficult to confirm this with 
the recombinant protein produced.  Size exclusion chromatography may be used 
to measure the approximate mass of a protein through the generation of a 
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calibration curve and subsequent equation using protein calibration standards.  
However in this case due to the fact that Lsr2 was always purified using SEC in a 
high salt buffer, the mass was not able to be predicted.  Lsr2 appeared to purify 
as a dimer or as other larger complexes in high salt conditions which suggests it 
has strongly interacting residues that enable the formation of oligomers.  
The modification of lysine residues in an attempt to alter the DNA binding ability 
of Lsr2 had a dramatic affect on E. coli cell growth both prior to and during the 
attempted expression of the recombinant proteins.  Poor cell growth was 
accompanied by inconsistent and insoluble protein expression.  These traits are 
often the result of protein toxicity.  Nevertheless, upon successful expression, 
Lsr2 mutants were observed in a dimeric form. 
The formation of higher order structures of Lsr2 was seen both in vitro and in 
vivo.  Evidence that Lsr2 naturally forms larger protein structures in complex with 
DNA was gathered through western blot analysis of M. smegmatis and M. bovis 
BCG cell lysates.  Lsr2 appears predominantly as a dimer, but also as a trimer and 
larger complexes under denaturing gel conditions which reinforces the tight 
association between key residues in Lsr2. 
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4 Chapter Four – DNA binding for three Lsr2 mutants 
 
4.1 Introduction 
During the expression, purification and characterisation of Lsr2 (in Chapter 
Three), the tight association between Lsr2 and E. coli genomic DNA was noted.  
Consistent co-purification of Lsr2 with genomic DNA during recombinant protein 
purification has only been noted in our work (Colangeli et al., 2009) and it 
creates technical challenges when working with this protein.  DNA removal using 
DNase was only partially successful however the use of a high salt buffer enabled 
DNA dissociation on a large scale.   
Molecular methods to reduce the DNA binding ability of Lsr2 were employed to 
potentially provide DNA-free purified protein.  In the early phase of this study, 
the N-terminal dimerisation domain and C-terminal DNA binding domain 
arrangement of Lsr2 and the residues involved in DNA binding were unknown.  
So a strategy of mutating the five positively charged lysine residues of Lsr2 was 
performed to change the overall charge of Lsr2 in an attempt (albeit unsuccessful) 
to alter the DNA binding properties and to enable effortless purification (Chapter 
Three).  A second approach to alter the DNA binding ability of Lsr2 would be to 
mutate arginine residues involved with DNA binding.   
This chapter focuses on the generation of Lsr2 mutants that have an altered 
ability to bind DNA.  The rationale for the production of DNA binding mutants 
was to achieve the purification of DNA-free protein that was homogenous and 
suitable for protein crystallisation studies.  
Lsr2 mutant design was made possible by the previous elucidation of the 3D 
structure of the C-terminal DNA binding domain of Lsr2 (Gordon et al., 2010).  
Earlier analysis of the C-terminal DNA binding domain structure of Lsr2 (using 
nuclear magnetic resonance (NMR) techniques) identified residues that were 
central to DNA binding and enabled a model of DNA binding to be proposed 
(Gordon et al., 2010).  The DNA binding domain consists of two α-helices, which 
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are perpendicular to each other and interact via hydrophobic residues.  NMR 
titration experiments using a short piece of DNA revealed potential DNA binding 
interfaces and modelling of Lsr2 in complex with DNA showed a two-component 
mechanism of DNA binding, with residues interacting in the minor groove and 
also along the edge of the major groove.   Residues R97-G98-R99 in the loop 
insert into the minor groove of the DNA with the two arginine side chains 
pointing away from each other whilst outside the major groove, side chains R77, 
S80, R84 and S95 interact with the sugar-phosphate backbone on either edge of 
the minor groove (Gordon et al., 2010).  The residues R84, R97 and R99 are all 
highly conserved among Lsr2 homologues and are proposed to be important for 
DNA binding and it was for these reasons that they were selected as candidates 
for mutagenesis and DNA binding studies (Figure ‎4.1). 
 
 
Figure ‎4.1.  The highly conserved residues R84, R97 and 
R99 in the DNA binding domain of Lsr2 are proposed to 
interact with DNA and are candidates for mutagenesis 
studies.  A cartoon representation of the NMR solution 
structure of the C-terminal DNA binding domain of Lsr2 
(PDB; 2KNG) showing residues as sticks.  The chain 
termini and residues are labelled and the protein 
depiction was rendered with PYMOL. 
 
 
 
 
To characterise and assess the function of the mutant forms of Lsr2 a number of 
biophysical methods can be employed such as thermal stability assays, dynamic 
light scattering and circular dichroism (CD).   A fluorescence-based thermal 
stability assay originally used for buffer optimisation and ligand-induced 
stabilisation of proteins can be used to assess the thermally induced melting 
point of proteins (Ericsson et al., 2006).  The theory behind this technique is that 
folded and unfolded proteins can be identified by their interaction with a 
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hydrophobic fluoroprobe.  In solution the probe is quenched but will bind to the 
unfolding hydrophobic interior of a protein, leading to a reduction in quenching 
and the detection of fluorescence emission that can be studied as a function of 
temperature.  The thermally induced unfolding process follows a two-state 
model of protein unfolding kinetics with a swift transition between the folded 
and unfolded state of a protein and the melting temperature (Tm) defined as the 
midpoint temperature of this transition.  Some studies have shown that melting 
temperatures obtained with the thermally induced unfolding method correlate 
with temperatures obtained by other biophysical methods such as CD and 
differential scanning calorimetry (Ericsson et al., 2006).  Through protein melting 
temperature changes, this thermal stability assay may reveal the effect of 
mutations of the DNA binding residues of Lsr2 and the effect on protein stability. 
CD spectroscopy is a useful technique for the analysis of the secondary structure 
of proteins.  CD measures the difference in the absorption of the two 
components of polarised light – left-handed polarised light and right-handed 
polarised light – that arise due to structural asymmetry.  The asymmetric carbon 
atoms present in the amino acid residues results in the protein displaying optical 
activity (Carpenter & Geoff Kneale, 1994).  A disordered structure will show zero 
CD intensity whereas an ordered structure will give a spectrum which can 
contain both negative and positive signals.  Using CD it is easy to observe 
changes in the secondary structure of proteins that may result from changes in 
pH, temperature,  and ligand binding.  Proteins that differ in their composition of 
α-helices, anti-parallel and parallel β-sheets will have CD spectra that show 
significant differences in shape and size (Johnson, 1988).   
CD spectroscopy in the “far-UV” spectral region (190-250 nm) allows secondary 
structure determination whereas CD spectroscopy in the “near-UV” spectral 
region (250-350 nm) can provide information about protein tertiary structure.  
Analysis of the spectrum of a protein for secondary structure may be done by 
comparison to reference CD spectra for pure secondary structures as shown in 
Figure ‎4.2 (Greenfield, 2007), by the use of online modelling (Cary & Kneale, 
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2008), or by using reference spectra derived from collected spectra of proteins 
with known secondary structure (Johnson, 1988). 
 
 
Figure ‎4.2  The CD spectra in the “far-UV” 
spectral region of pure poly-L-lysine 
secondary structures and placental collagen 
show distinct characteristic shape and size.  
Uniquely recognisable pieces of spectra from 
reference proteins can be compared against 
the spectrum from a tested protein to 
predict the proportion of each structural 
motif present.  Poly-L-lysine α-helix and anti-
parallel β-sheet conformations at pH 11.1 (1 
and 2, respectively) and poly-L-lysine 
extended conformations at pH 5.7 (3) and 
placental collagen in its native triple-helix 
and denatured forms (4 and 5, respectively) 
are shown.  This figure is from (Greenfield, 
2007). 
 
 
 
Work presented in this chapter demonstrates the successful production and 
expression of three Lsr2 mutants that show deficiencies in DNA binding.  Protein 
stability and secondary structure of these mutants differ from native Lsr2.   A 
double mutant with the least ability to bind DNA was a candidate for protein 
crystallisation attempts but poor protein homogeneity and solubility reduced the 
probability of yielding crystals. 
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4.2 Results 
4.2.1 Generation of Lsr2 DNA binding mutants 
Primer design was completed manually for the generation of four arginine to 
alanine residue mutations in Lsr2 using site directed mutagenesis.  These 
included single residue mutations for the residues R84, R97 and R99 and a 
double residue mutation for both R97 and R99 residues.  The recombinant Lsr2 
expression plasmid lsr2-pET30b was used as the template for mutagenesis 
experiments.  The double mutant R97A-R99A was successfully generated in the 
first round of site directed mutagenesis whilst repeat attempts at the two single 
mutations failed.  Primers for the remaining single residue mutations were 
redesigned based on the double mutant primer length and composition, and 
further rounds of site directed mutagenesis were performed.  The mutation 
R99A was successfully generated in the first round of site directed mutagenesis 
using the new primers with the R97A mutation following suit in the second round.  
Generation of a R84A mutant was unsuccessful.  Successful residue conversion in 
each mutant was confirmed by DNA sequencing. 
 
4.2.2 Expression and purification of the Lsr2 mutant R97A 
Lsr2 R97A mutant was expressed in E. coli as a 13.2 kDa recombinant protein 
fused to a C-terminal 6 x histidine tag (without a tag cleavage site).  Small scale 
expression testing utilising a histidine tag binding assay identified a protein of the 
correct size that was successfully captured on nickel sepharose beads (results not 
shown).  E. coli growth to an optical density suitable for recombinant protein 
induction was accomplished in only 2 hours compared with 6 hours for native 
Lsr2.  Large scale purification of R97A Lsr2 was performed using IMAC.  The 
chromatogram and corresponding SDS-PAGE and agarose gels (Figure ‎4.3) 
demonstrate the two peaks that result from IMAC purification of R97A Lsr2 with 
the protein of interest appearing in peak B.  Proteins bound non-specifically to 
the column were eluted during column equilibration with binding buffer and 
those with moderate interaction with the column were removed at around 40 % 
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elution buffer, whereas R97A was eluted at around 70% of elution buffer which 
corresponds to 700 mM imidazole (Figure ‎4.3A).  There is a small amount of 
genomic DNA co-purified with R97A (Figure ‎4.3B).  R97A Lsr2 mutant resolves as 
a 15 kDa recombinant protein on a 15 % SDS-PAGE gel (Figure ‎4.3C). 
 
 
 
Figure ‎4.3.  R97A Lsr2 mutant co-purifies with a reduced amount of genomic DNA during IMAC 
purification.   (A) Chromatogram of the elution buffer gradient and UV absorbance profile; (B) 1% 
agarose gel with sample lysate (L), column flow through (F) and fractions from peak A and B; (C) 
15%  SDS-PAGE gel of the corresponding lysate, flow through and fractions from peak A and B. 
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4.2.3 Expression and purification of the Lsr2 mutant R99A 
The Lsr2 R99A mutant was expressed in E. coli as a 13.2 kDa recombinant protein 
fused to a C-terminal 6 x histidine tag (without a tag cleavage site).  Small scale 
expression testing was omitted in favour of large scale expression.  E. coli growth 
to an optical density suitable for recombinant protein induction was 
accomplished in only 1.5 hours compared with 6 hours for native Lsr2.  The 
chromatogram and corresponding SDS-PAGE and agarose gels from the large 
scale IMAC purification of R99A (Figure ‎4.4) show protein spread across two 
merged peaks with the protein of interest appearing in region C.  Proteins bound 
non-specifically to the column are eluted during column equilibration with 
binding buffer and those with moderate interaction with the column are 
removed between 10 - 30 % elution buffer, whereas R99A is eluted between 
30 - 50 % of elution buffer which corresponds to 300 - 500 mM imidazole 
(Figure ‎4.4A).  There is a small amount of genomic DNA co-purified with R99A 
(Figure ‎4.4B).  R99A Lsr2 mutant resolves as a 15 kDa recombinant protein on a 
15 % SDS-PAGE gel (Figure ‎4.4C). 
 
4.2.4 Expression and purification of the Lsr2 mutant R97A-R99A 
The Lsr2 double mutant R97A-R99A was expressed in E. coli as a 13.2 kDa 
recombinant protein fused to a C-terminal 6 x histidine tag (without a tag 
cleavage site).  Small scale expression testing was omitted in favour of large scale 
expression.  E. coli growth to an optical density suitable for recombinant protein 
induction was accomplished in only 2-3 hours compared with 6 hours for native 
Lsr2.  The chromatogram and corresponding SDS-PAGE and agarose gels from 
the large scale IMAC purification of R97A-R99A Lsr2 (Figure ‎4.5) shows two peaks 
with the protein of interest appearing in peak B.  Proteins bound non-specifically 
to the column are eluted during column equilibration with binding buffer and 
those with moderate interaction with the column are removed at around 15 % 
elution buffer, whereas R97A-R99A is eluted around 50% of elution buffer which 
corresponds to 500 mM imidazole (Figure ‎4.5A).  In contrast to native Lsr2 IMAC 
purification, there is a negligible amount of genomic DNA co-purified with R97A-
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R99A that is barely visible on an agarose gel (Figure ‎4.5B).  R97A-R99A Lsr2 
mutant resolves as a 15 kDa recombinant protein on a 15 % SDS-PAGE gel 
(Figure ‎4.5C).  Interestingly, the SDS-PAGE gel reveals the presence of protein 
bands in fractions from peak A that correspond to the molecular weight of 
possible dimer and hexamer forms of a protein the size of Lsr2. 
 
 
Figure ‎4.4.  R99A Lsr2 mutant co-purifies with a reduced amount of genomic DNA during IMAC 
purification.   (A) Chromatogram of the elution buffer gradient and UV absorbance profile; (B) 1% 
agarose gel with sample lysate (L), column flow through (F) and fractions from regions A, B and C; 
(C) 15%  SDS-PAGE gel of the corresponding lysate, flow through and fractions from regions A, B 
and C. 
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Figure ‎4.5.  The Lsr2 double mutant R97A-R99A barely co-purifies with genomic DNA during 
IMAC purification.  (A) Chromatogram of the elution buffer gradient and UV absorbance profile 
during IMAC purification; (B) 1% agarose gel with sample lysate (L), column flow through (F) and 
fractions from peak A and B; (C) 15%  SDS-PAGE gel of the corresponding lysate, flow through and 
fractions from peak A and B and a control native Lsr2 sample for comparison. 
 
4.2.5 Lsr2 DNA binding mutants have reduced DNA binding ability 
It was apparent from the initial IMAC protein purification procedure that each 
residue mutation in Lsr2 had affected the ability of the protein to bind to DNA.  A 
comparison of the amount of co-purified DNA between each mutant and native 
Lsr2 by agarose gel analysis visibly shows this (Figure ‎4.6).  A bright stained DNA 
band represents the amount of co-purified DNA from a native Lsr2 purification in 
comparison to a slight smear of DNA for the single R97A and R99A mutants and a 
barely visible dusting of DNA for the double R97A-R99A Lsr2 mutant.  Practically 
it was also noted that bacterial cell lysis using sonication was quicker with Lsr2 
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mutants and loading of the cell lysate onto the column was easier and resulted in 
less column compaction than typically occurred with native Lsr2 lysate.   
 
 
Figure ‎4.6.  The amount of DNA co-purified with each Lsr2 mutant is much less than with native 
Lsr2.  A comparison of 1% agarose gel analysis of IMAC purified native Lsr2 (left), R97A mutant 
(second from left), R99A mutant (second from right) and R97A-R99A double mutant of Lsr2 
(right). 
 
Transmission electron microscopy (TEM) was used previously as a technique to 
examine the structures formed and the arrangement of native Lsr2 with co-
purified DNA (in Chapter Three).  Native Lsr2 bound with DNA shows a complex 
arrangement of strands or “fibrils” that represent DNA completely coated by Lsr2.  
Since a reduction of co-purified DNA was observed during protein purification of 
the Lsr2 mutants, it was of interest to use this technique to visualise the effects 
of residue mutation.  Analysis of negatively stained IMAC purified mutant Lsr2 
protein revealed striking differences between them (Figure ‎4.7).  The single 
mutant R97A showed an absence of an ability to form any of the fibril-like 
structures usually seen with native Lsr2 (Figure ‎4.7B) whereas the other single 
mutant R99A was capable of limited structure formation in the form of short 
independent DNA-coated strands (Figure ‎4.7C).  The double R97A-R99A Lsr2 
mutant was also incapable of forming any fibril-like structures (Figure ‎4.7D).  The 
difference in behaviour between the two single Lsr2 mutants may indicate that 
the role of each of the arginine residues in DNA binding and arrangement is 
significantly different. 
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Figure ‎4.7.  Electron micrograph images of IMAC purified Lsr2 mutants show a failure to form 
protein/DNA structures as normally observed with native Lsr2.  (A)  Negative stained purified 
native Lsr2 shows intertwined and coiled fibrils of mixed sizes representing DNA coated by the 
protein; (B) R97A mutant fails to form any noticeable fibril-like structures - staining artefacts seen 
only; (C) R99A mutant shows a limited number of single thin fibrils (examples in boxes areas) 
scattered throughout staining artefacts (upper left); (D) the double R97A-R99A Lsr2 mutant fails 
to form any DNA/protein structures – background staining seen only. 
 
 
 
 Chapter Four – DNA binding for three Lsr2 mutants 112 
4.2.6 Mutant protein stability and structure differs from native Lsr2 
Protein stability and secondary structure of the Lsr2 DNA binding mutants was 
characterised using two biophysical methods – fluorescence based thermal 
stability assay and circular dichroism.   
IMAC-purified recombinant native Lsr2, R97A, R99A and R97A-R99A mutant Lsr2 
proteins were subjected to thermal denaturation in the presence of a fluorescent 
dye (SYPRO orange) that has preference for hydrophobic residues that become 
exposed during protein unfolding.  In this assay fluorescence is detected over a 
temperature range with the fluorescence peak representing the point of 
complete protein unfolding and the following decrease in intensity indicating 
protein/probe complex precipitation. 
Results from the thermal stability assay show a reduction in protein stability with 
residue mutation (Figure ‎4.8).  The double mutant R97A-R99A has the most 
pronounced reduction in stability (52.0°C) compared to native Lsr2 (58.6°C) than 
either of the individual Lsr2 mutants R97A or R99A (54.8°C and 55.4°C, 
respectively).   
 
Figure ‎4.8.  Thermal shift assay results indicate a reduction in protein stability in Lsr2 mutants.  
A shift in the fluorescence peak towards lower assay temperatures indicates a reduction in 
protein stability. In order of protein stability, native Lsr2 unfolds at 58.6°C, whilst the mutant 
R99A unfolds at 55.4°C, the mutant R97A unfolds at 54.8°C and the double Lsr2 mutant R97A-
R99A unfolds at 52.0°C.   
 Chapter Four – DNA binding for three Lsr2 mutants 113 
However, these results should be interpreted with caution, as the prepared 
protein samples contained co-purified genomic DNA.  The thermal stability of 
each protein would be influenced by the amount of DNA that it was bound with.  
It is possible that thermal stability may be positively correlated with the amount 
of bound DNA. 
Secondary structure characterisation of native Lsr2 and the three DNA binding 
mutants R97A, R99A and R97A-R99A was undertaken using CD to determine if 
these mutations would affect protein conformation.  For this analysis, protein 
was further purified by SEC in buffer conditions containing 2 M NaCl to dissociate 
co-purified DNA from the protein as previously described in Chapter Three and 
dialysed into a buffer suitable for CD (5 mM phosphate (pH 7.4)).  Dialysis into 
phosphate buffer caused protein precipitation for all purified proteins however 
some soluble protein remained and was used for analysis.  Replicate CD spectra 
were collected, averaged and baseline and buffer spectra removed.   
The raw data from the collected CD spectrum for all protein samples shows 
subtle differences in the optical activity between native Lsr2, R97A, R99A and 
R97A-R99A Lsr2 mutants over the appointed wavelength range (Figure ‎4.9A).  All 
proteins were analysed for secondary structure at a consistent concentration 
(6 uM) and over a wavelength range of 190 – 240 nm using the K2D2 method 
(Perez-Iratxeta & Andrade-Navarro, 2008).  Secondary structure analysis using 
the K2D2 method translated the optical activity observed between the 
appropriate wavelengths into the proportion of α-helix and β-sheet structures 
(Figure ‎4.9B).  This analysis showed some differences in the percentage of α-helix 
and β-sheet structures between native Lsr2 and the Lsr2 DNA binding mutants.  
However, the secondary structure estimation error is high in the analysis of 
native Lsr2 which indicates the prediction was not very accurate.  Furthermore, 
as the optical activity detected for all proteins was small it is not wise to give too 
much weight to outcome of the secondary structure analysis.  These results may 
suggest that mutations of the proposed DNA binding residues of Lsr2 had an 
effect on protein stability and structure. 
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Figure ‎4.9.  The CD spectra for native Lsr2, R97A, R99A and R97A-R99A Lsr2 mutants show 
subtle differences in optical activity which translate into secondary structure variation.  (A)  
Raw data from the collected CD spectrum; (B) a table summarising the estimated proportion of 
α-helix and β-sheet structures in Lsr2 and the mutants R97A, R99A, R97A-R99A.  CD spectrum 
analysis was performed using K2D2 (Perez-Iratxeta & Andrade-Navarro, 2008).  Non-
experimental native Lsr2 α-helix and β-sheet secondary structure prediction proportions are also 
listed for comparison (http://www.predictprotein.org).  * is calculated as a percentage of the 
remaining residues that are neither a α-helix nor a β-sheet; 
#
 total error observed is high and 
structure prediction is not accurate. 
 
CD was also used in an attempt to characterise the DNA binding ability of native 
Lsr2 and the DNA binding mutants R97A, R99A and R97A-R99A.  CD spectra 
between 250 and 300 nm is dominated by the optical activity of nucleic acids and 
changes in conformation are attributed to the polynucleotide chain.  A suitable 
quantity of plasmid DNA that gave strong optical activity was established for this 
assay.  It was confirmed that Lsr2 did not contribute to the optical activity over 
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the appropriate wavelength and hence a titration experiment with native Lsr2 
was performed.  A reduction in the optical activity of DNA was observed 
between the DNA only control and the highest amount of protein added 
however analysis of the change in ellipticity with protein concentration did not 
demonstrate a typical binding curve (results not shown).    Further studies of 
DNA binding using CD spectra analysis were therefore abandoned for the Lsr2 
DNA binding mutants.   
Due to the lack of observable binding kinetics between Lsr2 and DNA, a thermal 
unfolding assay using CD was attempted with the theory that protein unfolding 
may be influenced by bound DNA.  Initial experiments with DNA-free native Lsr2 
demonstrated that using this technique, the protein did not unfold following a 
typical two-state model with a sharp transition between folded and unfolded 
protein.  Rather it showed a gradual unfolding over the temperature range 
(results not shown). 
 
4.2.7 Lsr2 mutant R97A-R99A is a crystallography candidate 
Results from IMAC purification of all three Lsr2 DNA binding mutants revealed 
that the double R97A-R99A mutant co-purified with the least amount of E. coli 
genomic DNA.  Hence, the R97A-R99A Lsr2 mutant was the best candidate for 
continued exploration and placing into crystallography trials, due to the 
increased chance of being able to completely remove the co-purified DNA and 
the possibility that the subsequently purified protein would not adhere to 
membrane surfaces like its native Lsr2 counterpart. 
Large scale preparative SEC in a buffer containing 2 M NaCl was used to prepare 
DNA-free R97A-R99A Lsr2 protein as was routinely used with native Lsr2 
(Figure ‎4.10).  The two peaks on the resulting chromatogram correspond to the 
DNA (A) and protein (B) which are eluted at the same volumes as observed for 
native Lsr2.  During SEC, DNA is detected by UV absorption at 280 nm and is 
eluted immediately after the column void volume whist the protein is retarded 
by the column and passes through at a slower rate. 
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Figure ‎4.10.  Size exclusion chromatography of R97A-R99A mutant Lsr2 in a 2 M NaCl buffer 
dissociates the protein from the co-purified genomic DNA.  (A)  Chromatogram of the UV 
absorbance profile of DNA (A) and R97A-R99A Lsr2 (B); (B) 1% agarose gel with sample load (L) 
and fractions from peak A and B; (C) 15% SDS-PAGE gel of the corresponding sample load (L) and 
fractions from peak A and B. 
 
Agarose gel and SDS-PAGE gel analysis of fractions collected during SEC confirm 
that the mutant protein R97A-R99A is separated from the DNA (Figure ‎4.10B and 
C).  Due to the high salt content of the buffer used for SEC the size of the Lsr2 
mutant R97A-R99A was not able to be accurately determined as the salt 
influences the mobility of the protein.  However it was eluted at the same 
volume as native Lsr2 did in high salt buffer. 
The ability of R97A-R99A mutant Lsr2 to bind to plasmid DNA was examined 
briefly.  Concentrated DNA-free R97A-R99A Lsr2 in a low salt buffer was 
combined with plasmid DNA in buffers of differing pH and analysed in a gel shift 
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assay (Figure ‎4.11B).  In comparison with native Lsr2, the R97A-R99A mutant was 
unable to demonstrate an ability to bind to plasmid DNA and retard its 
movement through an agarose gel.   
 
 
Figure ‎4.11.  The DNA binding mutant R97A-R99A is unable to bind to plasmid DNA.  A gel shift 
assay using 1 % agarose gels demonstrates that native Lsr2 is able to retard the movement of 
plasmid DNA through the gel (A) as opposed to mutant Lsr2 R97A-R99A which cannot (B).  
Plasmid only controls (P) of 100 ng (in A) or 50 ng (in B) and protein only (Lsr2 and R97A-R99A) 
samples (3 ug) are shown.  Reactions were setup under different pH conditions with 200 ng (L) 
and 400 ng (H) plasmid concentrations. 
 
These gel shift results in conjunction with the observation of a negligible amount 
DNA co-purified with the mutant and the successful removal of this DNA using 
SEC in high salt, provided support that the double mutant was a promising 
candidate for protein crystallisation with DNA-free homogenous protein.  
Purified R97A-R99A Lsr2 was subjected to robotic crystallisation screens at 
concentrations of 2 mg/ml on two separate occasions.  It was difficult to obtain 
higher protein concentrations.  Crystals were observed in some conditions and 
fine screens and additive screens were set up to screen around the crystallisation 
conditions.  All promising crystals were revealed to be salt after analysis by X-ray 
diffraction.  Dynamic light scattering analysis of concentrated protein used for 
crystallography attempts showed that the protein sample was not homogeneous. 
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4.3 Discussion 
Lsr2 is a basic protein rich in positively charged arginine residues (13.4 %).  It is 
hypothesised that these positively charged residues may interact with the 
negatively charged phosphates of the DNA backbone, which would explain the 
non-specific binding of Lsr2 to DNA.  The experimental substitution of a number 
of positively charged residues has been performed with M. smegmatis mc2155 
Lsr2 (Chen et al., 2008).  In these studies the M. smegmatis mc2155 Lsr2 arginine 
residues R86, R99 and R101 were individually mutated to alanine residues and 
the ability of the mutant recombinant protein to complement the phenotype of 
an M. smegmatis mc2155 Δlsr2 strain was assessed.  These residues are the 
equivalent of the M. tuberculosis H37Rv Lsr2 residues R84, R97 and R99 assessed 
in this study.  The M. smegmatis mc2155 study showed that changing residues 
R99 and R101 did not affect the in vivo function of Lsr2 however altering residue 
R86 did.  For in vitro work the equivalent R84A M. tuberculosis H37Rv Lsr2 
mutant was expressed and was shown to be critical for DNA binding (Chen et al., 
2008). 
In this study cloning of a M. tuberculosis H37Rv R84A Lsr2 mutant was 
unsuccessful due to a reoccurring base pair deletion in the gene and so the DNA 
binding function of this substitution was not assessed.  However, three Lsr2 
mutants comprising R97A, R99A and R97A-R99A were cloned, expressed and 
assessed for their DNA binding ability.  This study showed that the DNA binding 
ability of all three mutants was compromised with the double R97A-R99A 
mutant showing the least ability to interact with both genomic E. coli DNA and 
plasmid DNA.  These results are in contrast to the studies reported by 
researchers investigating in vivo complementation of an M. smegmatis mc2155 
lsr2 knockout (Chen et al., 2008).   
This research suggests that the residues R97 and R99 of Lsr2 are significant in the 
binding of DNA and if their mutation is not significant enough to disrupt the 
normal function of Lsr2 in vivo then this suggests that there are other crucial 
DNA binding residues that work in synergy with R97 and R99 and could 
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compensate in some way.  A hierarchy of residue DNA binding ability may be 
suggested by the DNA/Lsr2 structures seen using TEM.   
The double R97A-R99A Lsr2 mutant lacked the ability to form fibril-like structures 
that correspond to protein coating the DNA (in IMAC purified protein samples) as 
was usually seen in the native Lsr2 micrographs.  However it was interesting that 
a difference in structure formation was observed between the two single 
mutants R97A and R99A.  The mutant R97A was not capable of forming coiled-
strands or fibrils as was typically observed, however in the micrographs of R99A 
this protein showed a limited number of short strands that were fibril-like in 
structure.  The TEM images suggest, by their lack of DNA/Lsr2 structures, that 
the residue R97 has a stronger interaction with DNA than R99 and that altering 
both residues has an additive effect.  As the in vivo function of a R86A Lsr2 
mutant in a M. smegmatis mc2155 Δlsr2 was compromised it is possible that this 
residue has an even stronger interaction with DNA.  However if this was the case, 
we would see fibril-like structures in TEM images despite mutations of both R97 
and R99 residues. 
Analysis of protein thermal stability of the three DNA binding mutants showed 
that their denaturation temperature may have been influenced directly by the 
amount of bound DNA in the sample preparation.  Secondary structure analysis 
of DNA-free mutant proteins showed subtle differences between the proportion 
of α-helix and β-sheet structures.  However the buffer conditions required for CD 
analysis were not ideal for optimal protein solubility and this may have 
influenced the results.   
Protein crystallisation was attempted using the double R97A-R99A mutant in the 
belief that its reduced DNA binding ability would improve sample homogeneity 
and behaviour, thereby increasing the chances of successful crystallisation.  
However protein crystals were not successfully generated after thorough fine 
screening attempts. 
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5 Chapter Five – Structure of the N-terminal 
dimerisation domain of Lsr2 
 
5.1 Introduction 
One of the main objectives of this PhD research was to determine the 3D 
structure of the DNA binding protein Lsr2 from M. tuberculosis H37Rv as, at the 
time, this structure was unknown and this information would reveal critical 
functional information.  However, in 2010 an NMR structure of the C-terminal 
DNA binding domain of Lsr2 was published (Gordon et al., 2010).  The structure 
of the C-terminal DNA binding domain revealed a mechanism for DNA binding 
and identified residues crucial for this interaction.  A model of DNA binding by 
Lsr2 postulated that Lsr2 could bind DNA in two orientations by grabbing either 
edge of the minor groove like a clamp, orientating and inserting the conserved 
residues R97, G98 and R99 into the minor groove.  The publication of the 
structure of the C-terminal domain of Lsr2 forced a change in the focus and 
direction of this PhD research.  Further studies were therefore directed towards 
determining the 3D structure of the N-terminal dimerisation domain of Lsr2. 
Lsr2 is predicted to be organised into two functional domains, the N-terminal 
dimerisation domain and the C-terminal DNA binding domain, separated by a 
flexible linker.  Based on the elucidation of the 3D structure, the C-terminal DNA 
binding domain is thought to comprise residues 51-112 and the N-terminal 
dimerisation domain is between residues 1-65 based on in vivo complementation 
experiments (Gordon et al., 2010).  A multiple amino acid alignment of Lsr2 
across a number of bacterial species revealed that a number of highly conserved 
residues were present within the two aforementioned domains whereas there 
was little conservation in the proposed linking region (Figure 1.1).  Residue 
conservation is commonly indicative of the residue having a role in protein 
function or structure and as the conserved residues of Lsr2 were found within 
the two domains this supported the description of the domain organisation.   
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Secondary structure predictions showed that there is likely to be three 
sequential β-sheets followed by one α-helix within the proposed N-terminal 
dimerisation domain (residues 1-65) of Lsr2 (Figure 1.5).  The α-helix terminates 
at residue 56 which coincides with a reduction in residue conservation and a 
number of residues with low conservation and no predicted secondary structure 
follow this domain until residue 80.  Residue 80 is the beginning of the predicted 
α-helix secondary structure of the C-terminal domain.  The NMR structure of the 
residues 66-112 showed that residues 66-74 were flexible in nature and that the 
more rigid structure began at residue 78 with the first α-helix (Gordon et al., 
2010).  Therefore, it was proposed that a disordered and flexible region lies 
between the two domains (residues 56 and 80). 
A number of attempts to crystallise the full-length construct of Lsr2 by using 
alternative protein tag purification techniques, residue modification (Chapter 
Three) and site directed mutagenesis (Chapter Four) were made during the 
course of this investigation, all of which were unsuccessful in producing protein 
crystals.  It was proposed that the presence of a highly disordered and flexible 
region between the two domains of Lsr2 was the reason why crystallisation of 
the full construct was so difficult.  Flexibility in a protein is known to make 
crystallisation difficult (Benvenuti & Mangani, 2007).  Consequently, it is often 
beneficial to work with individual domains of proteins to remove poorly 
conserved and flexible regions and therefore increase the likelihood of successful 
crystallisation (Dale et al., 2003).  To increase the probability of crystallising Lsr2, 
the cloning, expression and purification of a number of different constructs of 
the N-terminal domain was undertaken. 
The domain organisation of Lsr2 is thought to be similar to that of the E. coli 
nucleoid-like DNA binding protein H-NS (Gordon et al., 2008).  These two 
proteins have been functionally compared using domain swapping experiments, 
which determined that the N-terminal domain of Lsr2 is capable of enabling 
protein dimerisation (Gordon et al., 2010).  In vitro complementary studies have 
shown that Lsr2 can complement phenotypes related to H-NS gene mutations in 
E. coli and that the reverse complementation of H-NS in the Lsr2 phenotype in 
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M. smegmatis mc2155 is possible, demonstrating functional similarity between 
these two DNA binding proteins (Gordon et al., 2008).  The H-NS N-terminal 
oligomerisation domain has recently been solved using crystallography, revealing 
that the protein is capable of higher order complexes via sequential interactions 
of this domain, forming oligomers (Arold et al., 2010).   
Crystallographic data of the N-terminal dimerisation domain of Lsr2 was 
obtained during this study and the work presented in this chapter shows the first 
3D structure of this domain of Lsr2 from M. tuberculosis H37Rv.  The structural 
detail shows the mechanism of complex oligomerisation of this protein.  
Evidence of the function of Lsr2 in DNA packaging was provided by further in 
vitro studies.  The structure shows that the mechanism of oligomerisation of Lsr2 
is distinct from that of H-NS and that although there is functional similarity 
between these proteins, their mode of DNA packaging is dissimilar. 
Work presented in this chapter was recently published in PLoS ONE (Summers et 
al., 2012). 
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5.2 Results 
5.2.1 Multiple N-terminal dimerisation domain constructs improve 
protein yield and solubility 
A number of constructs of the N-terminal domain of Lsr2 were designed 
(Table ‎5.1) and cloned into the E. coli expression vector pPROExHTb using the 
NcoI/Xho1 restriction sites, positioning a 6 x histidine tag and rTEV protease 
cleavage site at the N-terminal end of the expressed protein.  Lsr2 N-terminal 
domain variants were designed to range from 56 to 74 amino acids in length, 
with the shortest variant terminating at the end of the predicted α-helix region 
and the longest alternative terminating 5 residues prior to the α-helix of the 
C-terminal DNA binding domain.  The molecular weight of the expressed proteins 
ranged between 9.1 kDa and 10.9 kDa.  Out of interest, a single construct of the 
C-terminal DNA binding domain was also designed but it failed to express after a 
number of attempts at various expression temperatures and repeat 
transformations into an expression strain (results not shown). 
Table ‎5.1.  Seven N-terminal Lsr2 domain constructs were designed, cloned, expressed and 
purified.  The C-terminal boundaries of Lsr2 N-terminal constructs were terminated at random 
points between the two domains of Lsr2.  Exp. MW = expressed molecular weight in Daltons. 
 
Construct Amino Acid Sequence Residues Exp. MW 
Nterm 55 -  G R R V G 59 9413 
Nterm+ 55 -  G R R V G G R R R G R S G S 68 10383 
Nterm1 55 -  G R 56 9100 
Nterm2 55 -  G R R V G G R 61 9626 
Nterm3 55 -  G R R V G G R R R G 64 9996 
Nterm4 55 -  G R R V G G R R R G R S G S G R G 71 10653 
Nterm5 55 -  G R R V G G R R R G R S G S G R G R G A 74 10938 
 
Small scale expression testing and histidine tag binding assays were successful 
for all seven N-terminal Lsr2 constructs and the results revealed that Nterm1 was 
poorly expressed compared to the other constructs (results not shown).  Large 
scale expression and IMAC purification was performed for all but the Nterm1 
construct due to its reduced expression level (Figure ‎5.1).   
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Figure ‎5.1. Variation in IMAC purification of Nterm (A), Nterm+ (B), Nterm2 (C), Nterm3 (D), 
Nterm4 (E) and Nterm5 (F) N-terminal domains of Lsr2.  Chromatograms (left panel) and 18% 
SDS PAGE gels (right panel) show cell lysate (L), flow (F) and fractions from peaks (A-D). 
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The protein of interest was eluted toward the end of the elution gradient at 
approximately 40-50% elution buffer which corresponded to a buffer containing 
approximately 400-500 mM imidazole.  Variation in the protein expression level 
for each construct was apparent after purification.  Based on the absorbance 
level of the protein peak during IMAC purification, Nterm+ had the lowest 
protein yield, followed by Nterm5, and Nterm4 at a higher yield, and Nterm, 
Nterm2 and Nterm3 having similarly highest protein yields.   
SEC of the six purified N-terminal domain constructs was performed in a 
standard low salt buffer as it was determined by agarose gel electrophoresis of 
protein fractions, that there was no co-purified E. coli genomic DNA as had been 
typically observed with the full length Lsr2 protein (results not shown).  The four 
constructs Nterm, Nterm+, Nterm2 and Nterm3 were purified successfully by size 
exclusion chromatography (Figure ‎5.2), whereas the constructs Nterm4 and 
Nterm5 aggregated prior to chromatography, during protein concentration, 
leaving no soluble protein in solution.  Based on the absorbance level and SDS-
PAGE gel results, a very low yield of protein for Nterm+ was obtained after size 
exclusion (Figure ‎5.2B) in comparison to the higher yields of Nterm3, Nterm and 
Nterm2 in increasing yield respectively (Figure ‎5.2 D, A and C).  
Overall, the three Lsr2 N-terminal domain constructs Nterm, Nterm2 and Nterm3 
were expressed at high levels in E. coli, behaved favourably during preparation 
for size exclusion chromatography and were able to be purified and 
concentrated to amounts appropriate for protein crystallography trials.  
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Figure ‎5.2. Size exclusion chromatography of N-terminal domains Nterm (A), Nterm+ (B), 
Nterm2 (C) and Nterm3 (D) shows a variation in protein solubility and yield.  Chromatograms 
(left panel) and 18% SDS PAGE gels (right panel) which show loaded sample (L) and fractions from 
appropriate peaks (A-C).  IMAC purified Nterm4 and Nterm5 precipitated while concentrating and 
were unable to be purified by SEC while Nterm+ precipitated soon after concentration. 
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To obtain initial information regarding the ability of the N-terminal domain to 
assemble into larger subunits, a glutaraldehyde cross-linking experiment was 
performed which showed that Nterm had an ability to form multimers 
(Figure ‎5.3A).  Further analysis of cross-linked Nterm using a calibrated size 
exclusion column illustrated a number of protein species that showed an 
approximate doubling in size, suggesting that a dimer was the most common 
smallest denomination used in the assembly of larger structures (Figure ‎5.3B). 
 
 
Figure ‎5.3.  The construct Nterm of the N-terminal domain of Lsr2 forms oligomeric structures 
when incubated with 0.1% glutaraldehyde.  (A) IMAC purified Nterm forms dimers, trimers, 
tetramers and larger structures after 2 minutes with 0.1% glutaraldehyde (18% SDS-PAGE); (B) 
SEC analysis of Nterm crosslinked for 5 minutes illustrates larger complexes from over time (peak 
A) as smaller species such as dimers and tetramers diminish (peaks C and B, respectively).  The 
table lists calculated approximate molecular weight of species observed during SEC analysis 
(Superdex75 10/300 column). 
 
 
 Chapter Five – Structure of the N-terminal dimerisation domain of Lsr2 128 
5.2.2 Multiple N-terminal protein crystallography trials required for 
successful protein crystallisation 
Size exclusion chromatography purified Nterm protein was subjected to robotic 
crystallisation screens at a concentration of 7 mg/ml however no crystals were 
observed.   
Size exclusion chromatography purified Nterm2 and Nterm3 were subjected to 
robotic crystallisation screens at concentrations of 21 mg/ml and 2 mg/ml 
respectively and tiny crystals were observed in three conditions for Nterm2 only.  
Hanging drop fine screens around the crystallisation conditions and additive 
screens were prepared but resulted in limited crystal development.  At this time 
it was noted that limited crystal development only occurred when an older 
Nterm2 protein preparation was used and not with recently purified protein.  
SDS-PAGE analysis confirmed that there was still full length protein remaining in 
the older Nterm2 protein preparation (results not shown). 
The arrival of a liquid handling robot in the lab prompted new Hampton 
crystallisation screens to be completed with 3-week old Nterm2 at 15 mg/ml and 
this resulted in crystal development in a variety of conditions.  Extensive fine 
screening around a wide range of PEG conditions, including crystal seeding, use 
of microbridges and non-siliconised coverslips and additive screening was 
performed over a number of weeks using Nterm2 from the same purification and 
resulted in crystal growth in a greater variety of conditions. 
Further Hampton crystallisation screens were performed with Nterm2 at 
63 mg/ml after the removal of the histidine tag using rTEV protease and further 
purification but were unsuccessful in producing crystals.  Hampton crystallisation 
screens were also performed with Nterm2 at 15 mg/ml co-crystallised with 
trypsin at a ratio of 1:500 as detailed in section ‎5.2.3, resulting in crystals in a 
wide variety of conditions. 
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5.2.3 Protein ‘’maturation’’ or protease digestion facilitates successful 
diffraction quality crystal formation  
The development of diffraction quality crystals of the Nterm2 construct was a 
slow iterative process that took a number of months from the initial robotic 
crystallisation screens laid down in March 2011.  Initial crystals did not diffract 
however these results ruled out the formation of salt crystals and renewed 
efforts to produce better crystals (Figure ‎5.4A).  Subsequent testing of crystals at 
the Australian Synchrotron revealed that higher quality diffracting protein 
crystals were developing (Figure ‎5.4B) but that the data was not suitable due to 
multiple crystal plates forming together.  After further fine screening, crystals 
that were more singular and also diffracted reasonably well were tested using 
The University of Auckland home source X-ray beam (Figure ‎5.4C). 
 
 
Figure ‎5.4.  Iterative crystal improvements generate crystals of Nterm2 capable of diffracting 
strongly during X-ray analysis.  (A)  Initial crystals were confirmed to be non-diffracting protein; 
(B) high resolution but smeary data was achieved with a crystal from an additive screen; (C) 
crystal refinement gave lower resolution but less smeary data.  Protein crystal X-ray analysis was 
completed at the Australian Synchrotron for crystals A and B, and at The University of Auckland 
home source for crystal C. 
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Initial robotic screens performed at The University of Auckland with Nterm2 did 
not yield any crystals, however with the arrival of a liquid handling robot in the 
lab and the use of Hampton crystal screens, a number of promising crystallisation 
conditions were discovered.  Unexpectedly, it was difficult to produce good 
crystals in subsequent fine screen conditions.  It was proposed that the protein 
preparation was not fresh enough as it was initially used in the Hampton screens 
at an age of 3 weeks old and perhaps now contained a mixture of protein species.  
Size exclusion chromatography was used to re-purify the protein sample in an 
attempt to “refresh” the preparation.  Surprisingly, the results revealed that 
instead of expected protein degradation, that a number of larger multimers had 
naturally formed over time during protein aging, and protein peaks with 
calculated sizes of dimers, tetramers and larger complexes were seen 
(Figure ‎5.5A).  Analysis of protein from each peak on a 10% native gel illustrated 
that protein in these different complexes had a variety of electrophoretic 
properties however there were only two alternative protein sizes as shown by 
16.5% SDS-PAGE analysis (Figure ‎5.5B and C).  
This protein aging or “maturation” was recreated by purifying fresh Nterm2 and 
repeating identical fine screen conditions every two weeks in an attempt to try 
to mimic the conditions originally present for successful crystal generation.  At 
the same time, trypsin co-crystallisation techniques were used in fine screens at 
a dilution mass ratio of 1:500.  Samples of trypsin treated fresh Nterm2 protein 
were analysed on 10% native and 16.5% SDS-PAGE gels and compared to the 
results observed for “matured” Nterm2 (Figure ‎5.5B and C).  In a similar outcome 
to naturally “matured” Nterm2, trypsin treated Nterm2 produced a number of 
different native protein species but still resulted in only two main protein sizes. 
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Figure ‎5.5.  Re-purification of “matured” Nterm2 by size exclusion chromatography revealed 
that a number of multimers had naturally formed.  (A) Analytical size exclusion chromatography 
shows multimeric (A) tetrameric (B) and dimeric (C), forms of “matured” protein in comparison to 
“fresh” dimeric Nterm2 (D); (B) protein loaded (L) and fractions from each peak (A-D) display 
different electrophoresis properties on a 10% native gel; (C) analysis of the corresponding 
fractions on 16.5% SDS-PAGE shows two protein sizes.  Addition of trypsin in decreasing amounts 
(1:550, 1:5000, 1:50000 mass rations) to “fresh” Nterm2 (for protein crystallisation) artificially 
produces a number of protein species as seen on a 10% native gel (B), and results in only two 
protein sizes on 16.5% SDS-PAGE (C). 
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Nterm2 trypsin co-crystallisation fine screens at a dilution ratio of 1:500 resulted 
in rapid forming but small crystals.  Dilution ratios were optimised in an attempt 
to improve crystal quality.  It was hypothesised that reducing the amount of 
trypsin added to Nterm2 would slow the rate of crystal formation and produce 
higher quality crystals however dilution mass ratios of 1:5,000 and 1:50,000 
resulted in poorer quality crystals instead (Figure ‎5.6).  The original mass ratio of 
1:500 was subsequently selected for all further co-crystallisation attempts and 
further Hampton crystallisation screens with Nterm2 and trypsin produced 
crystals in a wide variety of conditions, leading to promising fine screen crystal 
development. 
 
 
Figure ‎5.6.  Crystal growth optimisation using a range of trypsin:Nterm2 dilution mass ratios.  
Crystals formed rapidly using trypsin co-crystallisation techniques.  A dilution ratio of 1:500 
trypsin to Nterm2 produced better quality crystals (A) compared with dilution ratios of 1:5,000 (B) 
and 1:50,000 (C). 
 
The successful collection of X-ray diffraction data from high quality Nterm2 
crystals was a culmination of the discovery of protein “maturation” being an 
essential factor in crystal development and the investigation of the ability of 
trypsin to artificially create this protein aging, in combination with the use of the 
Australian Synchrotron facility.  Crystals of Nterm2 from two different 
crystallisation conditions using “matured” and trypsin-added protein 
preparations provided suitable data for solving the structure of Nterm2. 
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Two singular diamond shaped Nterm2 crystals that grew within a mixture of 
crystal shapes successfully gave native data sets using the home source X-ray 
beam at The University of Auckland.  These crystals grew in 26% PEG 400, 0.1 M 
Tris (pH 8.5), 0.12 M (NH4)2SO4, in a hanging drop after four days, using “mature” 
Nterm2 protein that was approximately 10 weeks old (Figure ‎5.7A).  Data sets 
were collected to 1.73Å and 1.87Å in the P21 space group.   
A data set for a single hexagonal shaped Nterm2 crystal co-crystallised with 
trypsin was also collected at The University of Auckland however the slight 
smearing of the diffraction image spots made indexing of the data difficult.    This 
crystal grew in 0.1 M MES (pH 6.5), 0.01 M CoCl2, 1.4 M (NH4)2SO4, 7.5% 
1-4-dioxane, in a hanging drop fine screen after six days, using protein that was 5 
weeks old.  After transportation to the Australian Synchrotron, a data set to 
1.96Å resolution in the P3121 space group was collected for this crystal 
(Figure ‎5.7B). 
The successful collection of a diffraction pattern data set from a protein crystal is 
not all that is required to be able to solve the structure of a protein.  The phases 
associated with each diffraction spot also need to be determined.  A number of 
techniques are available to determine the phases.  Molecular replacement is a 
common technique that utilises the phase relationships from a related molecule 
and an attempt is made to fit the structure under investigation to a previously 
solved structure.  In the case of the N-terminal domain of Lsr2, there were no 
other known related structures solved at this point in time and hence molecular 
replacement could not be used.  The heavy atom selenium may be incorporated 
into a protein as selenomethionine enabling anomalous scattering techniques to 
be used for phase determination. 
The data collection statistics for the native and hexagonal data sets are shown in  
Table ‎5.2. 
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Figure ‎5.7.  Crystals generated from “matured” Nterm2 and Nterm2 co-crystallised with trypsin 
diffracted to a high resolution and provided high quality data.   (A) Two singular diamond 
shaped crystals grown in 26% PEG 400, 0.1 M Tris (pH 8.5), 0.12 M (NH4)2SO4, provided native 
data sets to 1.73Å and 1.87Å in a P21 space group; (B) a hexagonal shaped crystal co-crystallised 
with trypsin (1:500), grown in 0.1 M MES (pH 6.5), 0.01 M CoCl2, 1.4 M (NH4)2SO4, 7.5% 1-4-
dioxane, provided a data set to 1.96Å in a P3121 space group.  The corresponding diffraction 
pattern images are displayed on the right of the crystal photos.  Native data sets and the 
hexagonal data set were collected at the home source at The University of Auckland however a 
second higher quality hexagonal data set was subsequently collected at the Australian 
Synchrotron.   
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Table ‎5.2.  Crystallographic data collection statistics. 
 
 Nterm2 Nterm2 + Trypsin 
Data Collection   
Wavelength (Å) 1.5417 0.9786 
Space Group P1 21 1 P31 2 1 
Unit Cell (Å) 32.51, 27.03, 56.83  57.39, 57.39, 105.31  
Unit Cell (°) 90.0, 94.3, 90.0 90.0, 90.0, 120.0 
Resolution (Å)a 32.42-1.73 (1.82-1.73) 52.65-2.04 (2.15-2.04) 
R-merge 0.092 (0.308) 0.096 (0.562) 
Completeness (%) 99.4 (96.3) 100.0 (100.0) 
Redundancy 9.77 (9.18) 20.43 (20.45) 
No. of Observations 102957 (13617) 272612 (38858) 
No. of Unique Reflections 10538 (1483) 13341 (1900) 
Mean I/σ(I) 17.1 (6.9) 22.6 (6.2) 
a 
numbers in parentheses correspond to the highest resolution shell 
 
5.2.4 Generation of methionine mutants for selenomethionine 
labelling provides diffraction quality crystals 
The heavy atom selenium has been successfully used for phase determination via 
multiwavelength anomalous dispersion (MAD) after its incorporation into protein 
as the modified residue selenomethionine.  Mutant variants of Nterm2 were 
designed to incorporate the residue methionine into the protein for 
selenomethionine labelling, as there were only two existing methionine residues 
at the very N-terminal end of the protein and these were predicted to be 
unsuitable for labelling due to their location.   
Three alternative residues within Nterm2 (excluding the expressed tag and linker) 
were chosen for mutation to a methionine residue.  These residues were 
selected based on a number of variables that help predict residues that would 
least likely disrupt protein tertiary structure if altered.  Residues that have 
hydrophobic properties are likely to be buried within the protein structure and 
this also coincides with positioning within highly ordered regions of the protein 
such as in α-helices and β-sheets.  The residues I34, L44 and L48 were selected 
for mutation to methionine as they were highly conserved, hydrophobic, and 
positioned in structurally ordered regions as illustrated by the HMM logo and 
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secondary structure predictions (Figure ‎5.8).  It was predicted that each of these 
residues had less than 5% exposure to solvent which supported their selection as 
buried residues (www.predictprotein.org).  The presence of other hydrophobic 
residues valine and phenylalaine at the same positions as I34, L44 and L48 in the 
HMM logo confirmed that these were positions in the protein that showed 
conservation of hydrophobic, buried residues.  
 
 
Figure ‎5.8.  Hidden Markov Model (HMM) logo of the Nterm2 protein construct region shows 
highly conserved and structurally important residues which assisted in residue selection for site 
directed mutagenesis. Residues I34, L44 and L48 (circled) are highly conserved (as demonstrated 
by the large letter height and width), hydrophobic (yellow) and are found in structurally ordered 
regions as predicted by the secondary structure.  Letter height and width at each position is 
proportional to its occurrence and relative role, respectively.  Secondary structure prediction is 
shown underneath the M. tuberculosis Lsr2 amino acid sequence with β-sheets depicted by blue 
arrows and a α-helix by the pink cylinder.  HMM logo - http://pfam.sanger.ac.uk/family/PF11774. 
 
Site directed mutagenesis (using a QuikChange™ protocol) was successfully used 
to generate two of the methionine mutants, I34M and L48M, however this 
technique was unsuccessful for the mutant L44M and hence standard PCR and 
cloning techniques were employed to generate this methionine Nerm2 mutant 
(results not shown). 
The three methionine mutants were expressed in E. coli and purified using IMAC 
with an elution gradient.  The protein of interest eluted in the second peak at 
approximately 40% elution buffer which corresponded to a buffer containing 
approximately 400 mM imidazole (Figure ‎5.9).  The protein yield (determined by 
peak absorbance) of L44M was similar to that of the native Nterm2 (Figure ‎5.1) 
whereas I34M produced less, and L48M expression produced much larger 
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amounts, than native Nterm2.  These yields transferred through to SEC 
purification, and resulted in the mutant I34M with the lowest yield, L48M with 
the highest yield and L44M with a yield in between (Figure ‎5.10).  Analytical SEC 
confirmed that mutant variants of Nterm2 were still capable of forming and 
purifying as dimers (Figure ‎5.10). 
 
 
Figure ‎5.9.  Mutation of three alternative residues to methionine resulted in varying protein 
yields after expression in E. coli and purification by IMAC.  Chromatograms of the elution buffer 
gradient and UV absorbance profile from the purification of Nterm2 mutants I34M (A), L44M (B), 
L48M (C), and corresponding 16.5% SDS-PAGE gels showing sample lysate (L), column flow 
through (F) and fractions from peak A and B from each purification. 
 
For the production of selenomethionine labelled protein, gene expression in a 
methionine auxotroph, that is, a bacterial strain that is unable to synthesize the 
methionine required for its growth and metabolism, is required.  The E. coli 
expression strain DL41 was created by researchers for this purpose.  The L48M 
Nterm2 methionine mutant was selected over the other mutants as it gave the 
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highest yield.  After transformation into the DL41 strain, expression of 
selenomethionine protein was attempted using an auto-induction media method 
however this resulted in a failure to express recombinant protein.  After 
repeating the growth assay and omitting the toxic selenomethionine ingredient 
in addition to sampling over a time course, it was determined that this 
expression method was not suitable for this protein (results not shown). 
 
 
Figure ‎5.10.  Analytical size exclusion chromatography of the three alternative methionine 
mutants illustrates the variation in protein yield and purification of the expected dimeric form.   
Chromatograms of the UV absorbance and buffer conductivity profile from the purification of 
Nterm2 mutants I34M (A), L44M (B), L48M (C), and corresponding 16.5% SDS-PAGE gels showing 
sample load (L), and fractions from peak A and B from each purification. 
 
An alternative technique based on the inhibition of methionine biosynthesis that 
did not require the use of a methionine auxotroph strain was then used to 
express L48M Nterm2 recombinant protein.  The BL21 E. coli expression strain 
and a methionine pathway inhibition method was utilised for expression of 
selenomethionine labelled protein.  An adequate, but lower yield of L48M 
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Nterm2 protein compared with the native Nterm2 was achieved using this 
method after protein purification using IMAC (Figure ‎5.11A).  The L48M Nterm2 
mutant eluted in the second peak at approximately 40% elution buffer which 
corresponded to a buffer containing approximately 400 mM imidazole.  The 
mutant protein was further purified using preparative SEC column in a low salt 
buffer, providing protein of a single species that appeared to show tight 
dimerisation under SDS-PAGE denaturing conditions (Figure ‎5.11B). 
 
 
Figure ‎5.11.  Production of selenomethionine labelled L48M Nterm2 mutant protein by using a 
methionine pathway inhibition method provides an adequate yield of dimeric protein.  (A) 
Chromatogram of the UV absorbance and elution buffer profile from IMAC purification and the 
corresponding 16.5% SDS-PAGE gel showing sample lysate (L), column flow through (F) and 
fractions from peak A and B; (B) chromatogram of the UV absorbance and conductivity profile 
from preparative size exclusion chromatography and the corresponding 16.5% SDS-PAGE gel 
showing sample load (L) and fractions from peak A.  Selenomethionine incorporation was 
confirmed by MALDI-TOF-MS analysis (results not shown). 
 
Hanging drop crystallisation fine screens of L48M selenomethionine labelled 
Nterm2 were prepared based on the original native data set crystal conditions 
but with a range of lower pH buffers recommended for selenium labelled protein.  
These conditions were unsuccessful in producing crystals.  Later, after trypsin co-
crystallisation conditions had been optimised, hanging drop fine screens 
replicating the solutions that gave native crystals in the space group P3121 were 
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prepared with selenomethionine labelled L48M Nterm2.  Crystal growth was 
abundant in these conditions and a number of crystals grown in 0.1 M MES (pH 
6.5), 0.01 M CoCl2, 1.5-1.6 M (NH4)2SO4, and 0-5% 1-4-dioxane were transported 
to the Australian Synchrotron (Figure ‎5.12).  Multiwavelength data sets with 
resolution up to 1.63Å were collected on two occasions for the purposes of MAD 
structure determination however the data was twinned and was unable to be 
processed.  On close examination, crystal surfaces were not completely smooth 
and were slightly pitted. 
 
 
Figure ‎5.12.  Crystals from selenomethionine labelled L48M Nterm2 mutant diffracted to a high 
resolution but provided data that was “twinned”.   Prism-like shaped crystals co-crystallised 
with trypsin (1:500) grown in 0.1 M MES (pH 6.5), 0.01 M CoCl2, 1.5-1.6 M (NH4)2SO4, and 0-5% 1-
4-dioxane provided data sets to 1.63Å in an undetermined space group.  A corresponding 
diffraction pattern image is displayed on the right of the crystal photo. Data sets suitable for MAD 
analysis were collected at the Australian Synchrotron. 
 
5.2.5 Ab initio techniques solve the phase problem 
Both X-ray data sets collected at the home source from “matured” Nterm2 in the 
P21 space group were sent to Isabel Uson at Instituto de Biologia Molecular de 
Barcelona to see if they were suitable for ab initio phasing methods.  This 
technique is usually limited to small proteins diffracting at atomic resolution 
however advancement in methodology has enabled phase information to be 
determined for larger structures with diffraction data to 2Å resolution (Rodriguez 
et al., 2009).   
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Ab initio methods successfully solved the phase problem and a structure of two 
short α-helix strands with β-sheet fragments composed of alanine residues was 
revealed (Figure ‎5.13A).  Briefly, PHASER (McCoy et al., 2007) was used with 
short helical poly-alanine fragments to search for molecular replacement 
solutions.  Then for a large number of solutions, SHELXE (Sheldrick, 2010) was 
used to try to build longer fragments.  Solutions with correlation coefficients 
above the noise were then identified.  Initial rounds of structure building were 
attempted with the ab initio structure provided using molecular replacement 
techniques but the model did not refine well.  Residues A28, A29, A33 and A34 
were deleted from the ab initio structure, ”freeing” the β-sheet fragment that 
was thought to be possibly incorrectly joined between the two α-helical strands 
(Figure ‎5.13; boxes).  This modified poly-alanine structure was successfully used 
in repeated rounds of structure building using molecular replacement techniques 
and structure refinement (Figure ‎5.13B).  A second crystal structure of the 
N-terminal domain of Lsr2 was determined at 2.04Å from the crystal in the 
hexagonal space group P3121, by molecular replacement using the previously 
determined Nterm2 structure as a search model and its structure subsequently 
refined. 
 
 
Figure ‎5.13.  Cartoon diagrams of the ab initio poly-alanine structure of Nterm2 solved using 
two native data sets in the P21 space group.  (A) The original ab initio solved structure that was 
used in initial structure building and refinement cycles; (B) the ab initio structure after removal of 
residues that were calculated to be linking the two α-helical strands inappropriately.  The 
“trimmed” structure was used in the successful structure building and refinement of Nterm2.  
The boxed area illustrates the views before (A) and after (B) the removal of residues A28, A29, 
A33 and A34 which joined the bottom-most β-sheet to each of the α-helices.  Protein depictions 
were generated in PYMOL. 
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5.2.6 Lsr2 N-terminal domain structure reveals a mechanism of 
oligomerisation 
Each of the two crystal structures of the N-terminal dimerisation domain of Lsr2 
contained two copies of the protein in the asymmetric unit forming an intimate 
dimer that comprises residues K4 to V58 in chain A and K4 to G59 in chain B.  No 
interpretable electron density was observed for the N-terminal fusion tag, the 
N-terminal residues M1, A2, K3 or for the C-terminal residues G60 and R61.  The 
final models have a crystallographic R-factor of 0.16 and 0.25 and R-free factors 
of 0.18 and 0.28, for the P21 and P3121 space groups respectively.  The model 
has excellent geometry, with all residues in the favoured region of the 
Ramachandran plots as defined by MOLPROBITY and average root mean square 
deviations (RMSD) from ideal values for bond angles of 0.914° and 0.997° and  
bond lengths of 0.006Å and 0.008Å for P21 and P3121 space groups respectively.  
A summary of the refinement statistics is given in Table ‎5.3. 
 
The Lsr2 dimerisation domain forms a compact homodimeric α/β structure 
(Figure ‎5.14).  The monomer displays an extended N-terminus which is one 
strand of an anti-parallel β-sheet (the other stand provided by a symmetry 
related molecule), an anti-parallel β-sheet of two strands followed by an α-helix 
with a significant kink.  The residues L48 and K49 are responsible for this kink.  
The secondary structure elements in this crystal structure closely agree with the 
predicted secondary structure of the dimerisation domain.  The β-sheet is at an 
angle of approximately 45° to the α-helix and lies with its face flanking the 
N-terminal end of the helix (Figure ‎5.14A).  The dimer is formed in a “tail-to-tail” 
fashion, with the anti-parallel β-sheet of chain A alongside the anti-parallel 
β-sheet of chain B, both on the same plane and approximately 45° to the two α-
helices (Figure ‎5.14B).   
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Table ‎5.3.  Crystallographic refinement statistics. 
 
 Nterm2 Nterm2 + Trypsin 
Refinement   
R-factora 0.16 (0.19) 0.25 (0.28) 
R-free 0.18 (0.25) 0.28 (0.33) 
Protein Atoms 834 838 
Solvent Atoms 206 135 
Ramachandran Favoured 
(%) 
99.1 100.0 
Ramachandran Outliers 
(%) 
0.0 0.0 
Average B-value (Å2) 13.6 36.7 
RMSD   
      Bond Angles (°) 0.914 0.997 
      Bond Lengths (Å) 0.006 0.008 
a 
numbers in parentheses correspond to the highest resolution shell 
 
The kinked C-terminus of the helix allows it to pack against the β-strands of the 
neighbouring molecule in the dimer.  Residues that have been previously 
implicated in dimerisation – D28 and R45 (Chen et al., 2008) - anchor the anti-
parallel β-sheet of one chain to the α-helix of the other chain via a salt bridge 
(Figure ‎5.14C).  The dimer interface buries 1548.2 Å2, corresponding to 31% of 
the total surface area of each monomer.  The C-terminal residues of each 
monomer point downwards and away from the β-sheets of the compact 
homodimer.  Presumably the DNA binding domain of Lsr2 could be in a number 
of orientations but would be linked to the dimerisation domain via the flexible 
(approximately 16 amino acid residue) inter-domain region.  Ten residues are 
well-conserved across the N-terminal domain of the Lsr2 protein family (D11, 
D12, F25, Y32, I34, D35, L36, L44, L48 and W51, (Figure ‎5.8 and Figure ‎5.15). 
These cluster in the core of the dimer and provide a large number of tertiary 
hydrophobic and hydrogen bonding interactions that connect the β-sheet, 
α-helix and a large N-terminal loop (Figure ‎5.15).  This residue conservation in 
the loop region suggests that this conformation is of importance in the structure.  
Residues D12 and D35 point towards the solvent and are not involved in tertiary 
interactions in the dimer.  Rather, they are critical in linking the dimers together 
to form oligomers (Figure ‎5.16D). 
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Figure ‎5.14.  Cartoon diagrams of Lsr2 N-terminal domain in the P21 crystal structure.  (A) A 
depiction of the monomer: the α-helix, β-sheets and chain termini are labelled and the chain is 
coloured blue-red (N-terminus to C-terminus); (B) the dimer as seen in the crystal structure; (C) a 
90° rotation of figure B showing residues critical for dimerisation as grey, blue and red sticks; (D) 
Lsr2 N-terminal domain oligomerisation as generated by crystallographic symmetry.  The N-
terminus of one dimer becomes one strand of an anti-parallel β-sheet.  The second strand is 
presented by a neighbouring dimer.  The sheet linking two dimers is shown as β0; (E) 
crystallographic symmetry (in space group P21) showing the unit cell (in green) projected 
perpendicular to the b-axis.  The two-fold screw axis generates alternating Lsr2 chains that lay 
back to back in the horizontal plane this view.  For all figures protein depictions were rendered 
with PYMOL. 
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The primary protein interface is between the two interlocking protein monomers 
however there is a second interface of 380.9 Å2, corresponding to 7.7% of the 
total surface area of each monomer.  This second interface is between the 
extended N-terminus of one strand of a dimer and the extended N-terminus of 
another strand of a dimer, forming an anti-parallel β-sheet connecting the two 
dimers (Figure ‎5.14D).   
 
The crystal structure reveals a chain of dimers formed by crystallographic 
symmetry (Figure ‎5.14D and E).  In both crystallographic space groups (P21 and 
P3121) there is two-fold symmetry (for simplicity illustrated for P21 in 
Figure ‎5.14E) that generates alternating Lsr2 chains that lie back-to-back.  Each 
N-terminal end contributes one strand of an anti-parallel β-sheet (Figure ‎5.14D).  
This additional third β-sheet was predicted in secondary structure analysis.  In 
both structures from “matured” and trypsin co-crystallised Nterm2, the 
N-terminal histidine tag and rTEV cleavage site and residues M1, A2 and K3 are 
missing.  The fact that the structures are identical and one was the result of 
trypsin treatment led to the suspicion that the “matured” sample successfully 
crystallised due to traces of a contaminating protease.  
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Figure ‎5.15.  Conserved amino acids of the N-terminal domain of Lsr2 important for structural 
integrity.  The structure is for the P21 space group.  (A) Relative conservation of amino acids at 
different positions from a multiple sequence alignment are depicted using HMM Logo 
(http://pfam.sanger.ac.uk/family/PF11774.2). The height of the letters represents the relative 
entropy and the width represents the relative contribution of the position to the overall protein 
family. The pink bars represent regions of insertion in the alignment. Amino acid residue colours 
reflect their biological properties (red = charged; blues = polar, uncharged; yellows = aliphatic; 
greens = aromatic). The amino acid sequence for Lsr2 from M. tuberculosis is shown across the 
top of the HMM logo for comparison and residues that are well-conserved are in bold. (B) 
Cartoon diagram of Lsr2 N-terminal dimerisation domain showing conserved residues. The 
structure is for the P21 crystal form. Conserved residues for each chain are shown in yellow and 
orange respectively. Yellow residues from chain A are labelled. The chain termini are also labelled.  
Depiction was generated in PYMOL. 
 
Electrostatic surface potential analysis of the crystal structure illustrates the 
electrostatic complementarities between dimers (Figure ‎5.16).  The N-terminal 
ends of each dimer and the lysine residues along the α-helixes display a positive 
charge (Figure ‎5.16A) whereas the β-sheet side of the dimer has an overall 
negative charge that extends into the loop region (Figure ‎5.16B).  In a chain of 
dimers formed by crystallographic symmetry, it was noticed that the positively 
charged N-terminal ends of each overlapping β-strand interact with the 
negatively charged loop regions of the adjacent dimer (Figure ‎5.16C). 
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Figure ‎5.16.  Electrostatic surface potential diagrams of Lsr2 N-terminal domain and details of 
residues that interact for oligomerisation.  A dimer viewed from (A) the α-helices aspect and (B) 
the β-sheet aspect; (C) an oligomer of two dimers viewed from the β-sheet aspect; (D) an 
enlargement of the residues (shown as sticks) in the anti-parallel β-sheets that interact between 
two adjoining dimers.  Interacting residues are labelled and hydrogen bonding is represented by 
black dashed lines.  Colours indicate the surface electrostatic potential:  blue = positive (or above 
0.1 Volt), white = neutral and red = negative (or below 0.1 Volt).  The chain termini are labelled 
where visible.  Surface potential diagrams and protein depictions were generated in PYMOL. 
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Observation of the interaction between residue K4 (the N-terminus after 
truncation) of one dimer and those residues involved in the twisted loop 
conformation of the second dimer shows a number of non-covalent bonds 
(Figure ‎5.16D).  The oligomer is not only stabilised by interstrand hydrogen 
bonds between the overlapping β-strands, but also by a network of polar 
interactions between K4 and its oligomeric neighbour.  Positively charged amino 
groups of K4 form salt bridges with carbonyl groups and acidic groups from 
residues V10, D12 and D35 from the neighbouring dimer nestled alongside 
(Figure ‎5.16D).  This structural alignment could not occur if the N-terminal 
residues M1, A2 and K3 were present as the polar interactions between the K4 
backbone amide and V10, D12 and D35 could not form if a peptide bond were 
present (Figure ‎5.16D).  Within an individual dimer, R56 from one monomer in 
the dimer forms a salt bridge with both E33 and D35 from the other monomer 
(Figure ‎5.16D).   
The addition of trypsin in crystallisation conditions facilitated crystallisation in a 
different space group, P3121 (Figure ‎5.17).  The dimerisation and the linear 
oligomerisation of the N-terminal domain of Lsr2 is identical in this hexagonal 
space group when compared to the structure in the P21 crystals.  The difference 
between the two space groups is the arrangement of the linear chains of the 
molecules.  The linear oligomer strands lie side by side in the monoclinic crystals 
whereas the hexagonal crystals are made up of stacked layers of linear strands 
that are rotated by 120 degrees (Figure ‎5.14 and Figure ‎5.17A).  This provides 
further evidence that the tendency to form linear chains of dimers is a result of 
truncation of the N-terminus and is not a crystallographic artefact. 
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Figure ‎5.17.  A model for the chromosomal DNA organisation by Lsr2 as suggested by 
hexagonal crystal packing.  (A) The N-terminal Lsr2 dimerisation domain in the P3121 space 
group in two orientations; (B) the proposed orientation of DNA (in blue) between the N-terminal 
chains and a 90° rotation illustrating this from above.  The C-terminal DNA binding domains (in 
orange) have been positioned according to (Gordon et al., 2010); (C) our model of full-length Lsr2 
binding to DNA and forming chains, cross-linking multiple strands of DNA.  The dimension at the 
bottom of the figure is consistent with the compact fibrils seen in TEM analysis of Lsr2 with DNA 
(Figure ‎5.21).  Protein depictions were generated in PYMOL. 
 
The crystallographic data in the more complex P3121 space group reveals a 
possible mechanism of protein alignment and binding to DNA.  Figure ‎5.17A and 
B shows the arrangement of the Lsr2 N-terminal domain in this space group, the 
potential positioning of DNA strands and C-terminal DNA binding domain of Lsr2.  
Within the constraints of crystal packing, the stands of DNA can be uniformly 
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positioned underneath chains of N-terminal domains and the C-terminal DNA 
binding domain can sit adjacent to the N-terminal domain (Figure ‎5.17B).  
Interestingly, the protein is at a 120° angle to the DNA strand which would off-
set each strand of DNA to each other.  Crystal packing gives us an idea of how 
Lsr2 may be positioned on, and bind to, the DNA and oligomerisation of the 
nature seen in the crystal structure shows how many DNA strands, already 
bound by Lsr2, may be drawn together in a very uniform manner (Figure ‎5.17C). 
The model presented here provides a structural basis for chromosomal DNA 
condensation.  Evidence from the P3121 space group crystal packing of the 
N-terminal domain and TEM images of trypsin-activated Lsr2 oligomerisation on 
genomic DNA (Figure ‎5.21) shows a dynamic mechanism for DNA compaction.  
The modelled crystallographic dimensions of four strands of DNA in complex 
with the full length Lsr2 protein are consistent with the compact fibrils seen in 
TEM analysis of Lsr2 with DNA which is discussed further in section ‎5.2.7.1. 
Coordinate files and structure factors for structures in both monoclinic and 
hexagonal crystal forms have been deposited in the Protein Data Bank with PDB 
codes of 4E1P and 4E1R respectively. 
 
5.2.7 Proteolytic digestion of Nterm2 is necessary for formation of 
oligomeric structures 
Purification of Nterm2 by both analytical and preparative SEC after IMAC showed 
that the N-terminal domain was a dimer (Figure ‎5.18A).  Further SEC purification 
of concentrated Nterm2 protein that had previously been used in crystallography 
trials but had been stored at 18°C for some months revealed that much larger 
oligomeric forms had developed naturally over time and it was proposed that 
this was probably due to small amounts of contaminating proteases slowly 
degrading the protein (Figure ‎5.18B).  The crystal structures of the N-terminal 
domain in both the native monoclinic data set and the hexagonal data set 
strongly suggested that the removal of the first three residues was crucial for 
crystal organisation and protein oligomerisation.  Trypsin was added to fresh 
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dimeric Nterm2 protein at a 1:500 mass ratio (shown in Figure ‎5.18A) for 
5 minutes at room temperature and purified by SEC.  The results showed that the 
majority of the dimeric Nterm2 had now developed into larger multimers that 
are seen in peaks A and B (Figure ‎5.18C) with little of the dimer remaining (peak 
C).  This result was contradictory to what would normally be expected to occur to 
protein digested using trypsin but is in agreement with previous observations of 
“matured” Nterm2 protein preparations. 
Molecular weight analysis of equivalent Nterm2 protein preparations using 
MALDI-TOF-MS enabled clarification of the size of peptides present in “fresh”, 
trypsin-treated and “matured” samples in comparison to the crystallised protein 
retrieved by dissolving a single crystal (Figure ‎5.19).  The mass to charge ratio 
(m/z) represents the molecular weight of the protein.  Although the 
experimental masses given using this technique were not exactly as predicted 
(6199.8 Da), the results nonetheless confirmed that a molecular weight species 
of approximately 6137 Da representing Nterm2 without the N-terminal tag, 
spacer and the first three residues (M1, A2, and K3) was present in “fresh”, 
crystallised and trypsin treated preparations (Figure ‎5.19A-C).  Peptides of 
approximately 3254 Da representing the entire N-terminal tag through to the 
first three residues were present in the “fresh” and trypsin treated samples but 
not in the crystalline form.  A mass of 9431 Da, representing the full length 
Nterm2 protein was observed in the “fresh” preparation but was absent from 
the trypsin treated sample presumably as proteolysis had progressed further in 
this sample (Figure ‎5.19A and C).  Analysis of “matured” Nterm2 revealed that it 
had formed oligomeric structures up to seven dimers long (Figure ‎5.19D).  
Electrospray ionisation investigation of dissolved crystals accurately predicted a 
molecular weight of 6198.9 Da and 6200.1 Da for monoclinic and hexagonal 
crystals respectively (Figure ‎5.19E).  These figures compare closely to the 
calculated molecular weight of Nterm2 minus the N-terminal tag and the first 
three residues and are comparable with the protein species observed in MALDI-
TOF-MS investigations. 
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Figure ‎5.18.  The addition of trypsin to the N-terminal domain of Lsr2 (Nterm2) facilitates 
oligomerisation.  (A) Size exclusion chromatography of freshly purified Nterm2 showing a single 
dimer peak; (B) a chromatogram of the same protein construct used for crystallography (now 14 
weeks old) demonstrating larger oligomeric forms in solution; (C) the addition of trypsin (1:500) 
for 5 minutes at room temperature to a fresh sample of Nterm2 accelerates the formation of 
large oligomeric species in solution.  Corresponding 16.5% SDS-PAGE gels are on the right and 
show the sample load (L), and fractions from peaks A, B and C. 
 
 
 
 
 
 
 
 
 Chapter Five – Structure of the N-terminal dimerisation domain of Lsr2 153 
 
Figure ‎5.19.  MALDI-TOF-MS analysis of fresh and trypsin treated Nterm2 protein illustrates 
that species of the same size as those from dissolved crystals are seen across all samples.  (A) In 
a relatively fresh (4 week old) Nterm2 protein preparation several peaks corresponding to the 
full-length protein (9431 m/z), the protein with the histidine tag plus the first three residues 
(MAK) removed (6137 m/z) and the tag itself (3254 m/z) are seen; (B) a single dissolved crystal 
from identical crystallisation conditions as the P21 space group crystal structure shows that 
almost the entire sample is a species with the histidine tag plus the first three residues (MAK) 
removed (6139 m/z); (C) the addition of trypsin (1:500) accelerates the removal of the histidine 
tag and first three residues (3250 m/z), leaving the smaller 6137 m/z species; (D) “matured” 
Nterm2 (3 months old) illustrates the oligomerisation potential of the N-terminal dimerisation 
domain once the tag and first three residues are absent.  Mass to charge ratio peaks show dimers 
(12320 m/z), trimers (18517 m/z), tetramers (24375 m/z), pentamers (30272 m/z), hexamers 
(36209 m/z) and heptamers (42280 m/z); (E) electrospray ionisation investigation of dissolved 
hexagonal crystals gives an accurate molecular weight of 6200.1 Da the of the protein species 
observed in MALDI-TOF-MS investigations.   
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5.2.7.1 Lsr2 cleavage by trypsin allows DNA restructuring, compaction 
and protection 
The crystal structure of the dimerisation domain of Lsr2 revealed an interesting 
mechanism of oligomerisation but it would be more relevant to see if the full 
length protein was also capable of forming long chains.  The effect of N-terminal 
proteolytic processing and oligomerisation on full length Lsr2 bound to DNA was 
investigated.  Full length Lsr2 that is expressed in E. coli and purified using IMAC 
chromatography, results in a preparation of Lsr2 bound to E. coli genomic DNA 
(Colangeli et al., 2009).  When this sample was treated with DNAse for 1 hour, 
the majority of the DNA was digested and Lsr2 provides little or no protection 
(Figure ‎5.20, lanes 1 and 2).  However, proteolytic treatment of Lsr2 using trypsin 
in small amounts (1:500 mass ratio) for increasing periods of time, followed by 
DNase treatment, resulted in DNA condensation, providing increasing levels of 
protection of DNA against DNAse degradation (Figure ‎5.20, lanes 3-12).  
Intriguingly, processed Lsr2 appeared to protect stretches of DNA of a relatively 
uniform small size and this may hint at localised zippering of DNA by Lsr2 as 
opposed to long-range crosslinking of the DNA.  SDS PAGE analysis of equivalent 
samples showed that prior to proteolytic treatment, Lsr2 was relatively versatile 
and ran as a monomer, a dimer and higher oligomers on the gel.  However, after 
processing, Lsr2 ran exclusively as a dimer and higher order oligomers despite 
the denaturing challenge of SDS and heating prior to running the gel (Figure ‎5.20).  
Full length dimeric Lsr2 (from Figure ‎5.20, lane 1) was analysed by MALDI-
TOF-MS peptide mass analysis and confirmed the presence of a dimeric form of 
Lsr2 (results not shown). 
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Figure ‎5.20.  Trypsin digestion of full length Lsr2 co-purified with E. coli genomic DNA shows 
DNA compaction and DNase protection.  Trypsin (1:500) initiates the compaction of co-purified 
DNA by Lsr2 over 1 hour as visualised on a 1% agarose gel (SYBR® safe DNA stain).  Subsequent 
digestion of the compacted DNA using DNase shows protection of the DNA by Lsr2.  Equivalent 
samples were run on an SDS-PAGE gel to show the presence of Lsr2 (both monomer and dimer 
forms) in the sample after trypsin digestion.  Components are labelled:  C = condensation of DNA 
upon treatment with trypsin; P = protection of DNA; D = Lsr2 dimer; M = Lsr2 monomer. 
 
The effect of trypsin-induced oligomerisation of Lsr2 on DNA topology 
mentioned above was visualized using negative-stain TEM (Figure ‎5.21). Previous 
experimental evidence using TEM showed that IMAC purified Lsr2 decorated the 
length of DNA strands (Colangeli et al., 2009).  Trypsin was combined with IMAC 
purified Lsr2 and sampled over the same time course as above.  It was 
hypothesised that trypsin would cleave residues suitable to promote 
oligomerisation and would allow a change in protein organisation and hence 
DNA packing.  The effect of trypsin on the C-terminal histidine tag was unknown.  
Prior to proteolytic treatment, Lsr2/DNA strands were visible with diameters 
ranging between 40Å and 120Å (Figure ‎5.21A).  This was consistent with single 
lengths of double stranded DNA coated with Lsr2 dimers and in some cases, pairs 
of strands lying side-by-side. After treatment, larger, well ordered fibres (with 
diameters of ~200Å) were present along with condensed, knotted bundles of 
Lsr2/DNA strands (Figure ‎5.21B, arrows A and B, respectively).  A change in 
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Lsr2/DNA strand structure was evident after only 1 minute, and larger ordered 
fibres began to appear after 5 minutes of trypsin treatment (results not shown).  
The diameter of the fibrils suggests higher-order structuring of DNA.  The 
condensed knotted bundles became so dense after 1 hour that defocusing and 
image capture was challenging due to the uneven topology (results not shown). 
 
 
Figure ‎5.21.  Negatively stained Lsr2/DNA complexes visualised by transmission electron 
microscopy show obvious morphological changes upon trypsin treatment.  (A) Lsr2 co-purified 
with E. coli genomic DNA; (B) Lsr2 after trypsin digestion (1:500 ratio) for 30 minutes; Arrows A 
and B point to compacted structures commonly seen during the trypsin digestion time series 
(scale bars = 100 nm); (C) a cartoon representation of protein oligomerisation and DNA 
compaction after trypsin digestion.  Lsr2 N-terminal dimerisation domain is shown in green and 
C-terminal DNA binding domain in orange.  The downward pointing arrows correlate the features 
in (B) with their cartoon representations in (C). 
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5.3 Discussion 
Lsr2 from M. tuberculosis H37Rv is a DNA binding protein that likely influences 
gene regulation and the organisation of bacterial chromatin by binding to DNA 
and indeed it has been shown to be able to crosslink double stranded DNA in 
vitro (Chen et al., 2008).  Lsr2’s relationship to the E. coli nucleoid-associated 
protein H-NS discovered through domain swapping and in vitro 
complementation experiments also suggests a role in chromosome organisation 
(Gordon et al., 2010).  Although Lsr2 and H-NS share similarities in domain 
organisation and function, they share less than 20% amino acid sequence 
identity and they have different predicted secondary structure elements (Gordon 
et al., 2008).  The 3D structure of the DNA binding domain of Lsr2 has recently 
been solved by NMR methods and revealed that the structure is unique and 
distinct from that of H-NS.  A model of DNA binding of Lsr2 calculated that Lsr2 
can bind DNA in two orientations by grabbing either edge of the minor groove 
like a clamp (Gordon et al., 2010).  Whilst the mode of DNA binding by Lsr2 (via 
its C-terminal domain) is well characterized, the dimerisation and oligomerisation 
mechanisms have not been established.  This aspect of Lsr2 function is thought 
to be important with respect to the mechanism of DNA crosslinking, 
chromosome organization and gene regulation. 
In this study, the mechanism of dimerisation and oligomerisation of Lsr2 was 
established by focusing on determining the 3D structure of the N-terminal 
domain.  Earlier attempts to crystallise the full-length Lsr2 were unsuccessful.  
Lsr2 co-purifies with E. coli genomic DNA and whist the DNA can be dissociated 
by buffer exchange into high salt buffer and removed via SEC, the protein is not 
completely free of DNA and is prone to binding to other material afterwards.  
Also, the disordered and flexible region between the two domains was predicted 
to make protein crystallography difficult due to protein flexibility.  Seven 
N-terminal domain constructs differing in length and including a range of 
residues reaching into the unstructured inter-domain region were expressed and 
purified.  From these, three variants reached crystallisation trials and Nterm2 
successfully grew diffraction quality crystals that yielded a 1.73Å resolution 
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dataset.  Crystals grew only after many weeks and at that time, required an 
unknown “maturation” process for crystallization to proceed.  Nevertheless, 
these crystals provided high quality X-ray diffraction data that were suitable for 
structure determination via newly developed ab initio phasing techniques 
(Rodriguez et al., 2009).  The Nterm2 structure is a dimer that has no 
homologues in the structural databases and is unlike the oligomerisation domain 
of H-NS from E. coli despite its previously identified functional similarities.  The 
structure provides a rationalisation for the sequence conservation seen for this 
domain – the majority of the conserved residues form tertiary interactions in the 
structure.  
The structure showed linear chains of Lsr2 N-terminal domain oligomers that 
were the result of crystal packing.  The chain “links” were constructed by the 
tight association of a β-strand from each of the N-termini of neighbouring dimers.  
These links can only form if the N-terminus of the domain is truncated by three 
residues, and this provided a rationale for the “maturation” required for 
crystallization.  It also presented a hypothetical mechanism for protease-driven 
oligomerisation of Lsr2.  Artificial oligomerisation was promoted using trypsin 
and a second crystallographic structure was determined in a new hexagonal 
space group.  This also showed linear chains of Lsr2 N-terminal domain oligomers 
very similar to those seen in the monoclinic crystals.  However the linear 
oligomer strands were packed in the crystal in a hexagonal format as compared 
to the side-by-side format of the monoclinic crystals. 
Lsr2 oligomers were not only seen in the crystals of the N-terminal domain but 
also in solution for both purified Nterm2 and full-length Lsr2 protein.  The IMAC 
purified full-length Lsr2 protein, which co-purifies with DNA, oligomerised on 
treatment with trypsin.  This oligomerisation increasingly protects DNA from 
DNAse degradation.  Further, DNA compaction and crosslinking was induced by 
trypsin and could be visualized using electron microscopy.  Based on the TEM 
images, the hexagonal crystal lattice structure for Nterm2 was used to 
speculatively build a model for DNA organisation by full-length Lsr2. 
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The hexagonal crystals of the Lsr2 N-terminal domain had a higher solvent 
content when compared to the monoclinic crystals.  Pores running through the 
hexagonal crystal lattice were of the appropriate dimensions to accommodate 
long chains of double stranded DNA and adjacent spaces were appropriate to 
accommodate the Lsr2 C-terminal DNA binding domains and a model was 
developed accordingly.  The proposed model (Figure ‎5.17), is consistent with the 
dimensions of the fibres observed under TEM and the mode of DNA binding 
predicted previously (Gordon et al., 2010). 
In summary, this study revealed the first crystal structure of the N-terminal 
dimerisation domain of Lsr2 from M. tuberculosis H37Rv.  The arrangement of 
Lsr2 N-terminal domain oligomers differed from other known oligo-forming DNA 
binding proteins such as E. coli H-NS (Arold et al., 2010).  Oligomerisation was 
dependent upon proteolytic processing of the N-terminus of Lsr2 and both 
protein oligomerisation and DNA compaction could be induced by treating Lsr2 
with low concentrations of the protease typsin.  There are many trypsin-like 
proteases encoded in the genome of M. tuberculosis H37Rv which may indicate 
that proteolytic processing of proteins to cause oligomerisation could occur.  This 
mechanism may help to explain how Lsr2 is involved in regulating the expression 
of a large number of genes involved in cellular processes. 
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6 Chapter Six – Pellicle and biofilm formation in 
M. smegmatis mc2155 Δlsr2 and Lsr2 mutant strains 
6.1 Introduction 
Bacteria that form biofilms are abundant and present in most environments. 
Biofilm formation by the bacterial pathogen Pseudomonas aeruginosa has been 
the most extensively studied individual species but other gram-negative bacteria 
such as Pseudomonas fluorescens and E. coli have also been studied in detail 
(O'Toole et al., 2000; O'Toole & Kolter, 1998).  It is unclear if the human 
pathogen M. tuberculosis is capable of forming a biofilm (Ha et al., 2005) 
however it is well established that M. smegmatis and other environmental 
bacteria such as M. avium are capable of producing a biofilm (Carter et al., 2003; 
Ojha & Hatfull, 2007).   
Bacteria growing in a biofilm are noted to be more resistant to antibacterial 
compounds than their planktonic counterparts and this is a trait established in 
M. smegmatis mc2155 which is able grow within its biofilm unaffected by the 
antibiotic isoniazid at concentrations that are usually inhibitory (Teng & Dick, 
2003).  In other studies investigating isoniazid resistance in planktonic 
M. tuberculosis H37Rv, drug induced specific gene upregulation was responsible 
for conferring antibiotic resistance of the organism (Alland et al., 2000; Colangeli 
et al., 2005).  Continued investigation into the regulation of these antibiotic 
resistance genes identified the DNA binding protein Lsr2 which was capable of 
repressing these specific genes (Colangeli et al., 2007).   
Lsr2 has also been shown to play an important role in colony morphology and 
biofilm formation in M. smegmatis mc2155 (Chen et al., 2006).  When grown on 
either mycobacteria-specific (7H10/11 agar) or rich (LB agar) media, Δlsr2 mutant 
colonies were smooth, wet and round which was in contrast to the dry, rough 
and rugose morphology of the wild type parental strain (Arora et al., 2008; Chen 
et al., 2006; Colangeli et al., 2007; Kocíncová et al., 2008).   These Lsr2 mutants 
had differing abilities to form biofilms with some researchers observing a 
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reduction or lack of biofilm formation (Arora et al., 2008; Chen et al., 2006) 
whilst others saw an increase in biofilm formation (Kocíncová et al., 2008).  Cell 
aggregation studies in liquid cultures (without the addition of the detergent 
Tween 80) also showed contrasting behaviour of Δlsr2 mutants.  In one study, 
the growth of Δlsr2 mutants in liquid media resulted in increased cell aggregation 
(Arora et al., 2008) but in another there was less cell aggregation compared with 
the original M. smegmatis mc2155 strain (Kocíncová et al., 2008).  These 
contradictory morphological results suggested that further research was 
warranted in this area.   
A biofilm may be defined in simplistic terms as a community of microorganisms 
that are attached to a surface (O'Toole et al., 2000) or more comprehensively as 
a bacterial population embedded within a matrix which adheres to each other 
and to surfaces and interfaces (Costerton et al., 1995).  The formation of these 
bacterial communities depends upon the creation of a matrix which is self-
produced (Costerton et al., 1999) by the synthesis of extracellular substances 
(Branda et al., 2005).  Matrices are diverse in their construction and their 
composition varies depending on the local environmental conditions (Branda et 
al., 2005).  A complex mixture of extracellular polysaccharides, protein and DNA 
produced by biofilm bacteria form the matrix which holds the biofilm together 
(Costerton et al., 1995; Whitchurch et al., 2002).  Usually the addition of a 
detergent such as Tween 80 is required for growth of mycobacteria as a uniform 
cell suspension however Tween is omitted for biofilm formation to allow 
necessary cell-cell interaction (Arora et al., 2008).   
Studies on the effect of Lsr2 in M. smegmatis biofilm formation typically focus on 
surface-adhered bacterial populations however air-liquid floating biofilms or 
pellicles represent another type of biofilm (Branda et al., 2005).  There appears 
to be a lack of convention in using the term biofilm or pellicle to represent 
surface-adhered or air-liquid biofilms respectively.  Three publications to my 
knowledge have investigated the role of Lsr2 in pellicle formation however only 
one clearly used the term pellicle which leads to confusion when comparing and 
contrasting experimental results from a variety of researchers (Arora et al., 2008; 
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Chen et al., 2006; Nguyen et al., 2010).  Lsr2 mutants in the three 
aforementioned studies were defective in pellicle formation.  Results presented 
in this chapter from the examination of biofilm and pellicle formation in 
M. smegmatis mc2155 attempt to establish a convention of clearly distinguishing 
between the development of surface adhered biofilm and air-liquid pellicle 
formation. 
Examination of biofilm formation ability in M. smegmatis mc2155 is a common 
research technique used for assessing the impact of gene deletions and 
transposon mutagenesis in this bacterial species (Klepp et al., 2012; Recht et al., 
2000; Röse et al., 2004).  It is also used in studies to characterise mycobacteria 
species and strains (Esteban et al., 2008).  Examination of the methodology used 
in the study of M. smegmatis mc2155 biofilm formation reveals some similarities 
and notable differences.  The use of a M63 minimal media supplemented with 
amino acids, a carbon source (glucose, glycerol or dextrose), MgSO4 and CaCl2 
was routine in all but one examined research method, which used Middlebrook 
7H9 media instead (Esteban et al., 2008).  The study that used 7H9 media also 
differed in its use of basic fuchsine to stain cells for visual biofilm quantification 
whereas all other research methods used a crystal violet biofilm staining 
technique and quantified by stain extraction and absorbance measurement 
(Recht et al., 2000).   
A point of difference in culture technique was in the use of PVC or polystyrene 
plastic dishes and the dish well size.  Three publications examined biofilm 
formation in PVC 96-well plates (Recht & Kolter, 2001; Recht et al., 2000; Teng & 
Dick, 2003), whereas five used polystyrene plastic-ware (Esteban et al., 2008; 
Gopalaswamy et al., 2008; Ojha et al., 2005; Ojha & Hatfull, 2007; Röse et al., 
2004) and one did not mention what was used (Klepp et al., 2012).  Furthermore, 
of those studies that used polystyrene plastic the well size varied between 
60 mm dishes, 12-well, 24-well and tissue culture treated 96-well plates.  The 
incubation temperature used in these studies also varied between room 
temperature, 30°C and 37°C.  Another point of difference in these biofilm studies 
was that the researchers that used 60 mm polystyrene dishes were only 
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interested in pellicle formation (and did not perform biofilm staining) and as 
previously mentioned, they confusingly used the term biofilm instead of pellicle 
(Ojha et al., 2005; Ojha & Hatfull, 2007).  Overall, after reviewing research on 
biofilm formation in M. smegmatis mc2155, it was concluded that it was 
generally difficult to decipher if investigators were presenting pellicle or biofilm 
formation results and if their biofilm staining results were solely due to the 
surface-adhered biofilm or included the pellicle and biofilm together.  
This chapter focuses on the exploration of the M. smegmatis mc2155 Δlsr2 
mutant phenotype, establishing conditions suitable for pellicle and biofilm 
growth and the development of assays for quantifying pellicle and biofilm 
formation.  The rationale for this work was that once a phenotype was clearly 
established in the Δlsr2 mutant, the role of Lsr2 in pellicle and biofilm formation 
could be investigated.  If the mutant phenotype could be rescued by the 
introduction of M. tuberculosis H37Rv Lsr2 on a vector, then the role of specific 
DNA binding residues in the C-terminal domain could be investigated by the 
introduction of Lsr2 DNA binding mutants into M. smegmatis mc2155, and their 
effect on pellicle and biofilm formation examined.  Three Lsr2 DNA binding 
mutants were created and characterised earlier which showed deficiencies in 
DNA binding (Chapter Four).  These Lsr2 mutants in addition to native Lsr2 were 
conditionally expressed using a tetracycline inducible mycobacteria vector 
pMIND (Blokpoel et al., 2005) and their ability to rescue the Lsr2 mutant 
phenotype examined. 
Work presented in this chapter demonstrates that a limited phenotype for the 
M. smegmatis mc2155 Δlsr2 mutant was established and a technique to 
accurately examine both pellicle and biofilm growth was developed.  Analysis of 
pellicle and biofilm formation between wild type and Lsr2 mutant strains 
demonstrated only qualitative and not quantitative differences.  The expression 
of native Lsr2 and Lsr2 DNA binding mutants had no effect on pellicle and biofilm 
formation. 
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6.2 Results 
6.2.1 M. smegmatis Δlsr2 shows similar morphology to wild type 
M. smegmatis mc2155 containing an unmarked chromosomal deletion of the lsr2 
gene (MSMEG_6092) was supplied by R. Colangeli (Colangeli et al., 2007).  The 
Δlsr2 mutant colony morphology was similar to the M. smegmatis mc2155 lab 
strain when grown with both Middlebrook and LBT media.  The Δlsr2 mutant 
grown on Middlebrook 7H10 agar exhibited cream coloured, irregular, raised, 
dull, rough and dry colony morphology and in Middlebrook 7H9 media formed 
white aggregates (results not shown).  Grown on LBT agar, the Δlsr2 was more 
yellow in colour and colonies were raised, irregular, rough but slightly shiny 
(Figure ‎6.2A) and in LBT media formed yellow aggregates.  In this study the Δlsr2 
mutant did not exhibit a smooth mucoid colony type nor have a lack of cell 
aggregation as reported by others.  In shaking LB media cultures (grown 
overnight for seeding biofilm assays) both the lab strain and Δlsr2 begin growth 
in aggregate forms but grew to identical optical densities (Figure ‎6.2B).  In a trial 
growth curve assay performed in supplemented M63 biofilm media, the Δlsr2 
showed cell aggregation compared with the lab strain (Figure ‎6.2C) but had no 
observed reduction in growth.  Overall, the Δlsr2 strain appeared and behaved in 
a similar manner to the lab strain.  The Δlsr2 strain was checked for the deletion 
of the lsr2 gene by PCR analysis which confirmed that the gene was indeed 
absent (Figure ‎6.1). 
 
 
Figure ‎6.1.  PCR analysis of M. smegmatis mc
2
155 Δlsr2 
strain.  Primers were designed for M. smegmatis Lsr2 
(MSMEG_6092; Lane 1), M. tuberculosis Lsr2 (Rv3597c; lane 2) 
and pMIND multiple cloning site (lane 3). Control PCR 
products are shown in Figure 6.7 where this image was 
excised from. 
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Figure ‎6.2.  M. smegmatis Δlsr2 mutant did not show mucoid colony appearance and a lack of 
cell aggregation as reported by others.  (A) Colonies on LBT agar were more yellow in colour 
compared to the lab strain but similar in their raised, irregular and rough appearance; (B) the 
Δlsr2 strain showed identical growth to the lab strain in an overnight LB media culture; (C) in M63 
biofilm media the Δlsr2 showed greater cell aggregation compared with the lab strain however 
growth was unaffected. 
 
6.2.2 Culture method and media affects pellicle and biofilm formation 
For the optimisation of biofilm formation a number of media were extensively 
trialled; LB medium, auto-induction media (Studier, 2005), Hartman’s de Bont, 
M63 minimal media and finally M63 supplemented with 0.2% glycerol, 0.5% 
bacto-tryptone, 1  mM MgSO4 and 0.7% mM CaCl2 based on published media 
(Chen et al., 2006).  Biofilm assays were also optimised by trials in tissue culture 
flasks, 60 mm polystyrene dishes and a number of multi-well plates.  Tissue 
culture flasks and 60 mm polystyrene dishes failed to consistently form an 
obvious pellicle or biofilm (results not shown).  Tissue culture treated 6-well 
dishes showed development of both pellicle and biofilm structures (Figure ‎6.3A) 
and some difference between the lab and mutant strain were observed.  Tissue 
culture treated 24-well dishes were trialled to improve throughput and efficiency.  
Pellicle and biofilm structures were observed in 24-well dishes however the 
assay error within replicates was much higher due to the practicality of using a 
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smaller well size (Figure ‎6.3C).  An intermediate sized non tissue-culture treated 
12-well dish showed striking differences in pellicle morphology compared with 
the tissue culture treated 6- and 24-well dishes (Figure ‎6.3B).  It was decided that 
the pellicle and biofilm assays would proceed using 6-well tissue culture dishes 
due to their ease of use and their accurate and consistent assay results. 
 
 
Figure ‎6.3.  Pellicle and biofilm formation assays in a variety of tissue culture treated and non 
treated multi-well plates was assessed and revealed subtle differences.  (A) The use of 6-well 
tissue culture (TC) treated plates and supplemented M63 media was settled upon due to their 
ease of use and consistent assay results; (B) cultures in 12-well non tissue culture treated dishes 
showed differences in pellicle morphology compared with treated dishes; (C) smaller 24-well 
dishes developed a suitable pellicle and biofilm but were not practical for accurate biofilm 
analysis. 
 
6.2.3 A modified technique for pellicle and biofilm estimation 
Results from the biofilm growth optimisation experiments demonstrated that 
M. smegmatis mc2155 was capable of developing both a pellicle and a biofilm 
and a technique to quantify both was developed.  Pellicle wet weight was initially 
measured by using a wide scalpel blade to scrape the surface of the media 
however it was obvious that some material remained behind on the surface.   
Instead, thick blotting paper cut to size for the 6-well dishes was used to collect 
the entire pellicle in one manoeuvre by gently laying it on top of the pellicle 
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(Figure ‎6.4A) for a few seconds and then removing the paper using the side tag 
(Figure ‎6.4B).  Blotting paper was dried at 50°C and pre-weighed prior to use and 
subsequently dried and weighed to record pellicle dry weight.  Very little pellicle 
material remained on the surface after removal and the underlying biofilm 
remained undisturbed (Figure ‎6.4C) allowing a commonly used crystal violet 
staining technique to be performed (Figure ‎6.4D).  Figure ‎6.4 follows the same 
three wells of M. smegmatis mc2155 during pellicle removal and at the end of CV 
staining and ready for stain dissolving and quantification by OD570.  During 
biofilm formation optimisation in a range of multi-well dishes it was noted that 
there was a tendency to accidentally mechanically disturb the biofilm while 
removing spent media and washing the wells.  This was a particular problem 
when using 24-well dishes and this issue contributed to the final selection of 
6-well dishes for experimental assays.   
 
 
Figure ‎6.4.  The use of custom made paper discs with tabs enabled distinct pellicle and biofilm 
quantification.  (A) Typical pellicle formation of M. smegmatis mc
2
155 lab strain in triplicate wells 
of a 6-well dish prior to pellicle removal; (B) the underside of dried paper discs that have pellicle 
from the above wells attached; (C) almost no pellicle remains in the wells after pellicle removal 
and the biofilm is undisturbed; (D) the resulting crystal violet stained biofilm. 
 
6.2.4 M. smegmatis Δlsr2 exhibits different pellicle morphology 
Pellicle and biofilm growth of M. smegmatis mc2155 and M. smegmatis mc2155 
Δlsr2 in biofilm media appeared very similar however differences in pellicle 
morphology were noted.  In contrast to the very smooth and glossy pellicle 
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exhibited by the lab strain, the Δlsr2 strain had a thinner pellicle with clumps of 
cellular material dispersed on top (Figure ‎6.5A).  Examination of the lab strain 
pellicle under a light microscope showed a uniform distribution of cells in 
comparison to the Δlsr2 which had clumped regions (out of focus) overlaid on 
more uniformly distributed cells (Figure ‎6.5B).  DNA staining of the pellicle 
illustrates a more uniform matrix in the lab strain in contrast to irregular thin and 
thick matrix regions in the Δlsr2 (Figure ‎6.5C). 
 
 
Figure ‎6.5.  The pellicle of M. smegmatis Δlsr2 grown in M63 biofilm media is irregular and 
clumped.  (A) Photographs illustrate the smooth and glossy lab strain pellicle, in contrast to the 
Δlsr2; (B) light microscopy images show cell clumping in the Δlsr2; (C) SYTO®9 DNA staining of the 
pellicle highlight the uneven matrix distribution in the Δlsr2 strain.  
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6.2.5 Complementation with native Lsr2 or Lsr2 DNA binding mutants 
fails to rescue the pellicle morphology phenotype 
An investigation into the ability of M. tuberculosis H37Rv Lsr2 and Lsr2 mutants 
deficient in DNA binding to complement the morphological difference in pellicle 
formation between M. smegmatis mc2155 lab strain and the Δlsr2 was 
undertaken.  M. tuberculosis H37Rv lsr2 (Rv3597c) and DNA binding mutants 
were cloned into the tetracycline inducible mycobacteria expression vector 
pMIND supplied by R. O’Toole (Blokpoel et al., 2005).  The transcripts of the 
introduced genes, cloned versions of Lsr2 and the three DNA binding mutants 
were generated both with and without a ribosome binding site (RBS) ahead of 
the gene.  Lsr2 and mutants were induced in the M. smegmatis mc2155 Δlsr2 
strain and all strains (including controls) were grown in triplicate in M63 biofilm 
media in 6-well dishes and assayed for pellicle and biofilm growth.  The unusual 
clumped pellicle morphology observed in the Δlsr2 was unable to be restored to 
that of the smooth and glossy lab strain by the expression of Lsr2 or any of the 
Lsr2 mutants (results not shown) cloned either with or without an RBS.  The 
reason for this was unkown.  There was no difference in pellicle dry weight 
(Figure ‎6.6A) or biofilm formation (Figure ‎6.6B) between control and 
experimental strains of M. smegmatis mc2155.  Figure ‎6.6 represents the 
combined data from three replicate non-RBS pMIND cloned experiments and five 
replicate RBS-pMIND cloned experiments.  Three experiments were also 
completed for RBS-pMIND cloned strains in 12-well and 24-well dishes which 
also had the same outcome (results not shown). 
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Figure ‎6.6.  M. smegmatis Δlsr2 is not deficient in pellicle or biofilm formation and is not 
influenced by complementation with M. tuberculosis Lsr2 or DNA binding variants.  (A)  Dry 
pellicle weight of control strains, Lsr2 and DNA binding mutant Lsr2 genes introduced in a vector 
excluding a RBS (pMIND) and including a RBS (RBS-pMIND) (standard deviation error bars shown); 
(B) biofilm growth quantified by crystal violet staining and UV absorption of control strains, Lsr2 
and DNA binding mutant Lsr2 genes introduced in a vector excluding a RBS (pMIND) and 
including a RBS (RBS-pMIND) (standard deviation error bars shown). 
 
Molecular techniques were used to confirm that the genes for Lsr2 and Lsr2 
mutants were present in the pMIND vector, that the pMIND vector was present 
in the appropriate M. smegmatis mc2155 strain and that the correct lab strain or 
Δlsr2 strain was used for each experimental condition.  PCR analysis of crudely 
lysed M. smegmatis mc2155 cells confirmed the correct strain, vector and insert 
for each experimental condition (methods section 2.5.6).  Primers designed for 
M. smegmatis mc2155 lsr2 (MSMEG_6092; lane 1) amplified this gene (345 bp) in 
the lab strain “mc2155” and lab strain containing pMIND “mc2155 + pMIND” only.  
Primers used in cloning M. tuberculosis H37Rv lsr2 (Rv3597c; lane 2) successfully 
amplified lsr2 (360 bp) and the mutant forms (lower panel) and apart from some 
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non-specific priming, did not amplify a gene from the four control strains (upper 
panel).  Primers designed to encompass either side of the multiple cloning site of 
pMIND (lane 3) successfully amplified this region devoid of a gene (190 bp) in the 
control strains “mc2155 + pMIND” and “Δ Lsr2 + pMIND” (upper panel) and 
amplified this region inclusive of lsr2 (550 bp) in the experimental strains (lower 
panel).  PCR analysis was performed for both the RBS inclusive and exclusive 
strains - the figure below illustrate results of the analysis of the RBS-pMIND 
strains.  These techniques were used a number of times to repeatedly confirm 
the correct strains. 
 
 
Figure ‎6.7.  PCR analysis of control and experimental strains confirms correct M. smegmatis 
mc
2
155 strain, vector and gene insert.  Primers were designed for M. smegmatis mc
2
155 Lsr2 
(MSMEG_6092; Lane 1), M. tuberculosis H37Rv Lsr2 (Rv3597c; lane 2) and pMIND multiple 
cloning site (lane 3).  The upper panel illustrates the two M. smegmatis mc
2
155 strains including 
empty vector controls and the lower panel illustrates the four experimental variants. 
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6.3 Discussion 
It is well established that M. smegmatis mc2155 is capable of producing a biofilm 
(Ojha & Hatfull, 2007).  A number of researchers have shown that the DNA 
binding protein Lsr2 is involved in biofilm formation and have observed that 
M. smegmatis mc2155 Δlsr2 mutants grow as smooth, wet and round colonies on 
mycobacteria-specific media which is in contrast to the dry, rough and rugose 
colony morphology displayed by the wild type strain (Arora et al., 2008; Chen et 
al., 2006).  These Δlsr2 mutants were generated by the insertion of a transposon 
element into the lsr2 gene (Chen et al., 2006) and a single base pair deletion 
arising from a spontaneous mutation that resulted in a truncated Lsr2 product 
(Arora et al., 2008)(Table 1.2). 
An M. smegmatis mc2155 Δlsr2 mutant containing a clean deletion of the gene 
was obtained for this study and its ability to form a biofilm examined.  In contrast 
to other published research, examination of this mutant strain showed colony 
morphology that was similar to the lab strain M. smegmatis mc2155.  A modified 
technique for pellicle quantification was developed during this study to be able 
to clearly define the differences between growth of the air-surface pellicle and 
the surface-attached biofilm as published studies were ambiguous in this regard.  
After extensive experimental development to establish conditions for pellicle and 
biofilm growth, it was concluded that there was no difference in pellicle and 
biofilm growth between the lab strain and Δlsr2.  These results are in contrast to 
other studies (Arora et al., 2008; Chen et al., 2006).  However a difference in 
pellicle morphology between the lab strain and Δlsr2 was noted.  The usually 
smooth and glossy pellicle of the lab strain became thin and clumped in the 
mutant.  Alterations in the surface of the pellicle between an M. smegmatis wild 
type strain and mutant such as observed in this work have been reported in a 
recent study which similarly discovered no differences in biofilm formation 
between the examined strains (Klepp et al., 2012). 
To examine if Lsr2 could rescue the morphological pellicle phenotype observed in 
the Δlsr2 strain, lsr2 was introduced in a tetracycline inducible vector.  Also, a 
number of DNA binding mutants of Lsr2 had been generated in previous studies 
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and it was of interest to see what influence these proteins may have on pellicle 
morphology.  The mycobacteria expression vector pMIND was selected as it had 
been successfully used for inducible expression in our lab (Robson et al., 2009) 
and the genes of interest were cloned into the vector in two ways - with and 
without an RBS - to account for any issues with translation in M. smegmatis.  The 
expression of Lsr2 and DNA binding mutants in the mutant strain did not rescue 
the pellicle morphology phenotype and did not influence pellicle or biofilm 
formation. 
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7 Chapter Seven – Discussion 
 
7.1 General background 
Lsr2 from M. tuberculosis H37Rv is a small (12 kDa) and basic protein (pI of 10) 
that is highly conserved in mycobacteria and related actinomycetes (Gordon et 
al., 2008).  Lsr2 was first identified as an immunodominant T-cell antigen of 
M. leprae (Laal et al., 1991; Oftung et al., 2000; Singh, Narayanan et al., 1994) 
and it continues to be studied in an effort to identify critical residues that are 
responsible for generating an immune response.  DNA sequence analysis reveals 
that lsr2 orthologues are present in all sequenced mycobacterial genomes, 
including M. smegmatis, M. bovis and M. bovis BCG, and the high amino acid 
sequence similarity among the Lsr2 homologues suggests that they perform a 
similar function. 
Lsr2’s highly basic, arginine rich and positively charged nature implies an ability 
for it to interact with negatively charged phosphate groups such as those on the 
DNA backbone.  Lsr2 has been shown to be able to down-regulate the 
transcription of genes involved in cell wall synthesis and metabolic functions in 
M. tuberculosis H37Rv and it has been suggested that it could do this by 
controlling chromosomal topology (Colangeli et al., 2007).  Knock-out mutants of 
Lsr2 in M. smegmatis mc2155 show altered colony morphology and reduced 
biofilm formation (Arora et al., 2008; Chen et al., 2006), however to date, an Lsr2 
knock-out in M. tuberculosis H37Rv has been unsuccessful suggesting that Lsr2 is 
an essential gene in M. tuberculosis.  
This project was undertaken to investigate the biochemical and structural 
characteristics of the DNA binding protein Lsr2 from M. tuberculosis H37Rv.   
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7.2 Lsr2 is a non-specific DNA binding protein 
Lsr2 was expressed as a recombinant protein in E. coli to generate large amounts 
of protein that could be purified using affinity chromatography.  It was known 
that Lsr2 had been expressed by other researchers in this manner for 
experimental work however, there was no mention in published work that Lsr2 
co-purified with large amounts of E. coli genomic DNA, as was discovered during 
this study.  The presence of this DNA with Lsr2 was beneficial at times for 
characterising the behaviour of Lsr2 however in general the DNA was a 
hindrance in most of the techniques used throughout this project. 
It was determined that the DNA could be removed most efficiently by an 
incubation step with a buffer containing 2 M NaCl, followed by a separation of 
the DNA from protein using SEC.  After DNA removal, the highly positively 
charged nature of Lsr2 influenced its behaviour and it would stick to centrifugal 
concentrator membranes and aggregated when it was highly concentrated.  As a 
consequence of this, the majority of DNA-free Lsr2 handling was performed in a 
high salt buffer.  In contrast to these technical difficulties, purified Lsr2 
(co-purified with DNA) was stable even after several months of storage at 4°C. 
TEM analysis of negatively stained Lsr2 in complex with co-purified with DNA 
revealed a regular fibril-like arrangement of protein coating the DNA strands of 
around 90 Å in diameter.  The results suggested that Lsr2 bound to the DNA 
following its helical topology.  Changes in Lsr2 and DNA topology by preparation 
of Lsr2 in high salt buffers were examined using TEM.  As salt concentration 
increased, weakening the interaction between Lsr2 and the DNA, fibrils became 
more dispersed and less entwined suggesting that Lsr2 was also capable of 
drawing multiple strands of DNA together. 
After obtaining concentrated, DNA-free, native Lsr2 protein from two different 
recombinant protein expression systems, crystallisation trials were performed 
but protein crystals were not forthcoming. 
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7.3 Properties of the C-terminal DNA binding domain of Lsr2 
An NMR structure of the C-terminal DNA binding domain of Lsr2 from 
M. tuberculosis H37Rv was published part way through this study and this 
prompted a change in experimental focus.  Authors of the NMR structure 
publication also identified and defined the boundaries of the N-terminal and 
C-terminal domains of Lsr2 that they had determined through domain swapping 
experiments with another DNA binding protein, H-NS (Gordon et al., 2010).  Prior 
to their research, the domain structure of Lsr2 had not been established.  To bind 
to DNA, Lsr2 interacts with the minor groove of the DNA via the residues R97, 
G98, and R99.   
Three Lsr2 DNA binding mutants were generated in this study to investigate the 
influence of these specific residues on DNA binding; denoted R97A, R99A and 
R97A-R99A.  The DNA binding ability of these three mutants was reduced 
considerably, especially by the mutation of both arginine residues.  TEM analysis 
of affinity purified Lsr2 mutants visually showed that the formation of fibrils of 
DNA coated by Lsr2 was minimal after mutating single arginine residues and was 
abolished by the double mutation. 
Protein thermal stability was affected by residue mutation.  However, the order 
of reduction in thermal stability suggested that the amount of DNA bound with 
each protein in the preparations used may have had the greater influence in 
thermal stability than residue mutation itself. 
Protein secondary structure was slightly affected by residue mutation.  Circular 
dichroism analysis of SEC purified Lsr2 and mutant proteins showed that the 
proportion of α-helix and β-sheet structures was altered.  However, as the 
difference in optical activity between proteins was small the outcome of the 
secondary structure analysis is not conclusive.   
Crystallisation trials were performed with the R97A-R99A mutant but protein 
crystals were not forthcoming. 
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7.4 Lsr2 DNA binding mutants and Mycobacterium 
smegmatis mc2155 biofilm and pellicle formation 
It is unclear if the human pathogen M. tuberculosis is capable of forming a 
biofilm (Ha et al., 2005) however it is well established that M. smegmatis mc2155 
is capable (Ojha & Hatfull, 2007).  Lsr2 has been shown to play an important role 
in biofilm formation in M. smegmatis mc2155 (Chen et al., 2006) with Lsr2 
mutant strains having a range of biofilm forming abilities (Arora et al., 2008; 
Kocíncová et al., 2008).  Access to a M. smegmatis mc2155 Δlsr2 lab strain was 
provided by R. Colangeli and this strain was used to explore the biofilm 
phenotype and to investigate the role of Lsr2 and three Lsr2 DNA binding 
mutants in biofilm formation.   
It was established that the M. smegmatis mc2155 lab strain was capable of 
producing both an air-surface pellicle and a surface-adhered biofilm after growth 
in M63 biofilm media.  Specific techniques were developed for the consistent 
individual measurement of both the pellicle and biofilm which had not been 
reported previously.  Custom-made filter paper sampling devices were used to 
remove the pellicle prior to biofilm staining (using crystal violet), and the dry 
pellicle weight and stain optical density was measured to quantify pellicle and 
biofilm formation, respectively.   
A limited pellicle phenotype was established for the Δlsr2 strain whereby the 
pellicle formed in grainy patches instead of a smooth surface.   The introduction 
of M. tuberculosis H37Rv lsr2 and the three lsr2 DNA binding mutants on a 
tetracycline-inducible mycobacterial vector (pMIND) failed to rescue the 
phenotype observed in the Δlsr2.  The reason for this was unknown. 
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7.5 Crystallisation and characterisation of the N-terminal 
dimerisation domain of Lsr2 
After the publication of the C-terminal DNA binding domain NMR structure of 
Lsr2 part way through this study, the research focus switched to the expression 
and purification of the N-terminal dimerisation domain of Lsr2.  The technique 
used to prepare protein for NMR analysis of the C-terminal domain of Lsr2 
included expression of the full-length protein followed by limited trypsin 
digestion to remove the N-terminal domain.  This approach is not suited to 
protein crystallographic techniques and instead separate protein domain 
expression was used.  The publication of the crystallographic structure of the 
dimerisation domain of an E. coli DNA binding protein, H-NS, encouraged focus in 
this undertaking as the higher order structure of the N-NS dimerisation domain 
was intriguing (Arold et al., 2010). 
Seven alternative constructs of the N-terminal dimerisation domain of Lsr2 were 
expressed and purified with three of these proving sufficiently well-behaved to 
proceed into crystallisation trials.  SEC estimation of the molecular weight of all 
the N-terminal domain constructs indicated that this domain was purifying as a 
dimer, however in vitro glutaraldehyde cross-linking experiments also showed 
that the N-terminal domain was capable of forming much larger structures.  
Crystallisation trials were performed with Nterm, Nterm2 and Nterm3 N-terminal 
domain constructs of Lsr2, with Nterm2 successfully producing diffraction quality 
crystals. 
Crystals of Nterm2 formed only after a “maturation” period where some 
unknown modification of the protein was taking place in solution prior to use in 
crystallisation techniques, or after the addition of trypsin (at a 1:500 mass ratio) 
to the protein immediately before crystallisation screens were performed.  
Analysis of “matured” Nterm2 using SEC showed that a number of larger 
multimeric forms were developing over time and it was determined that this 
effect could be recreated by the addition of trypsin to purified Nterm2. 
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Figure ‎7.1.  The 3D structure of the N-terminal domain of Lsr2 was determined in two different 
crystallographic space groups.  (A) A cartoon diagram of the crystallographic symmetry of the 
N-terminal domain in the P21 crystal structure showing the unit cell (in green) perpendicular to 
the b-axis.  The two-fold screw axis generates two Lsr2 chains that lay back to back in the 
horizontal plane shown here; (B) a cartoon diagram of the crystallographic symmetry of the 
N-terminal domain in the P3121 crystal structure, showing the unit cell (in green).  A two-fold 
symmetry (as a result of this space group) is visible in the horizontal plane and the first tier of 
Lsr2 chains in the three-fold vertical screw c-axis is shown. 
 
An X-ray diffraction data set was collected from a crystal from “matured” Nterm2 
and a crystal from trypsin co-crystallised Nterm2, both at a high resolution.  Due 
to the fact that there were no structures similar to the N-terminal domain of Lsr2 
in the protein data bank, molecular replacement techniques for structure solving 
were not available.  A partnership between ourselves and scientists using ab 
initio techniques for solving the crystallographic phase problem was formed and 
the phase problem was completed, and an initial poly-alanine structure was 
solved and provided.  The initial structure was modified to remove residues 
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suspected of being incorrectly positioned and it was then used in completing 
Nterm2 structure building and refinement.  This study produced the first crystal 
structure of the N-terminal dimerisation domain of Lsr2 from M. tuberculosis 
H37Rv. 
The crystal from “matured” Nterm2 provided a structure in the P21 space group, 
whereas the crystal formed by co-crystallistion with trypsin, provided a structure 
in the P3121 space group (Figure ‎7.1).  The Lsr2 dimerisation domain forms a 
compact homodimeric α/β structure that locks together in a head-to-head 
fashion.  Both structures reveal chains of the N-terminal domain of Lsr2 (shown 
by crystallographic symmetry), with the N-terminal end of each monomer 
forming one strand of an anti-parallel β-sheet that allows oligomerisation to 
occur.  In both structures the N-terminal expression tag and the first three 
residues M1, A2 and K3 are missing and it is proposed that these residues are 
required to be absent for oligomerisation to occur.  The fact that the two 
structures have identical residues missing (due to either “maturation” or trypsin 
treatment) has led to the hypothesis that oligomerisation of the N-terminal 
domain could be an in vivo mechanism initiated by the activation of a site-
specific protease. 
The crystallographic data in the higher symmetry P3121 space group reveals a 
possible mechanism of protein alignment and binding to DNA (Figure ‎7.2).  
Within the constraints of crystal packing, strands of DNA can be uniformly 
positioned at a 120° angle to and underneath chains of the N-terminal domain.  
The C-terminal DNA binding domain (PDB 2KNG) can be positioned adjacent to 
the N-terminal domain dimer.  This model provides a possible mechanism for the 
binding and compaction of chromosomal DNA. 
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Figure ‎7.2.  The P3121 crystal packing 
allows modelling of a possible 
arrangement of a chain of the full-
length Lsr2 protein across multiple 
strands of DNA.  DNA strands (in grey) 
could be bridged by dimeric Lsr2 after 
its oligomerisation via anti-parallel 
β-sheet formation (in blue) in the 
N-terminal domains (in rainbow colour).  
Crystallographic spacing allows the 
placement of a single DNA strand 
below the N-terminal domain at a 120° 
angle.  The C-terminal DNA binding 
domain (PDB 2KNG) is able to be 
positioned flanking either side of the 
N-terminal domain and binds to the 
DNA via its conserved RGR residues in 
the loop between the two helices. 
 
 
This model was tested by the addition of trypsin to full-length affinity purified 
Lsr2 protein co-purified with genomic DNA.  Proteolytic treatment of Lsr2 with 
small amounts of trypsin (1:500 mass ratio) resulted in DNA condensation and 
the formation of thick helical structures which were visualised using TEM, and 
which also provided protection of the DNA from DNase digestion as observed by 
agarose gel electrophoresis.  Typically, protease treatment of protein would 
result in protein degradation rather than the formation of larger structures and 
therefore this result appears to be a specific feature of Lsr2. 
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7.6 Future research 
Research presented in this thesis provides a hypothesis for the mechanism of 
DNA binding and chromosome compaction of the non-specific DNA binding 
protein Lsr2 from M. tuberculosis H37Rv.  Further characterisation of the 
N-terminal domain could be undertaken by the mutation of specific residues as 
identified by the 3D structure, to identify those that are essential for the 
formation of higher order structures.  It would also be of interest to further 
examine the compact structures observed with TEM after the addition of trypsin 
to Lsr2, to build a 3D model of the arrangement of Lsr2 on the strands of DNA.  
For those researchers with the ability to perform in vivo experiments, the affect 
of creating Lsr2 mutants that are unable to form oligomers due to residue 
modification or due to a “non-cleavable” N-terminus could be investigated.  
Alternatively, controlled oligomerisation of Lsr2 in vivo could be examined to 
investigate the influence of Lsr2 on chromosome packaging and cell growth.  
Continued work on the mechanism of DNA binding and compaction by Lsr2 may 
present a research avenue to interrupt gene regulation and DNA protection by 
this protein, and elucidate the details surrounding its biological function. 
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Appendices 
Appendix A: Buffers, solutions, growth media, bacterial 
strains, plasmids and antibiotics 
A1:  Buffers and solutions 
Electrophoresis buffers were made with distilled water whereas chromatography 
buffers were made with MQ water and were then filtered with a 0.2 μm filter 
prior to use.  Loading dye was made using MQ water. 
 
BLOTTO   10% (w/v) non fat milk powder in 1 x TBS-T 
10 x DNA loading dye 0.4% (w/v) bromophenol blue, 0.4% (w/v) xylene cyanol, 
50% (v/v) glycerol 
Fairbanks A stain  0.05% (w/v) coomassie blue R-250, 25% (v/v)  
    isopropanol, 10% (v/v) acetic acid 
Fairbanks B stain  0.005% (w/v) coomassie blue R-250 10% (v/v)  
    isopropanol, 10% (v/v) acetic acid 
Fairbanks C stain  0.002% (w/v) coomassie blue, 10% (v/v) acetic acid 
Fairbanks D stain  10% (v/v) acetic acid 
Mounting media 45 ml glycerol, 5 ml H2O, 0.0008 g Na2CO3, 0.036g 
NaHCO3  
5 x native loading dye 300m M Tris-HCl pH 6.8, 50% (v/v) glycerol and 0.05% 
(w/v) bromophenol blue 
PEG200/KOH 30 g PEG 200, 19.5 ml dH2O, 465 μl 2M KOH, pH 13.49 
PBS (10 x) 0.2 M phosphate (0.038 M NaH2PO4, 0.162 M Na2HPO4), 
1.5 M NaCl, pH 7.4 
PBS (1 x)   100 ml 10 x PBS + 900 ml dH2O 
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50 mM phosphate (pH 7.4) A 500 ml volume of 50 mM phosphate buffer at pH 7.4 
was made by combining 38.7 ml of 0.5 M Na2HPO4 and 
11.3 ml of 0.5 M NaH2PO4.  NaCl and imidazole were 
then added to appropriate concentrations  
Ponceau S stain   0.2% (w/v) ponceau red, 1% (v/v) acetic acid 
Resolving buffer  1.5 M Tris-HCl, pH 8.8 
4 x SDS loading dye 200 mM Tris-HCl pH 6.8, 8% (w/v) SDS, 40% (v/v) 
glycerol, 0.4% (w/v) bromophenol blue, 400 mM 
β-mercaptoethanol 
Stacking buffer   1.0 M Tris-HCl, pH 6.8 
50 x TAE 242 g Tris base, 57.1 ml glacial acetic acid, 100 ml 0.5 M 
EDTA (pH 8.0) 
10 x TAE   400 mM Tris-acetate, 10 mM EDTA 
1 x TAE    100 ml 10 x TAE + 900 ml H2O 
1 x TBS    20 mM Tris-HCl pH 7.6, 150 mM NaCl 
1 x TBS-T 20 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1% (v/v) tween 20 
TE    10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0 
TG-SDS running buffer  25 mM Tris-HCl pH 8.3, 250 mM glycine, 0.1% (w/v) SDS 
TG running buffer  25 mM Tris-HCl pH 8.5, 250 mM glycine 
Transfer buffer 25 mM Tris-HCl, 192 mM glycine, 20% methanol, 0.01% 
(w/v) SDS 
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A2:  Growth media 
Dehydrated Difco™, BDL™ and Bacto™ media and ADC enrichment media was 
supplied by Becton, Dickinson and Company, USA.  Growth media was made up 
in distilled water and sterilised by autoclaving at 121°C for 15 minutes. 
 
Hartman’s de Bont Tween 80 omitted for biofilm assay.  Add in order:  1 x trace 
metal stock*, 15 mM (NH4)2SO4, 0.2% (v/v) glycerol, 0.05% (v/v) 
tween 80, 50 mM MOPS, pH 7.0, autoclave then add 1 x 
phosphate stock **  
LB  1% (w/v) bactotryptone or bactopeptone, 0.5% (w/v) yeast 
extract, 1% (w/v) NaCl, pH 8.0, autoclave 
LB agar  1% (w/v) bactotryptone or bactopeptone, 0.5% (w/v) yeast 
extract, 1% (w/v) NaCl, 15 g/L agar, pH 8.0, autoclave 
LBT 1% (w/v) bactotryptone or bactopeptone, 0.5% (w/v) yeast 
extract, 1% (w/v) NaCl, pH 8.0, autoclave then add 0.05% (v/v) 
sterile tween 80 at 45°C 
LBT agar  1% (w/v) bactotryptone or bactopeptone, 0.5% (w/v) yeast 
extract, 1% (w/v) NaCl, 15 g/L agar, pH 8.0, autoclave then add 
0.05% (v/v) sterile tween 80 at 50°C 
Low salt LB 1% (w/v) bactotryptone or bactopeptone, 0.5% (w/v) yeast 
extract, 0.5% (w/v) NaCl, pH 8.0, autoclave 
Low salt LB agar 1% (w/v) bactotryptone, or bactopeptone 0.5% (w/v) yeast 
extract, 0.5% (w/v) NaCl, 15 g/L agar, pH 8.0, autoclave 
M63 minimal 100 mM KH2PO4, 15 mM (NH4)2SO4, 1.7 μM FeSO4·7H2O, pH to 
7.0 with KOH, autoclave, then add 1 mM MgSO4, 0.2% glycerol 
(v/v) 
M63 biofilm media 100 mM KH2PO4, 15 mM (NH4)2SO4, 1.7 μM FeSO4·7H2O, pH to 
7.0 with KOH, autoclave, then add sterile 1 mM MgSO4, 0.2% 
(v/v) glycerol, 0.5% (w/v) bactotryptone and 0.7 mM CaCl2 
M9 salts 42 mM Na2HPO4, 22 mM KH2PO4, 19 mM NH4Cl, 8.5 mM NaCl, 
pH to 7.4 with 10 M NaOH, autoclave 
M9 minimal 42 mM Na2HPO4, 22 mM KH2PO4, 19 mM NH4Cl, 8.5 mM NaCl, 
pH to 7.4 with 10 M NaOH, autoclave, then add sterile 2 mM 
MgSO4, 0.1 mM CaCl2 and 0.4% (w/v) glucose 
 
 
 Appendix A: Buffers, solutions, growth media, bacterial strains, plasmids 186 
PA-0.5G 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM 
MgSO4, 0.5% (w/v) glucose, 0.1 x metals mix***, 100 µg/ml
 each 
of 17 amino acids (no Cys, Tyr or Met). For methionine 
auxotroph DL41 add 100 µg/ml methionine. Individual 
components autoclaved or sterile filtered before adding to 
sterile dH2O 
PASM-5052 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM 
MgSO4, 0.5% (w/v) glycerol, 0.05% (w/v) glucose, 0.2% (w/v) α-
lactose, 1 x metals mix***, 100 nM vitamin B12, 200 µg/ml each 
of 17 amino acids (no Cys, Tyr or Met), 10 μg/ml methionine, 
125 μg/ml selenomethionine 
Rich media + glucose 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl, 0.2% (w/v) glucose 
SOC 2% (w/v) bactotryptone or bactopeptone, 0.5% (w/v) yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 10 mM MgCl2, 
autoclave.  Once cooled add sterile glucose to 20 mM 
TB 1.2% (w/v) bactotryptone, 2.4 % (w/v) yeast extract, 0.4% (w/v) 
glycerol in 9 part volume, autoclave.  Once cooled, combine 
with a 1 part volume of sterile 0.17 M KH2PO4, 0.72 M K2HPO4 
7H9/ADC/T 0.47 g 7H9 powder, 0.2% (w/v) glycerol in 90 ml H2O, autoclave 
then add 10 ml ADC enrichment and 0.05% (v/v) tween 80 at 
45°C 
7H10/ADC/T agar 1.9 g 7H10 powder, 0.5% (w/v) glycerol in 90 ml H2O, autoclave 
then add 10 ml ADC enrichment and 0.05% (v/v) tween 80 at 
50°C 
 
*100 x trace metals stock for HdB media: EDTA [0.1 g], MgCl2.6H2O [1 g], CaCl2.2H2O 
[10 mg], NaMoO4.2H2O [2 mg], CoCl2.6H2O [4 mg], MnCl2.2H2O [10 mg], ZnSO4.7H2O 
[20 mg], FeSO4.7H2O [50 mg], CuSO4.5H2O to 100 ml with dH2O. 
 
**100 x phosphate stock for HdB media: K2HPO4 [15.5g], NaH2PO4.2H2O [11.1g] to 100 
ml with dH2O. 
 
***1000 x metals mix made up from the sterile stock solutions of each component to 
give the following concentrations: 50 µM FeCl3 in 0.12 M HCl (filter sterile), 20 µM CaCl2, 
10 µM MnCl2, 10 µM ZnSO4, 2 µM CoCl2, 2 µM CuCl2, 2 µM NiCl2, 2 µM Na2MoO4, 2 µM 
Na2SeO3, 2 µM H3BO3. 
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A3:  Bacterial strains, plasmids and antibiotics 
 
Table A.1.  Bacterial strains used in the study. 
Strain Description 
Escherichia coli  
TOP10 High efficiency transformation and plasmid copy number. 
Inactivated endonuclease I for high plasmid DNA yield.  LacZ 
for blue/white colony screening. 
DH5α High efficiency transformation and high plasmid copy 
number.  Inactivated intracellular endonucleases for high 
plasmid DNA yield.   
BL21 (DE3) DE3 lysogen contains T7 polymerase upon IPTG induction. 
This strain is deficient of lon and omp-t proteases and is 
therefore suitable for expression of non-toxic genes. 
DL41 Methionine auxotroph suitable for expression of 
selenomethionine labelled protein. 
Mycobacterium smegmatis  
mc2155 Electrocompetent wild-type M. smegmatis mc2155 lab strain. 
mc2155 Δlsr2 The wild-type M. smegmatis mc2155 lab strain with a clean 
unmarked deletion of MSMEG_6092 lsr2 (NJS22; Colangeli et 
al., 2007). 
 
Table A.2.  Plasmids used in the study. 
Plasmid Description 
pET30b E. coli expression vector.  T7 promoter.  Encodes either an N-
terminal 6 x histidine tag-thrombin-S·tag or C-terminal 6 x 
histidine expression tag with no cleavage site.  Kanamycin 
resistance (Colangeli et al., 2007). 
pMAL-c2x E. coli expression vector. Tac promoter.  Encodes malE for 
expression of an N-terminal MBP fusion tag with a Factor Xa 
protease cleavage site.  Ampicillin resistance (NEB, USA). 
pPROExHTb E. coli expression vector.  Trc promoter.  Encodes an N-
terminal 6 x histidine tag with an rTEV protease cleavage site.  
Ampicillin resistance (Invitrogn, USA). 
pMIND M. smegmatis tetracycline inducible expression vector.  
TetRO promoter. Kanamycin and hygromycin resistance 
(Bolkpoel et al., 2005). 
pDEST17 E. coli expression vector.  T7 promoter.  Encodes an N-
terminal 6 x histidine tag with no protease cleavage site.  
Ampicillin and chloromphenicol resistance (Invitrogen, USA). 
 
Table A.3.  Antibiotic stocks and concentrations used in the study. 
Antibiotic Stock  Final Concentration 
Ampicillin 100 mg/ml  100 μg/ml 
Hygromycin   50 mg/ml    50 μg/ml 
Kanamycin   50 mg/ml    50 μg/ml 
Tetracyline  0.2 mg/ml 0.02 μg/ml 
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Table A. 4.  Plasmid constructs used in the study. 
 
Plasmid Description Reference 
lsr2-pET30b pET30 with M. tuberculosis H37Rv lsr2 inserted 
into NdeI/XhoI restriction sites. 
Colangeli et al., (2007) 
lsr2-pMAL-c2x pMAL-c2x with M. tuberculosis H37Rv lsr2 
inserted into XbaI/PstI restriction sites. 
This study 
lsr2-pMIND pMIND with M. tuberculosis H37Rv lsr2 
inserted into PstI/SpeI restriction sites. 
This study 
R97A-pET30b Site directed mutagenesis mutant of lsr2-
pET30b with R97A mutation. 
This study 
R99A-pET30b Site directed mutagenesis mutant of lsr2-
pET30b with R99A mutation. 
This study 
R97AR99A-pET30b Site directed mutagenesis mutant of lsr2-
pET30b with R97AR99A mutation. 
This study 
R97A-pMIND pMIND with R97A lsr2 mutant inserted into 
PstI/SpeI restriction sites. 
This study 
R99A-pMIND pMIND with R99A lsr2 mutant inserted into 
PstI/SpeI restriction sites. 
This study 
R97AR99A-pMIND pMIND with R97AR99A lsr2 mutant inserted 
into PstI/SpeI restriction sites. 
This study 
R97A-RBSpMIND pMIND with RBS and R97A lsr2 mutant 
inserted into PstI/SpeI restriction sites. 
This study 
R99A-RBSpMIND pMIND with RBS and R99A lsr2 mutant 
inserted into PstI/SpeI restriction sites. 
This study 
R97AR99A-RBSpMIND pMIND with RBS and R97AR99A lsr2 mutant 
inserted into PstI/SpeI restriction sites. 
This study 
Nterm-pPROExHTb pPROExHTb with Lsr2 N-terminal residues 1-59 
inserted into NcoI/XhoI restriction sites. 
This study 
Nterm+-pPROExHTb pPROExHTb with lsr2 N-terminal residues 1-68 
inserted into NcoI/XhoI restriction sites. 
This study 
Nterm1-pPROExHTb pPROExHTb with Lsr2 N-terminal residues 1-56 
inserted into NcoI/XhoI restriction sites. 
This study 
Nterm2-pPROExHTb pPROExHTb with Lsr2 N-terminal residues 1-61 
inserted into NcoI/XhoI restriction sites. 
This study 
Nterm3-pPROExHTb pPROExHTb with Lsr2 N-terminal residues 1-64 
inserted into NcoI/XhoI restriction sites. 
This study 
Nterm4-pPROExHTb pPROExHTb with Lsr2 N-terminal residues 1-71 
inserted into NcoI/XhoI restriction sites. 
This study 
Nterm5-pPROExHTb pPROExHTb with Lsr2 N-terminal residues 1-74 
inserted into NcoI/XhoI restriction sites. 
This study 
I34M-pPROExHTb Site directed mutageneis mutant of Nterm2-
pPROExHTb with I34M mutation. 
This study 
L44M-pPROExHTb Site directed mutageneis mutant of Nterm2-
pPROExHTb with L44M mutation. 
This study 
L48M-pPROExHTb Site directed mutageneis mutant of Nterm2-
pPROExHTb with L48M mutation. 
This study 
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